Target gene name,Name,DrugBank ID,ATC Codes,Description,Category,Target name,Target actions
ADORA3; VMAT2; FAAH; SLC29A1; UGT1A1; PDE5A; ALOX5; CTSS; CTSL; ABL1; CPK1; pknB; RPS6KA6; TYK2; COQ8A; JAK1; MET; NIM1K; STK26; PRKACA; STK24; STK3; TEC; SYK; STK33; STK35; STK36; STK38; STK38L; STK39; TAOK1; TAOK2; TAOK3; TBK1; TEK; TESK1; TGFBR1; TGFBR2; TIE1; TLK1; TLK2; TNIK; TNK1; TNK2; TNNI3K; TSSK1B; TTK; TXK; TYRO3; ULK1; ULK2; ULK3; WEE1; YES1; MAP3K19; ZAK; ZAP70; AAK1; ABL2; ACVR1; ACVR1B; COQ8B; ALK; ANKK1; AURKA; AURKB; AURKC; AXL; BLK; BMP2K; BMPR1B; BMPR2; BMX; BRAF; BTK; CAMK1; CAMK1D; CAMK1G; CAMK2A; CAMK2B; CAMK2D; CAMK2G; CAMKK1; CAMKK2; CASK; CSN3; CDK1; CDC42BPG; CDK4; CDKL1; CDKL2; CHEK1; CHEK2; CIT; CLK1; CLK2; CLK3; CLK4; CSF1R; CSK; CSNK1A1; CSNK2A1; CSNK2A2; DAPK1; DAPK2; DAPK3; DCLK1; DCLK2; DCLK3; DDR1; DDR2; DYRK1A; DYRK1B; EGFR; EIF2AK1; EIF2AK2; EIF2AK4; EPHA1; EPHA2; EPHA3; EPHA4; EPHA5; EPHA6; EPHA7; EPHA8; EPHB1; EPHB2; EPHB4; EPHB6; ERBB2; ERBB4; ERN1; FER; FES; FGFR1; FGFR2; FGFR3; FGR; FLT1; FLT3; FLT4; MTOR; FRK; FYN; GAK; GSK3A; GSK3B; HCK; HIPK2; HIPK3; ICK; IKBKB; IKBKE; INSR; INSRR; IRAK1; IRAK3; IRAK4; ITK; JAK2; JAK3; KDR; SIK3; KIT; LATS1; LCK; LIMK1; LIMK2; LRRK2; LTK; LYN; MAP2K2; MAP2K3; MAP2K5; MAP2K6; MAP3K1; MAP3K10; MAP3K11; MAP3K12; MAP3K13; MAP3K15; MAP3K2; MAP3K3; MAP3K4; MAP3K6; MAP3K9; MAP4K1; MAP4K2; MAP4K3; MAP4K4; MAP4K5; MAPK10; MAPK13; MAPK14; MAPK15; MAPK4; MAPK7; MAPK9; MAPKAPK5; MARK1; MARK2; MARK3; MARK4; CLASP1; MAST1; MATK; MELK; MERTK; MINK1; MKNK1; MKNK2; MST1R; MUSK; MYLK; MYLK2; MYLK3; MYLK4; MYO3A; NEK1; NEK11; NEK2; NEK3; NEK4; NEK5; NEK9; NTRK1; NTRK2; NTRK3; NUAK1; NUAK2; OXSR1; PAK1; PAK2; PAK3; PAK4; PAK6; PAK5; CDK16; CDK17; PDGFRA; PDGFRB; PDPK1; CDK15; PHKG1; PI4KB; PIK3C2B; PIK3C2G; PIK3CD; PIK3CG; PIM1; PIM3; PIP4K2B; PIP4K2C; PKMYT1; PKN1; PKN2; PLK1; PLK2; PLK3; PLK4; PRKAA1; PRKAA1; PRKAA2; PRKAB1; PRKAB2; PRKAG1; PRKAG2; PRKAG3; PRKACB; PRKCD; PRKCE; PRKCG; PRKCI; PRKCQ; PRKD1; PRKG2; PRPF4B; PTK2; PTK2B; PTK6; RAF1; RET; RIOK1; RIOK2; RIOK3; RIPK1; RIPK2; RIPK4; ROCK2; ROS1; RPS6KA1; RPS6KA3; SBK1; SBK3; SGK3; SIK1; SIK2; SLK; SNRK; SRC; SRMS; STK10; STK16; STK17A; STK17B; STK32A; CYP3A4; ABCG2; ABCB5; UGT1A9,Fostamatinib,DB12010,B02BX09,"Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA [L2644].

Recently, fostamatinib has been identified as a potential therapeutic for controlling acute respiratory distress syndrome (ARDS) in patients with severe COVID-19 through its ability to modulate the SYK kinase.[A235008, A235013, A235018]","Amines; BCRP/ABCG2 Inhibitors; Blood and Blood Forming Organs; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Experimental Unapproved Treatments for COVID-19; Hemostatics; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Kinase Inhibitor; Oxazines; Phosphodiesterase 5 Inhibitors; Pyridines; Tyrosine Kinase Inhibitors; UGT1A1 Inhibitors; UGT1A9 Substrates; Vasodilating Agents","Adenosine receptor A3; vesicular monoamine transporter 2 (VMAT2); Fatty-acid amide hydrolase 1; Equilibrative nucleoside transporter 1; UDP-glucuronosyltransferase 1-1; cGMP-specific 3',5'-cyclic phosphodiesterase; Arachidonate 5-lipoxygenase; Cathepsin S; Cathepsin L1; Tyrosine-protein kinase ABL1; Calcium-dependent protein kinase 1; Serine/threonine-protein kinase PknB; Ribosomal protein S6 kinase alpha-6; Non-receptor tyrosine-protein kinase TYK2; Atypical kinase COQ8A, mitochondrial; Tyrosine-protein kinase JAK1; Hepatocyte growth factor receptor; Serine/threonine-protein kinase NIM1; Serine/threonine-protein kinase MST4; cAMP-dependent protein kinase catalytic subunit alpha; Serine/threonine-protein kinase 24; Serine/threonine-protein kinase 3; Tyrosine-protein kinase Tec; Tyrosine-protein kinase SYK; Serine/threonine-protein kinase 33; Serine/threonine-protein kinase 35; Serine/threonine-protein kinase 36; Serine/threonine-protein kinase 38; Serine/threonine-protein kinase 38-like; STE20/SPS1-related proline-alanine-rich protein kinase; Serine/threonine-protein kinase TAO1; Serine/threonine-protein kinase TAO2; Serine/threonine-protein kinase TAO3; Serine/threonine-protein kinase TBK1; Angiopoietin-1 receptor; Dual specificity testis-specific protein kinase 1; TGF-beta receptor type-1; TGF-beta receptor type-2; Tyrosine-protein kinase receptor Tie-1; Serine/threonine-protein kinase tousled-like 1; Serine/threonine-protein kinase tousled-like 2; TRAF2 and NCK-interacting protein kinase; Non-receptor tyrosine-protein kinase TNK1; Activated CDC42 kinase 1; Serine/threonine-protein kinase TNNI3K; Testis-specific serine/threonine-protein kinase 1; Dual specificity protein kinase TTK; Tyrosine-protein kinase TXK; Tyrosine-protein kinase receptor TYRO3; Serine/threonine-protein kinase ULK1; Serine/threonine-protein kinase ULK2; Serine/threonine-protein kinase ULK3; Wee1-like protein kinase; Tyrosine-protein kinase Yes; Mitogen-activated protein kinase kinase kinase 19; Mitogen-activated protein kinase kinase kinase MLT; Tyrosine-protein kinase ZAP-70; AP2-associated protein kinase 1; Abelson tyrosine-protein kinase 2; Activin receptor type-1; Activin receptor type-1B; Atypical kinase COQ8B, mitochondrial; ALK tyrosine kinase receptor; Ankyrin repeat and protein kinase domain-containing protein 1; Aurora kinase A; Aurora kinase B; Aurora kinase C; Tyrosine-protein kinase receptor UFO; Tyrosine-protein kinase Blk; BMP-2-inducible protein kinase; Bone morphogenetic protein receptor type-1B; Bone morphogenetic protein receptor type-2; Cytoplasmic tyrosine-protein kinase BMX; Serine/threonine-protein kinase B-raf; Tyrosine-protein kinase BTK; Calcium/calmodulin-dependent protein kinase type 1; Calcium/calmodulin-dependent protein kinase type 1D; Calcium/calmodulin-dependent protein kinase type 1G; Calcium/calmodulin-dependent protein kinase type II subunit alpha; Calcium/calmodulin-dependent protein kinase type II subunit beta; Calcium/calmodulin-dependent protein kinase type II subunit delta; Calcium/calmodulin-dependent protein kinase type II subunit gamma; Calcium/calmodulin-dependent protein kinase kinase 1; Calcium/calmodulin-dependent protein kinase kinase 2; Peripheral plasma membrane protein CASK; Kappa-casein; Cyclin-dependent kinase 1; Serine/threonine-protein kinase MRCK gamma; Cyclin-dependent kinase 4; Cyclin-dependent kinase-like 1; Cyclin-dependent kinase-like 2; Serine/threonine-protein kinase Chk1; Serine/threonine-protein kinase Chk2; Citron Rho-interacting kinase; Dual specificity protein kinase CLK1; Dual specificity protein kinase CLK2; Dual specificity protein kinase CLK3; Dual specificity protein kinase CLK4; Macrophage colony-stimulating factor 1 receptor; Tyrosine-protein kinase CSK; Casein kinase I isoform alpha; Casein kinase II subunit alpha; Casein kinase II subunit alpha'; Death-associated protein kinase 1; Death-associated protein kinase 2; Death-associated protein kinase 3; Serine/threonine-protein kinase DCLK1; Serine/threonine-protein kinase DCLK2; Serine/threonine-protein kinase DCLK3; Epithelial discoidin domain-containing receptor 1; Discoidin domain-containing receptor 2; Dual specificity tyrosine-phosphorylation-regulated kinase 1A; Dual specificity tyrosine-phosphorylation-regulated kinase 1B; Epidermal growth factor receptor; Eukaryotic translation initiation factor 2-alpha kinase 1; Interferon-induced, double-stranded RNA-activated protein kinase; eIF-2-alpha kinase GCN2; Ephrin type-A receptor 1; Ephrin type-A receptor 2; Ephrin type-A receptor 3; Ephrin type-A receptor 4; Ephrin type-A receptor 5; Ephrin type-A receptor 6; Ephrin type-A receptor 7; Ephrin type-A receptor 8; Ephrin type-B receptor 1; Ephrin type-B receptor 2; Ephrin type-B receptor 4; Ephrin type-B receptor 6; Receptor tyrosine-protein kinase erbB-2; Receptor tyrosine-protein kinase erbB-4; Serine/threonine-protein kinase/endoribonuclease IRE1; Tyrosine-protein kinase Fer; Tyrosine-protein kinase Fes/Fps; Fibroblast growth factor receptor 1; Fibroblast growth factor receptor 2; Fibroblast growth factor receptor 3; Tyrosine-protein kinase Fgr; Vascular endothelial growth factor receptor 1; Receptor-type tyrosine-protein kinase FLT3; Vascular endothelial growth factor receptor 3; Serine/threonine-protein kinase mTOR; Tyrosine-protein kinase FRK; Tyrosine-protein kinase Fyn; Cyclin-G-associated kinase; Glycogen synthase kinase-3 alpha; Glycogen synthase kinase-3 beta; Tyrosine-protein kinase HCK; Homeodomain-interacting protein kinase 2; Homeodomain-interacting protein kinase 3; Serine/threonine-protein kinase ICK; Inhibitor of nuclear factor kappa-B kinase subunit beta; Inhibitor of nuclear factor kappa-B kinase subunit epsilon; Insulin receptor; Insulin receptor-related protein; Interleukin-1 receptor-associated kinase 1; Interleukin-1 receptor-associated kinase 3; Interleukin-1 receptor-associated kinase 4; Tyrosine-protein kinase ITK/TSK; Tyrosine-protein kinase JAK2; Tyrosine-protein kinase JAK3; Vascular endothelial growth factor receptor 2; Serine/threonine-protein kinase SIK3; Mast/stem cell growth factor receptor Kit; Serine/threonine-protein kinase LATS1; Tyrosine-protein kinase Lck; LIM domain kinase 1; LIM domain kinase 2; Leucine-rich repeat serine/threonine-protein kinase 2; Leukocyte tyrosine kinase receptor; Tyrosine-protein kinase Lyn; Dual specificity mitogen-activated protein kinase kinase 2; Dual specificity mitogen-activated protein kinase kinase 3; Dual specificity mitogen-activated protein kinase kinase 5; Dual specificity mitogen-activated protein kinase kinase 6; Mitogen-activated protein kinase kinase kinase 1; Mitogen-activated protein kinase kinase kinase 10; Mitogen-activated protein kinase kinase kinase 11; Mitogen-activated protein kinase kinase kinase 12; Mitogen-activated protein kinase kinase kinase 13; Mitogen-activated protein kinase kinase kinase 15; Mitogen-activated protein kinase kinase kinase 2; Mitogen-activated protein kinase kinase kinase 3; Mitogen-activated protein kinase kinase kinase 4; Mitogen-activated protein kinase kinase kinase 6; Mitogen-activated protein kinase kinase kinase 9; Mitogen-activated protein kinase kinase kinase kinase 1; Mitogen-activated protein kinase kinase kinase kinase 2; Mitogen-activated protein kinase kinase kinase kinase 3; Mitogen-activated protein kinase kinase kinase kinase 4; Mitogen-activated protein kinase kinase kinase kinase 5; Mitogen-activated protein kinase 10; Mitogen-activated protein kinase 13; Mitogen-activated protein kinase 14; Mitogen-activated protein kinase 15; Mitogen-activated protein kinase 4; Mitogen-activated protein kinase 7; Mitogen-activated protein kinase 9; MAP kinase-activated protein kinase 5; Serine/threonine-protein kinase MARK1; Serine/threonine-protein kinase MARK2; MAP/microtubule affinity-regulating kinase 3; MAP/microtubule affinity-regulating kinase 4; CLIP-associating protein 1; Microtubule-associated serine/threonine-protein kinase 1; Megakaryocyte-associated tyrosine-protein kinase; Maternal embryonic leucine zipper kinase; Tyrosine-protein kinase Mer; Misshapen-like kinase 1; MAP kinase-interacting serine/threonine-protein kinase 1; MAP kinase-interacting serine/threonine-protein kinase 2; Macrophage-stimulating protein receptor; Muscle, skeletal receptor tyrosine-protein kinase; Myosin light chain kinase, smooth muscle; Myosin light chain kinase 2, skeletal/cardiac muscle; Myosin light chain kinase 3; Myosin light chain kinase family member 4; Myosin-IIIa; Serine/threonine-protein kinase Nek1; Serine/threonine-protein kinase Nek11; Serine/threonine-protein kinase Nek2; Serine/threonine-protein kinase Nek3; Serine/threonine-protein kinase Nek4; Serine/threonine-protein kinase Nek5; Serine/threonine-protein kinase Nek9; High affinity nerve growth factor receptor; BDNF/NT-3 growth factors receptor; NT-3 growth factor receptor; NUAK family SNF1-like kinase 1; NUAK family SNF1-like kinase 2; Serine/threonine-protein kinase OSR1; Serine/threonine-protein kinase PAK 1; Serine/threonine-protein kinase PAK 2; Serine/threonine-protein kinase PAK 3; Serine/threonine-protein kinase PAK 4; Serine/threonine-protein kinase PAK 6; Serine/threonine-protein kinase PAK 5; Cyclin-dependent kinase 16; Cyclin-dependent kinase 17; Platelet-derived growth factor receptor alpha; Platelet-derived growth factor receptor beta; 3-phosphoinositide-dependent protein kinase 1; Cyclin-dependent kinase 15; Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform; Phosphatidylinositol 4-kinase beta; Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta; Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gamma; Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform; Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform; Serine/threonine-protein kinase pim-1; Serine/threonine-protein kinase pim-3; Phosphatidylinositol 5-phosphate 4-kinase type-2 beta; Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma; Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase; Serine/threonine-protein kinase N1; Serine/threonine-protein kinase N2; Serine/threonine-protein kinase PLK1; Serine/threonine-protein kinase PLK2; Serine/threonine-protein kinase PLK3; Serine/threonine-protein kinase PLK4; 5'-AMP-activated protein kinase catalytic subunit alpha-1; 5'-AMP-activated protein kinase; cAMP-dependent protein kinase catalytic subunit beta; Protein kinase C delta type; Protein kinase C epsilon type; Protein kinase C gamma type (PRKCG); Protein kinase C iota type; Protein kinase C theta type; Serine/threonine-protein kinase D1; cGMP-dependent protein kinase 2; Serine/threonine-protein kinase PRP4 homolog; Focal adhesion kinase 1; Protein-tyrosine kinase 2-beta; Protein-tyrosine kinase 6; RAF proto-oncogene serine/threonine-protein kinase; Proto-oncogene tyrosine-protein kinase receptor Ret; Serine/threonine-protein kinase RIO1; Serine/threonine-protein kinase RIO2; Serine/threonine-protein kinase RIO3; Receptor-interacting serine/threonine-protein kinase 1; Receptor-interacting serine/threonine-protein kinase 2; Receptor-interacting serine/threonine-protein kinase 4; Rho-associated protein kinase 2; Proto-oncogene tyrosine-protein kinase ROS; Ribosomal protein S6 kinase alpha-1; Ribosomal protein S6 kinase alpha-3; Serine/threonine-protein kinase SBK1; Uncharacterized serine/threonine-protein kinase SBK3; Serine/threonine-protein kinase Sgk3; Serine/threonine-protein kinase SIK1; Serine/threonine-protein kinase SIK2; STE20-like serine/threonine-protein kinase; SNF-related serine/threonine-protein kinase; Proto-oncogene tyrosine-protein kinase Src; Tyrosine-protein kinase Srms; Serine/threonine-protein kinase 10; Serine/threonine-protein kinase 16; Serine/threonine-protein kinase 17A; Serine/threonine-protein kinase 17B; Serine/threonine-protein kinase 32A; Cytochrome P450 3A4; ATP-binding cassette sub-family G member 2; ATP-binding cassette sub-family B member 5; UDP-glucuronosyltransferase 1-9",antagonist; inhibitor; substrate
rpsD; rpsI; ; IL1B; ALOX5; MMP9; VEGFA; CASP1; CASP3; CYCS; SLC22A6; SLC22A7; ompF; ompC; MAPK1; MAPK10; MAPK11; MAPK12; MAPK13; MAPK14; MAPK15; MAPK3; MAPK4; MAPK6; MAPK7; MAPK8; MAPK9; NOS2,Minocycline,DB01017,J01AA08; J01AA20; A01AB23,"Minocycline was first described in the literacture in 1966.[A190681] It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria.[A190723] Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetracyclines.[A190723]

Minocycline was granted FDA approval on 30 June 1971.[L11695]","Agents Causing Muscle Toxicity; Agents that produce neuromuscular block (indirect); Alimentary Tract and Metabolism; Anti-Bacterial Agents; Anti-Infective Agents; Antibacterials for Systemic Use; Antiinfectives and Antiseptics for Local Oral Treatment; Antiinfectives for Systemic Use; Drugs causing inadvertant photosensitivity; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Medications that reduce magnesium levels; Naphthacenes; OAT1/SLC22A6 inhibitors; OAT3/SLC22A8 Inhibitors; Photosensitizing Agents; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Stomatological Preparations; Tetracyclines","30S ribosomal protein S4; 30S ribosomal protein S9; 16S ribosomal RNA; Interleukin-1 beta; Arachidonate 5-lipoxygenase; Matrix metalloproteinase-9; Vascular endothelial growth factor A; Caspase-1; Caspase-3; Cytochrome c; Solute carrier family 22 member 6; Solute carrier family 22 member 7; Outer membrane protein F; Outer membrane porin C; Mitogen-activated Protein Kinases; Nitric oxide synthase, inducible",inhibitor; modulator; negative modulator; substrate
MMP2; MMP9; MMP3; MMP1; MMP10; MMP7; MMP8; MMP11; MMP12; MMP13; MMP14; MMP15; MMP16; MMP17; MMP19; MMP20; MMP21; MMP23A; MMP24; MMP25; MMP26; MMP27; MMP28,Marimastat,DB00786,"","Used in the treatment of cancer, Marmiastat is an angiogenesis and metastasis inhibitor. As an angiogenesis inhibitor it limits the growth and production of blood vessels. As an antimetatstatic agent it prevents malignant cells from breaching the basement membranes.","Amines; Carboxylic Acids; Enzyme Inhibitors; Hydroxy Acids; Hydroxylamines; Metalloendopeptidases, antagonists & inhibitors",72 kDa type IV collagenase; Matrix metalloproteinase-9; Stromelysin-1; Interstitial collagenase; Stromelysin-2; Matrilysin; Neutrophil collagenase; Stromelysin-3; Macrophage metalloelastase; Collagenase 3; Matrix metalloproteinase-14; Matrix metalloproteinase-15; Matrix metalloproteinase-16; Matrix metalloproteinase-17; Matrix metalloproteinase-19; Matrix metalloproteinase-20; Matrix metalloproteinase-21; Matrix metalloproteinase-23; Matrix metalloproteinase-24; Matrix metalloproteinase-25; Matrix metalloproteinase-26; Matrix metalloproteinase-27; Matrix metalloproteinase-28,inhibitor; antagonist
ABL2; ABCA1; ACSS2; ALK; NAE1; PRKAA1; ARAF; ACVRL1; ACSL1; NT5C2; ASNA1; ABCC9; AKT1; ADRBK1; APAF1; ACSS1; ACVR1B; ACVR1; ABCB11; ASNS; CDK15; SLC25A4; ABCC8; ASS1; AFG3L2; ADRBK2; AMHR2; TNK2; ABL1; ADCY1; ABCB1; ABCG1; ABCC2; ADK; ABCC6; ABCC4; ABCC1; CFTR; PIK3CA; CSNK2A1; CSNK2B; P2RY11; PPP5C,ATP,DB00171,"",An adenine nucleotide containing three phosphate groups esterified to the sugar moiety. In addition to its crucial roles in metabolism adenosine triphosphate is a neurotransmitter.,"Adenine Nucleotides; Adenosine Triphosphate; Dietary Supplements; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Nucleic Acids, Nucleotides, and Nucleosides; Nucleotides; Purine Nucleotides; Purines; Ribonucleotides; Supplements","Abelson tyrosine-protein kinase 2; ATP-binding cassette sub-family A member 1; Acetyl-coenzyme A synthetase, cytoplasmic; ALK tyrosine kinase receptor; NEDD8-activating enzyme E1 regulatory subunit; 5'-AMP-activated protein kinase catalytic subunit alpha-1; Serine/threonine-protein kinase A-Raf; Serine/threonine-protein kinase receptor R3; Long-chain-fatty-acid--CoA ligase 1; Cytosolic purine 5'-nucleotidase; ATPase ASNA1; ATP-binding cassette sub-family C member 9; RAC-alpha serine/threonine-protein kinase; Beta-adrenergic receptor kinase 1; Apoptotic protease-activating factor 1; Acetyl-coenzyme A synthetase 2-like, mitochondrial; Activin receptor type-1B; Activin receptor type-1; Bile salt export pump; Asparagine synthetase [glutamine-hydrolyzing]; Cyclin-dependent kinase 15; ADP/ATP translocase 1; ATP-binding cassette sub-family C member 8; Argininosuccinate synthase; AFG3-like protein 2; Beta-adrenergic receptor kinase 2; Anti-Muellerian hormone type-2 receptor; Activated CDC42 kinase 1; Tyrosine-protein kinase ABL1; Adenylate cyclase type 1; P-glycoprotein 1; ATP-binding cassette sub-family G member 1; Canalicular multispecific organic anion transporter 1; Adenosine kinase; Multidrug resistance-associated protein 6; Multidrug resistance-associated protein 4; Multidrug resistance-associated protein 1; Cystic fibrosis transmembrane conductance regulator; Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform; Casein kinase II subunit alpha; Casein kinase II subunit beta; P2Y purinoceptor 11; Serine/threonine-protein phosphatase 5",inhibitor; substrate; cofactor
IKBKB; JUN; CCND1; MAPK3; MAPK1; AKT1; ABCC2; TXNRD1; ABCB1; CYP3A4; CDKN1A; HDAC1; PML; ALB,Arsenic trioxide,DB01169,L01XX27,"Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of dangerous adverse effects. The enzyme thioredoxin reductase has recently been identified as a target for arsenic trioxide.",Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Arsenicals; Cardiotoxic antineoplastic agents; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Drugs that are Mainly Renally Excreted; Highest Risk QTc-Prolonging Agents; Hyperglycemia-Associated Agents; Hypotensive Agents; Immunosuppressive Agents; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; Oxides; Oxygen Compounds; P-glycoprotein inhibitors; QTc Prolonging Agents,"Inhibitor of nuclear factor kappa-B kinase subunit beta; Transcription factor AP-1; G1/S-specific cyclin-D1; Mitogen-activated protein kinase 3; Mitogen-activated protein kinase 1; RAC-alpha serine/threonine-protein kinase; Canalicular multispecific organic anion transporter 1; Thioredoxin reductase 1, cytoplasmic; P-glycoprotein 1; Cytochrome P450 3A4; Cyclin-dependent kinase inhibitor 1; Histone deacetylase 1; Protein PML; Serum albumin",inducer; antagonist; inhibitor; substrate
ADRA1A; ADRA2A; ADRB2; MAOA; ADRB1; SLC6A3; SLC6A2; SLC6A4; NFATC1; TNF; NFKB1; ATF1; ATF2; ATF3; ATF4; ATF5; ATF6; ATF7; JDP2; FOS; JUN; IL2; ALB,Pseudoephedrine,DB00852,R01BA52; R01BA02,"Pseudoephedrine is structurally related to [ephedrine] but exerts a weaker effect on the sympathetic nervous system.[A188820,A188823] Both drugs naturally occur in in ephedra plant which have a history of use in traditional Eastern medicine and were first researched in the west in 1889.[A188823] The decongestant effect of pseudoephedrine was described in dogs in 1927.[A188823]",Adrenergic Agonists; Adrenergic alpha-1 Receptor Agonists; Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Adrenergic beta-Agonists; Agents producing tachycardia; Agents that produce hypertension; Alcohols; Alpha-and Beta-adrenergic Agonists; Amines; Amino Alcohols; Amphetamines; Anti-Asthmatic Agents; Autonomic Agents; Bronchodilator Agents; Cardiovascular Agents; Ethylamines; Hyperglycemia-Associated Agents; Monoamine Oxidase A Inhibitors  for interaction with Monoamine Oxidase A substrates; Nasal Decongestants; Nasal Decongestants for Systemic Use; Nasal Preparations; Norepinephrine Releasing Agent; Peripheral Nervous System Agents; Phenethylamines; Propanolamines; Propanols; Respiratory System; Respiratory System Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Sympathomimetic (Adrenergic) Agents; Sympathomimetics; Tumor Necrosis Factor Blockers; Vasoconstrictor Agents,"Alpha-1A adrenergic receptor; Alpha-2A adrenergic receptor; Beta-2 adrenergic receptor; Amine oxidase [flavin-containing] A; Beta-1 adrenergic receptor; Sodium-dependent dopamine transporter; Sodium-dependent noradrenaline transporter; Sodium-dependent serotonin transporter; Nuclear factor of activated T-cells, cytoplasmic 1; Tumor necrosis factor; Nuclear factor NF-kappa-B p105 subunit; activator protein 1; Interleukin-2; Serum albumin; Sodium-dependent noradrenaline transporter; Sodium-dependent dopamine transporter; Sodium-dependent serotonin transporter",agonist; partial agonist; inhibitor; binder
MAP2K1; MAP2K2; MAP2K3; MAP2K4; MAP2K5; MAP2K6; MAP2K7,Pimasertib,DB14904,"",Pimasertib is under investigation in clinical trial NCT01378377 (Combination Trial of Pimasertib (MSC1936369B) With Temsirolimus).,"Acids, Heterocyclic; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Nicotinic Acids; Protein Kinase Inhibitors; Pyridines",Mitogen-activated protein kinase kinase (MAPKK),inhibitor
MMP2; MMP9; MMP13; PTK2; SELE; CYP19A1,Endostatin,DB06423,"",,"Amino Acids, Peptides, and Proteins; Angiogenesis Inhibitors; Angiogenesis Modulating Agents; Angiogenic Proteins; Angiostatic Proteins; Antineoplastic Agents; Biological Factors; Collagen; Collagen Type XVIII; Compounds used in a research, industrial, or household setting; Extracellular Matrix Proteins; Growth Inhibitors; Growth Substances; Intercellular Signaling Peptides and Proteins; Non-Fibrillar Collagens; Peptides; Proteins; Scleroproteins",72 kDa type IV collagenase; Matrix metalloproteinase-9; Collagenase 3; Focal adhesion kinase 1; E-selectin; Cytochrome P450 19A1,substrate
IL6; TNF; IL1B; UGT1A1; CYP1A2; CYP2C19; MAP3K1; MAP2K2,Binimetinib,DB11967,L01XE41,"Binimetinib, also known as _Mektovi_, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with [Encorafenib] [A34275,L3335].

On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array BioPharma Inc.) in combination for patients with unresectable or metastatic melanoma with the BRAF V600E or V600K mutations, as detected by an FDA-approved test.[L3335]","Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Kinase Inhibitor; MAP Kinase Kinase 1, antagonists & inhibitors; MAP Kinase Kinase 2, antagonists & inhibitors; MAP Kinase, antagonists & inhibitors; Narrow Therapeutic Index Drugs; P-glycoprotein substrates with a Narrow Therapeutic Index; Protein Kinase Inhibitors; UGT1A1 Substrates; UGT1A1 Substrates with a Narrow Therapeutic Index",Interleukin-6; Tumor necrosis factor; Interleukin-1 beta; UDP-glucuronosyltransferase 1-1; Cytochrome P450 1A2; Cytochrome P450 2C19; Mitogen-activated protein kinase kinase kinase 1; Dual specificity mitogen-activated protein kinase kinase 2,substrate; inhibitor
PTGS1; PTGS2; AKR1C1; SLC22A6; ABCB1; CYP2C19; CYP2C9; PRKAA1; PRKAA2; PRKAB1; PRKAB2; PRKAG1; PRKAG2; PRKAG3; EDNRA; TP53; HSPA5; RPS6KA3; NFKBIA; TNFAIP6; CASP1; CASP3; IKBKB; MAPK1; MAPK15; MAPK3; MAPK4; MAPK6; MAPK7; CCND1; MYC; PCNA; ; UGT1A6; NAT2; SLC22A8; NEU1,Acetylsalicylic acid,DB00945,B01AC06; C07FX04; C10BX04; M01BA03; N02BA71; C10BX02; B01AC56; N02AJ07; N02AJ02; N02BA01; C10BX05; N02BA51; A01AD05; C10BX01; C07FX03; N02AJ18; C10BX12; C10BX08; C10BX06; C07FX02,"Also known as _Aspirin_, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects.  This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI) [FDA label].  

Interestingly, the results of various studies have demonstrated that long-term use of acetylsalicylic acid may decrease the risk of various cancers, including colorectal, esophageal, breast, lung, prostate, liver and skin cancer [A177325]. Aspirin is classified as a _non-selective cyclooxygenase (COX) inhibitor_ [A32682, A177268] and is available in many doses and forms, including chewable tablets, suppositories, extended release formulations, and others [L5968]. 

Acetylsalicylic acid is a very common cause of accidental poisoning in young children. It should be kept out of reach from young children, toddlers, and infants [FDA label].","Acids, Carbocyclic; Agents causing angioedema; Agents causing hyperkalemia; Agents that produce hypertension; Alimentary Tract and Metabolism; Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Inflammatory Agents, Non-Steroidal (Non-Selective); Antiinflammatory and Antirheumatic Products; Antiplatelet agents; Antipyretics; Benzene Derivatives; Blood and Blood Forming Organs; Carboxylic Acids; Cardiovascular Agents; Cardiovascular System; Cyclooxygenase Inhibitors; Cytochrome P-450 CYP2C19 Inducers; Cytochrome P-450 CYP2C19 Inducers (strength unknown); Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Decreased Platelet Aggregation; Decreased Prostaglandin Production; Drugs that are Mainly Renally Excreted; Hematologic Agents; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydroxybenzoates; Musculo-Skeletal System; Nephrotoxic agents; Non COX-2 selective NSAIDS; OAT1/SLC22A6 inhibitors; OAT3/SLC22A8 Inhibitors; P-glycoprotein inducers; P-glycoprotein substrates; Peripheral Nervous System Agents; Platelet Aggregation Inhibitors Excl. Heparin; Salicylates; Salicylic Acid and Derivatives; Sensory System Agents; Stomatological Preparations; UGT1A6 substrate",Prostaglandin G/H synthase 1; Prostaglandin G/H synthase 2; Aldo-keto reductase family 1 member C1; Solute carrier family 22 member 6; P-glycoprotein 1; Cytochrome P450 2C19; Cytochrome P450 2C9; 5'-AMP-activated protein kinase; Endothelin-1 receptor; Cellular tumor antigen p53; 78 kDa glucose-regulated protein; Ribosomal protein S6 kinase alpha-3; NF-kappa-B inhibitor alpha; Tumor necrosis factor-inducible gene 6 protein; Caspase-1; Caspase-3; Inhibitor of nuclear factor kappa-B kinase subunit beta; Extracellular signal-regulated kinase (ERK); G1/S-specific cyclin-D1; Myc proto-oncogene protein; Proliferating cell nuclear antigen; Cyclin A; UDP-glucuronosyltransferase 1-6; Arylamine N-acetyltransferase 2; Solute carrier family 22 member 8; Sialidase-1,inhibitor; substrate; inducer; modulator; activator; binder; downregulator
TNF; IL1B; IL6; NFKB2; NFKB1,Andrographolide,DB05767,"",Andrographolide (HMPL-004) is a botanical product extracted from a herb that occurs naturally in China. The herb has an extensive history of use in TCM for the treatment of upper respiratory tract infections and other inflammatory and infectious diseases.,"Analgesics; Analgesics, Non-Narcotic; Anti-Infective Agents; Anti-Inflammatory Agents; Antiparasitic Agents; Antiplatelet agents; Antiprotozoals; Antirheumatic Agents; Biological Products; Colitis, Ulcerative, drug therapy; Hematologic Agents; Hydrocarbons; Peripheral Nervous System Agents; Plant Preparations; Sensory System Agents; Stereoisomerism; Terpenes",Tumor necrosis factor; Interleukin-1 beta; Interleukin-6; Nuclear factor NF-kappa-B p100 subunit; Nuclear factor NF-kappa-B p105 subunit,""
ABL1; ABL2; SRC; FYN; LCK; YES1; KIT; PDGFRB; EPHA2; STAT5B; CYP3A4; ABCB1; ABCG2; CYP1A1; CYP1A2; CYP1B1; CYP3A5; FMO3; BTK; NR4A3; BCR; CSK; EPHA5; EPHB4; FGR; FRK; HSPA8; LYN; ZAK; MAPK14; PPAT,Dasatinib,DB01254,L01XE06,"Dasatinib is an oral dual BCR/ABL and Src family tyrosine kinase inhibitor approved for use in patients with chronic myelogenous leukemia (CML). The main targets of Dasatinib, are BCRABL, SRC, Ephrins and GFR.","Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Azoles; BCRP/ABCG2 Inhibitors; BCRP/ABCG2 Substrates; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (weak); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs causing inadvertant photosensitivity; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Immunosuppressive Agents; Kinase Inhibitor; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; P-glycoprotein inhibitors; P-glycoprotein substrates; P-glycoprotein substrates with a Narrow Therapeutic Index; Photosensitizing Agents; Potential QTc-Prolonging Agents; Protein Kinase Inhibitors; Pyrimidines; QTc Prolonging Agents; Sulfur Compounds; Thiazoles; Tyrosine Kinase Inhibitors",Tyrosine-protein kinase ABL1; Abelson tyrosine-protein kinase 2; Proto-oncogene tyrosine-protein kinase Src; Tyrosine-protein kinase Fyn; Tyrosine-protein kinase Lck; Tyrosine-protein kinase Yes; Mast/stem cell growth factor receptor Kit; Platelet-derived growth factor receptor beta; Ephrin type-A receptor 2; Signal transducer and activator of transcription 5B; Cytochrome P450 3A4; P-glycoprotein 1; ATP-binding cassette sub-family G member 2; Cytochrome P450 1A1; Cytochrome P450 1A2; Cytochrome P450 1B1; Cytochrome P450 3A5; Dimethylaniline monooxygenase [N-oxide-forming] 3; Tyrosine-protein kinase BTK; Nuclear receptor subfamily 4 group A member 3; Breakpoint cluster region protein; Tyrosine-protein kinase CSK; Ephrin type-A receptor 5; Ephrin type-B receptor 4; Tyrosine-protein kinase Fgr; Tyrosine-protein kinase FRK; Heat shock cognate 71 kDa protein; Tyrosine-protein kinase Lyn; Mitogen-activated protein kinase kinase kinase MLT; Mitogen-activated protein kinase 14; Amidophosphoribosyltransferase,multitarget; inhibitor; antagonist; substrate
MAPK14; TNF; IL1B; MT-CO2,Talmapimod,DB05412,"",Talmapimod is the first-generation oral p38 MAP kinase inhibitor developed by Scios. It has shown to be effective to cure inflammatory diseases such as Rheumatoid Arthritis.,"Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring",Mitogen-activated protein kinase 14; Tumor necrosis factor; Interleukin-1 beta; Cytochrome c oxidase subunit 2,""
MAPK14; TNF; IL1B; IL6,VX-702,DB05470,"","VX-702 is a small molecule investigational oral anti-cytokine therapy for treatment of inflammatory diseases, specifically rheumatoid arthritis (RA). It acts as a p38 MAP kinase inhibitor. In the future, VX-702 may be investigated for combination with methotrexate, a commonly used therapy for RA.","Amides; Benzene Derivatives; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic",Mitogen-activated protein kinase 14; Tumor necrosis factor; Interleukin-1 beta; Interleukin-6,""
TNFRSF1A; TNFRSF1B,Tasonermin,DB11626,L03AX11,Tasonermin is recombinant soluble form tumor necrosis factor &alpha; produced via _Escherichia coli_ cell culture.  It was approved for use by the European Medicines Agency in April of 1999 for use as an adjunt to surgery for the subsequent removal of the tumor and in palliative care for irresectable soft tissue sarcoma of the limbs as the product Beromun. It is administered with [DB01042] via mild hyperthermic isolated limb perfusion.,"Adjuvants, Immunologic; Antineoplastic and Immunomodulating Agents",Tumor necrosis factor receptor superfamily member 1A; Tumor necrosis factor receptor superfamily member 1B,agonist
IL1B; IL1A; IL1RN,Rilonacept,DB06372,L04AC04,"Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome (FCAS) and Muckle-Wells Syndrome (MWS), in adults and children greater than 12 years old.","Agents reducing cytokine levels; Amino Acids, Peptides, and Proteins; Anti-Inflammatory Agents; Antineoplastic and Immunomodulating Agents; Immunosuppressive Agents; Immunotherapy; Interleukin Inhibitors; Interleukin-1 Receptor Accessory Protein; Proteins; Receptors, Interleukin-1 Type I; Recombinant Proteins",Interleukin-1 beta; Interleukin-1 alpha; Interleukin-1 receptor antagonist protein,binder
CDK1; CDK2; MAPK3; MAPK1; CDK7; CDK9; CSNK1E; PTGS2,Seliciclib,DB06195,"","R-roscovitine (Seliciclib or CYC202) is a cyclin-dependent kinase (CDK) inhibitor that preferentially inhibits multiple enzyme targets including CDK2, CDK7 and CDK9, which alter the growth phase of treated cells. Developed by Cyclacel, seliciclib is being researched for the treatment of non-small cell lung cancer (NSCLC), leukemia, HIV infection, herpes simplex infection, and the mechanisms of chronic inflammation disorders.","Anti-Infective Agents; Antineoplastic Agents; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Protein Kinase Inhibitors; Purines",Cyclin-dependent kinase 1; Cyclin-dependent kinase 2; Mitogen-activated protein kinase 3; Mitogen-activated protein kinase 1; Cyclin-dependent kinase 7; Cyclin-dependent kinase 9; Casein kinase I isoform epsilon; Prostaglandin G/H synthase 2,inhibitor
TNF; IL1R1,SD118,DB05207,"","SD118 was previously under investigation in Japan for a different indication and now, following re-profiling and evaluation in experimental animal models, has demonstrated its potential as a new oral therapy for neuropathic pain.","",Tumor necrosis factor; Interleukin-1 receptor type 1,""
IL6; FLT1; IL1R1; TGFBR2; FGF1; IFNG; FGFR2; CSF2RA; PDGFRB; TGFB1; TNF,Foreskin fibroblast (neonatal),DB10770,"","Foreskin fibroblast-like stromal cells (FDSCs) are progenitors isolated from human tissue that can differentiate into various cell types [A32660].

Also known as Dermagraft, this device is a cryopreserved human fibroblast-derived dermal substitute. Composed of fibroblasts, extracellular matrix, and a bioabsorbable scaffold, it effectively supports wound healing [L2418].

Dermagraft has only been available in the United States as an investigational device (IDE). Dermagraft for the treatment of diabetic foot ulcers was approved for sale in Canada in 1997. Dermagraft was introduced in the United Kingdom in October 1997, and several other European countries, as well as New Zealand and Australia. The device is available for commercial distribution in Australia, Canada, Finland, France, Hong Kong, Ireland, The Netherlands, New Zealand, Singapore, and The United Kingdom [L2418].

The impact of diabetic foot ulcers (DFU) on individuals and society is devastating. Failure to observe proper wound care in this condition often results in amputation. If wound closure is achieved, it is likely to delay the need for surgical intervention and provide other benefits such as improvements in productivity, mental outlook, social interactions, and time at work, in addition to decreased mortality [L2438].

Interestingly, it has been shown that human foreskin cells possess immunosuppressive properties, which are mediated by other processes than that reported for bone marrow/stromal stem cells [A32655].  Dermagraft has been combined with [DB10772] to create a drug beneficial to patients with open burn wounds [L2427].",Allogeneic Cultured Cell Scaffold,Interleukin-6; Vascular endothelial growth factor receptor 1; Interleukin-1 receptor type 1; TGF-beta receptor type-2; Fibroblast growth factor 1; Interferon gamma; Fibroblast growth factor receptor 2; Granulocyte-macrophage colony-stimulating factor receptor subunit alpha; Platelet-derived growth factor receptor beta; Transforming growth factor beta-1; Tumor necrosis factor,agonist
TNF; IL1R1,OMS-103HP,DB05303,"","OMS103HP is the first drug being developed to improve joint function following arthroscopic surgery, one of the most common procedures performed today by orthopedic surgeons.","Acids, Carbocyclic; Azoles; Benzocycloheptenes; Carboxylic Acids; Dibenzocycloheptenes; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Imidazoles; Pharmaceutical Preparations; Phenylpropionates; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic",Tumor necrosis factor; Interleukin-1 receptor type 1,""
SOD1; AOC1; LOX; SLC31A1; SLC11A2; ALB; A2M; CP; ATOX1; ATP7A; ATP7B; CCS; COX17; MT-CO1; TYR; DBH; PAM; MAOA; MAOB; ANG; APP; HEPH; PRNP; AHCY; F5; F8; MTF1; MT1HL1; MT1A; MT1B; MT1E; MT1F; MT1G; MT1H; MT1L; MT1M; MT1X; MT2A; MT3; MT4; MT1DP; TESMIN; SLC31A2; HIST1H2BC; GAPDH; NME1; HIST1H1E; PRDX1; S100A8; RPSA; ACTG1; ENO1; EEF1A1; KRT8; P4HB; PDIA3; HSPD1; HSPA13; HSPA5; HSP90B1; TF; Lyar; RPS2; SRSF1; HNRNPA2B1; HNRNPH1; HNRNPH3; cbiD; HNRNPL; SFPQ; SF3A2; RACK1; ACTN1; ACY1; ANXA4; ANXA5; CALR; PKM; AKR1A1; CYB5R3; GSR; TKT; PRDX2; PRDX6; PPIA; HSPA8; HSP90AA1; PTGES3; STIP1; EEF1A1L14; EIF6; EIF4A1; GPI; LDHA; PGK1; TUBA3C; TUBB; CFL1; YWHAB; GOT1; GSS; HDGF; IDH3A; CLIC1; PSME1; PEBP1; PGAM1; RANBP1; UGDH; B2M; SCO1; GLRA1; HTT; NEIL1; NEIL2; HEPHL1; SERPINE1; S100A2; S100A4; SNCA; BDNF; PARK7; IAPP; TAC3; A1BG; AFM; AGT; AHSG; APCS; APOA1; APOA2; APOA4; APOBR; APOC2; APOC3; APOD; APOE; APOH; AZGP1; C1QC; C1S; C3; C4B; C4BPA; C5; C8B; C9; CFH; CFI; CLEC3B; CLU; F2; C1QBP; GSN; HBA1; HBB; CBX5; HPR; IGFALS; IGHG1; IGHG4; ; IGLL1; ITIH2; KNG1; KRT1; KRT10; KRT2; KRT9; LRG1; LUM; PGLYRP2; PLG; PON1; PPBP; SERPINA1; SERPINA4; SERPINA6; SERPINA7; SERPINC1; SERPIND1; SERPINF1; SERPINF2; SERPING1; TTR; VTN; APLP1,Copper,DB09130,"","Copper is a transition metal and a trace element in the body. It is important to the function of many enzymes including cytochrome c oxidase, monoamine oxidase and superoxide dismutase [FDA Label]. Copper is commonly used in contraceptive intrauterine devices (IUD) [L801].","Copper-containing Intrauterine Device; Decreased Embryonic Implantation; Decreased Sperm Motility; Diet, Food, and Nutrition; Elements; Food; Inhibit Ovum Fertilization; Metals; Metals, Heavy; Micronutrients; Minerals; Physiological Phenomena; Replacement Preparations; Trace Elements; Transition Elements","Superoxide dismutase [Cu-Zn]; Amiloride-sensitive amine oxidase [copper-containing]; Protein-lysine 6-oxidase; High affinity copper uptake protein 1; Natural resistance-associated macrophage protein 2; Serum albumin; Alpha-2-macroglobulin; Ceruloplasmin; Copper transport protein ATOX1; Copper-transporting ATPase 1; Copper-transporting ATPase 2; Copper chaperone for superoxide dismutase; Cytochrome c oxidase copper chaperone; Cytochrome c oxidase subunit 1; Tyrosinase; Dopamine beta-hydroxylase; Peptidyl-glycine alpha-amidating monooxygenase; Monoamine oxidase; Angiogenin; Amyloid beta A4 protein; Hephaestin; Major prion protein; Adenosylhomocysteinase; Coagulation factor V; Coagulation factor VIII; Metallothionein; Probable low affinity copper uptake protein 2; Histone H2B type 1-C/E/F/G/I; Glyceraldehyde-3-phosphate dehydrogenase; Nucleoside diphosphate kinase A; Histone H1.4; Peroxiredoxin-1; Protein S100-A8; 40S ribosomal protein SA; Actin, cytoplasmic 2; Alpha-enolase; Elongation factor 1-alpha 1; Keratin, type II cytoskeletal 8; Protein disulfide-isomerase; Protein disulfide-isomerase A3; 60 kDa heat shock protein, mitochondrial; Heat shock 70 kDa protein 13; 78 kDa glucose-regulated protein; Endoplasmin; Serotransferrin; Cell growth-regulating nucleolar protein; 40S ribosomal protein S2; Serine/arginine-rich splicing factor 1; Heterogeneous nuclear ribonucleoproteins A2/B1; Heterogeneous nuclear ribonucleoprotein H; Heterogeneous nuclear ribonucleoprotein H3; Cobalt-precorrin-5B C(1)-methyltransferase; Heterogeneous nuclear ribonucleoprotein L; Splicing factor, proline- and glutamine-rich; Splicing factor 3A subunit 2; Receptor of activated protein C kinase 1; Alpha-actinin-1; Aminoacylase-1; Annexin A4; Annexin A5; Calreticulin; Pyruvate kinase PKM; Alcohol dehydrogenase [NADP(+)]; NADH-cytochrome b5 reductase 3; Glutathione reductase, mitochondrial; Transketolase; Peroxiredoxin-2; Peroxiredoxin-6; Peptidyl-prolyl cis-trans isomerase A; Heat shock cognate 71 kDa protein; Heat shock protein HSP 90-alpha; Prostaglandin E synthase 3; Stress-induced-phosphoprotein 1; Translation elongation factor 1 alpha 1-like 14; Eukaryotic translation initiation factor 6; Eukaryotic initiation factor 4A-I; Glucose-6-phosphate isomerase; L-lactate dehydrogenase A chain; Phosphoglycerate kinase 1; Tubulin alpha-3C/D chain; Tubulin beta chain; Cofilin-1; 14-3-3 protein beta/alpha; Aspartate aminotransferase, cytoplasmic; Glutathione synthetase; Hepatoma-derived growth factor; Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial; Chloride intracellular channel protein 1; Proteasome activator complex subunit 1; Phosphatidylethanolamine-binding protein 1; Phosphoglycerate mutase 1; Ran-specific GTPase-activating protein; UDP-glucose 6-dehydrogenase; Beta-2-microglobulin; Protein SCO1 homolog, mitochondrial; Alternative prion protein; Glycine receptor subunit alpha-1; Huntingtin; Endonuclease 8-like 1; Endonuclease 8-like 2; Hephaestin-like protein 1; Plasminogen activator inhibitor 1; Protein S100-A2; Protein S100-A4; Alpha-synuclein; Brain-derived neurotrophic factor; Protein DJ-1; Islet amyloid polypeptide; Tachykinin-3; Alpha-1B-glycoprotein; Afamin; Angiotensinogen; Alpha-2-HS-glycoprotein; Serum amyloid P-component; Apolipoprotein A-I; Apolipoprotein A-II; Apolipoprotein A-IV; Apolipoprotein B receptor; Apolipoprotein C-II; Apolipoprotein C-III; Apolipoprotein D; Apolipoprotein E; Beta-2-glycoprotein 1; Zinc-alpha-2-glycoprotein; Complement C1q subcomponent subunit C; Complement C1s subcomponent; Complement C3; Complement C4-B; C4b-binding protein alpha chain; Complement C5; Complement component C8 beta chain; Complement component C9; Complement factor H; Complement factor I; Tetranectin; Clusterin; Prothrombin; Complement component 1 Q subcomponent-binding protein, mitochondrial; Gelsolin; Hemoglobin subunit alpha; Hemoglobin subunit beta; Chromobox protein homolog 5; Haptoglobin-related protein; Insulin-like growth factor-binding protein complex acid labile subunit; Ig gamma-1 chain C region; Ig gamma-4 chain C region; Ig kappa chain V-III region GOL; Immunoglobulin lambda-like polypeptide 1; Inter-alpha-trypsin inhibitor heavy chain H2; Kininogen-1; Keratin, type II cytoskeletal 1; Keratin, type I cytoskeletal 10; Keratin, type II cytoskeletal 2 epidermal; Keratin, type I cytoskeletal 9; Leucine-rich alpha-2-glycoprotein; Lumican; N-acetylmuramoyl-L-alanine amidase; Plasminogen; Serum paraoxonase/arylesterase 1; Platelet basic protein; Alpha-1-antitrypsin; Kallistatin; Corticosteroid-binding globulin; Thyroxine-binding globulin; Antithrombin-III; Heparin cofactor 2; Pigment epithelium-derived factor; Alpha-2-antiplasmin; Plasma protease C1 inhibitor; Transthyretin; Vitronectin; Amyloid-like protein 1",cofactor; substrate; binder; allosteric modulator
SLCO1B3; CCKAR; RAF1; MAPK3; EGF; PRKCB; CCKBR; SLCO1B1; SLCO2B1,Cholecystokinin,DB08862,V04CK02,"Cholecystokinin ( also known as _CCK or CCK-PZ_) is a peptide hormone of the gastrointestinal system which is responsible for stimulating the digestion of fat and protein. Cholecystokinin, previously called _pancreozymin_, is synthesized and secreted by enteroendocrine cells in the duodenum (the first portion of the small intestine) and leads to the release of bile and digestive enzymes. CCK also acts as an appetite suppressant and has been studied for weight management regimens [L1637]. 

Normally, it is an endogenous hormone but is available commercially for diagnostic processes and replacement in pancreatic insufficiency [L1646, L1647, L1648]. in the octapeptide form.



Cholecystokinin is one of the first gastrointestinal hormones discovered, identified more than 90 years ago due to its ability to stimulate gallbladder contraction in 1928. Soon after, it was recognized to be identical to the factor responsible for stimulating pancreatic exocrine secretion in 1943 [L1636]. This hormone has also been shown to have positive effects on enteric smooth muscle contraction and on nerve activity at multiple locations in the peripheral and central nervous system. In addition to its roles in promoting smooth muscle cell contraction/exocrine cell secretion, CCK promotes cell growth, energy production, gene expression and protein synthesis, processes that have profound for drug development [L1636].  This drug has also been investigated for possible antipsychotic properties, owing to its effect on CCK receptors in the brain [L1638].

Recent studies have suggested that cholecystokinin also plays a major role in inducing drug tolerance to opioids such as morphine and heroin, and is partially implicated in experiences of pain hypersensitivity during opioid withdrawal [A32101].","Amino Acids, Peptides, and Proteins; Cholagogues and Choleretics; Cholecystokinin, agonists; Cholecystokinin, antagonists & inhibitors; Diagnostic Agents; Gastrointestinal Agents; Gastrointestinal Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; OATP1B1/SLCO1B1 Inhibitors; OATP1B1/SLCO1B1 Substrates; OATP1B3 substrates; Organic Anion Transporting Polypeptide 2B1 Inhibitors; Peptides; Tests for Pancreatic Function",Solute carrier organic anion transporter family member 1B3; Cholecystokinin receptor type A; RAF proto-oncogene serine/threonine-protein kinase; Mitogen-activated protein kinase 3; Pro-epidermal growth factor; Protein kinase C beta type; Gastrin/cholecystokinin type B receptor; Solute carrier organic anion transporter family member 1B1; Solute carrier organic anion transporter family member 2B1,substrate; agonist; inhibitor
BDKRB1; MGMT; ALDOA; EEF1A1; ENO1; GAPDHS; NME1; P4HB; PDIA3; PRDX1; PSPH; TPI1; TUFM; ESR1; IL3; MT2A; CCS; HDAC1; HDAC4; MPG; SEMG1; SOD1; HDAC8; SIVA1; GLRA1; MDM2; INS; UTRN; ASPA; S100A8; S100A9; MMP9; TP73; S100A2; TP53; MT3; MT1A; A2M; AHSG; APOA1; APOBR; APOE; APOL1; C1QB; C1QC; C1R; C1S; C3; C4B; C4BPA; C4BPB; C5; BRCC3; CFH; CLU; CP; CPN1; CPN2; DCD; FGA; FN1; HBA1; HBB; HP; IGFALS; ITIH1; ITIH2; ITIH3; ITIH4; JCHAIN; KLKB1; KNG1; KRT9; ORM2; PGLYRP2; PON1; PZP; S100A7; SEPP1; SERPINA1; SERPINA3; SERPINA6; SERPIND1; SHBG; TF; TTR; VTN; APLP1; APLP2; APP; PARP1; CPE; ADH1C; IDE; CA2; ALB; SLC39A10; SLC30A7; SLC30A4; SLC39A6; SLC39A5; SLC39A2; SLC30A9; SLC30A1; SLC30A2; SLC39A7; SLC39A4; SLC30A3; SLC30A8; SLC39A12; SLC30A5; SLC30A10; SLC39A13; SLC39A8; SLC39A1; SLC39A14; SLC39A3; SLC39A9; SLC39A11; SLC30A6; APOB; HPX; HRG; F11; APOBEC1; SEMG2,"Zinc sulfate, unspecified form",DB14548,C05AX04,"Zinc sulfate is a common zinc supplement in parenteral nutrition.[A216916,L12888]",Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use; Cardiovascular System; Copper Absorption Inhibitor; Metal cations; Metal divalent cations; Vasoprotectives; Zinc Compounds,"B1 bradykinin receptor; Methylated-DNA--protein-cysteine methyltransferase; Fructose-bisphosphate aldolase A; Elongation factor 1-alpha 1; Alpha-enolase; Glyceraldehyde-3-phosphate dehydrogenase, testis-specific; Nucleoside diphosphate kinase A; Protein disulfide-isomerase; Protein disulfide-isomerase A3; Peroxiredoxin-1; Phosphoserine phosphatase; Triosephosphate isomerase; Elongation factor Tu, mitochondrial; Estrogen receptor alpha; Interleukin-3; Metallothionein-2; Copper chaperone for superoxide dismutase; Histone deacetylase 1; Histone deacetylase 4; DNA-3-methyladenine glycosylase; Semenogelin-1; Superoxide dismutase [Cu-Zn]; Histone deacetylase 8; Apoptosis regulatory protein Siva; Glycine receptor subunit alpha-1; E3 ubiquitin-protein ligase Mdm2; Insulin; Utrophin; Aspartoacylase; Protein S100-A8; Protein S100-A9; Matrix metalloproteinase-9; Tumor protein p73; Protein S100-A2; Cellular tumor antigen p53; Metallothionein-3; Metallothionein-1A; Alpha-2-macroglobulin; Alpha-2-HS-glycoprotein; Apolipoprotein A-I; Apolipoprotein B receptor; Apolipoprotein E; Apolipoprotein L1; Complement C1q subcomponent subunit B; Complement C1q subcomponent subunit C; Complement C1r subcomponent; Complement C1s subcomponent; Complement C3; Complement C4-B; C4b-binding protein alpha chain; C4b-binding protein beta chain; Complement C5; Lys-63-specific deubiquitinase BRCC36; Complement factor H; Clusterin; Ceruloplasmin; Carboxypeptidase N catalytic chain; Carboxypeptidase N subunit 2; Dermcidin; Fibrinogen alpha chain; Fibronectin; Hemoglobin subunit alpha; Hemoglobin subunit beta; Haptoglobin; Insulin-like growth factor-binding protein complex acid labile subunit; Inter-alpha-trypsin inhibitor heavy chain H1; Inter-alpha-trypsin inhibitor heavy chain H2; Inter-alpha-trypsin inhibitor heavy chain H3; Inter-alpha-trypsin inhibitor heavy chain H4; Immunoglobulin J chain; Plasma kallikrein; Kininogen-1; Keratin, type I cytoskeletal 9; Alpha-1-acid glycoprotein 2; N-acetylmuramoyl-L-alanine amidase; Serum paraoxonase/arylesterase 1; Pregnancy zone protein; Protein S100-A7; Selenoprotein P; Alpha-1-antitrypsin; Alpha-1-antichymotrypsin; Corticosteroid-binding globulin; Heparin cofactor 2; Sex hormone-binding globulin; Serotransferrin; Transthyretin; Vitronectin; Amyloid-like protein 1; Amyloid-like protein 2; Amyloid beta A4 protein; Poly [ADP-ribose] polymerase 1; Carboxypeptidase E; Alcohol dehydrogenase 1C; Insulin-degrading enzyme; Superoxide dismutase [Cu-Zn]; Carbonic anhydrase 2; Serum albumin; Zinc transporter ZIP10; Zinc transporter 7; Zinc transporter 4; Zinc transporter ZIP6; Zinc transporter ZIP5; Zinc transporter ZIP2; Zinc transporter 9; Zinc transporter 1; Zinc transporter 2; Zinc transporter SLC39A7; Zinc transporter ZIP4; Zinc transporter 3; Zinc transporter 8; Zinc transporter ZIP12; Zinc transporter 5; Zinc transporter 10; Zinc transporter ZIP13; Zinc transporter ZIP8; Zinc transporter ZIP1; Zinc transporter ZIP14; Zinc transporter ZIP3; Zinc transporter ZIP9; Zinc transporter ZIP11; Zinc transporter 6; Apolipoprotein B-100; Hemopexin; Histidine-rich glycoprotein; Coagulation factor XI; C->U-editing enzyme APOBEC-1; Semenogelin-2",agonist; stabilization; ligand; binder; inhibitor; cofactor; regulator; chaperone; inactivator; chelator; inducer; antagonist; modulator; component of; substrate; activator
BDKRB1; MGMT; ALDOA; EEF1A1; ENO1; GAPDHS; NME1; P4HB; PDIA3; PRDX1; PSPH; TPI1; TUFM; ESR1; IL3; MT2A; CCS; HDAC1; HDAC4; MPG; SEMG1; SOD1; HDAC8; SIVA1; GLRA1; MDM2; INS; UTRN; ASPA; S100A8; S100A9; MMP9; TP73; S100A2; TP53; MT3; PDCD6; DAND5; MT1A; A1BG; A2M; AGT; AHSG; APCS; APOA1; APOA2; APOA4; APOBR; APOE; APOL1; C1QB; C1QC; C1R; C1S; C3; C4B; C4BPA; C4BPB; C5; BRCC3; C8A; C8B; C8G; CFB; CFH; CFI; CLU; CP; CPN1; CPN2; DCD; DSP; F12; F13B; F2; FCN3; FGA; FN1; GSN; HBA1; HBB; HPR; HRNR; IGFALS; IGHA1; IGHM; IGKV1-17; ; IGLV3-21; ITIH1; ITIH2; ITIH3; ITIH4; JCHAIN; JUP; KLKB1; KNG1; KRT1; KRT10; KRT14; KRT16; KRT2; KRT5; KRT6A; KRT9; ORM2; PGLYRP2; PON1; PZP; S100A7; SEPP1; SERPINA1; SERPINA3; SERPINA4; SERPINA6; SERPIND1; SHBG; TF; TTR; VTN; APLP1; APLP2; APP; PARP1; CA1,Zinc,DB01593,C05AX04,"A metallic element of atomic number 30 and atomic weight 65.38. It is a necessary trace element in the diet, forming an essential part of many enzymes, and playing an important role in protein synthesis and in cell division. Zinc deficiency is associated with anemia, short stature, hypogonadism, impaired wound healing, and geophagia. It is identified by the symbol _Zn_ [L2098].

A newer study suggests implies that an imbalance of zinc is associated with the neuronal damage associated with traumatic brain injury, stroke, and seizures [A32465].

 Understanding the mechanisms that control brain zinc homeostasis is, therefore, imperative to the development of preventive and treatment regimens for these and other neurological disorders [A32465].

In addition to the above, recent review articles have already demonstrated the important role of zinc in the pathophysiology and treatment of affective disorders, plus discussed the potential value of zinc as a marker of these diseases [L2097].  Most recently, research has shown that polymorphism of the common polymorphism in zinc transporter _SLC30A8/ZnT8_ may increase susceptibility to type 2 diabetes provided novel insights into the role of zinc in diabetes [A32416].","Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use; Cardiovascular System; Copper Absorption Inhibitor; Diet, Food, and Nutrition; Elements; Food; Metal cations; Metal divalent cations; Metals; Metals, Heavy; Micronutrients; Minerals; Physiological Phenomena; Trace Elements; Transition Elements; Vasoprotectives; Zinc Compounds","B1 bradykinin receptor; Methylated-DNA--protein-cysteine methyltransferase; Fructose-bisphosphate aldolase A; Elongation factor 1-alpha 1; Alpha-enolase; Glyceraldehyde-3-phosphate dehydrogenase, testis-specific; Nucleoside diphosphate kinase A; Protein disulfide-isomerase; Protein disulfide-isomerase A3; Peroxiredoxin-1; Phosphoserine phosphatase; Triosephosphate isomerase; Elongation factor Tu, mitochondrial; Estrogen receptor alpha; Interleukin-3; Metallothionein-2; Copper chaperone for superoxide dismutase; Histone deacetylase 1; Histone deacetylase 4; DNA-3-methyladenine glycosylase; Semenogelin-1; Superoxide dismutase [Cu-Zn]; Histone deacetylase 8; Apoptosis regulatory protein Siva; Glycine receptor subunit alpha-1; E3 ubiquitin-protein ligase Mdm2; Insulin; Utrophin; Aspartoacylase; Protein S100-A8; Protein S100-A9; Matrix metalloproteinase-9; Tumor protein p73; Protein S100-A2; Cellular tumor antigen p53; Metallothionein-3; Programmed cell death protein 6; DAN domain family member 5; Metallothionein-1A; Alpha-1B-glycoprotein; Alpha-2-macroglobulin; Angiotensinogen; Alpha-2-HS-glycoprotein; Serum amyloid P-component; Apolipoprotein A-I; Apolipoprotein A-II; Apolipoprotein A-IV; Apolipoprotein B receptor; Apolipoprotein E; Apolipoprotein L1; Complement C1q subcomponent subunit B; Complement C1q subcomponent subunit C; Complement C1r subcomponent; Complement C1s subcomponent; Complement C3; Complement C4-B; C4b-binding protein alpha chain; C4b-binding protein beta chain; Complement C5; Lys-63-specific deubiquitinase BRCC36; Complement component C8 alpha chain; Complement component C8 beta chain; Complement component C8 gamma chain; Complement factor B; Complement factor H; Complement factor I; Clusterin; Ceruloplasmin; Carboxypeptidase N catalytic chain; Carboxypeptidase N subunit 2; Dermcidin; Desmoplakin; Coagulation factor XII; Coagulation factor XIII B chain; Prothrombin; Ficolin-3; Fibrinogen alpha chain; Fibronectin; Gelsolin; Hemoglobin subunit alpha; Hemoglobin subunit beta; Haptoglobin-related protein; Hornerin; Insulin-like growth factor-binding protein complex acid labile subunit; Ig alpha-1 chain C region; Ig mu chain C region; Immunoglobulin kappa variable 1-17; Ig kappa chain V-III region GOL; Immunoglobulin lambda variable 3-21; Inter-alpha-trypsin inhibitor heavy chain H1; Inter-alpha-trypsin inhibitor heavy chain H2; Inter-alpha-trypsin inhibitor heavy chain H3; Inter-alpha-trypsin inhibitor heavy chain H4; Immunoglobulin J chain; Junction plakoglobin; Plasma kallikrein; Kininogen-1; Keratin, type II cytoskeletal 1; Keratin, type I cytoskeletal 10; Keratin, type I cytoskeletal 14; Keratin, type I cytoskeletal 16; Keratin, type II cytoskeletal 2 epidermal; Keratin, type II cytoskeletal 5; Keratin, type II cytoskeletal 6A; Keratin, type I cytoskeletal 9; Alpha-1-acid glycoprotein 2; N-acetylmuramoyl-L-alanine amidase; Serum paraoxonase/arylesterase 1; Pregnancy zone protein; Protein S100-A7; Selenoprotein P; Alpha-1-antitrypsin; Alpha-1-antichymotrypsin; Kallistatin; Corticosteroid-binding globulin; Heparin cofactor 2; Sex hormone-binding globulin; Serotransferrin; Transthyretin; Vitronectin; Amyloid-like protein 1; Amyloid-like protein 2; Amyloid beta A4 protein; Poly [ADP-ribose] polymerase 1; Carbonic anhydrase 1",cofactor; substrate
IGF1R; SRC; ABL1; ABL2,XL228,DB05184,"","XL228 is a novel anticancer compound designed to inhibit the insulin-like growth factor type-1 receptor (IGF1R), Src and Abl tyrosine kinases  targets that play crucial roles in cancer cell proliferation, survival and metastasis.","",Insulin-like growth factor 1 receptor; Proto-oncogene tyrosine-protein kinase Src; Tyrosine-protein kinase ABL1; Abelson tyrosine-protein kinase 2,""
AKT1; MAPK1; PRKCA,Perifosine,DB06641,"",Perifosine is a novel alkylphospholipid with antiproliferative properties attributed to protein kinase B inhibition.,Amines; Onium Compounds; Quaternary Ammonium Compounds; Trimethyl Ammonium Compounds,RAC-alpha serine/threonine-protein kinase; Mitogen-activated protein kinase 1; Protein kinase C alpha type,""
HSD11B1; AKR1C4; AKR1C3; AKR1C2; TNF; CASP3; NFKB2; NFKB1; LPL; ALB; ABCB11,Glycyrrhizic acid,DB13751,A05BA08,"Glycyrrhizic acid is extracted from the root of the licorice plant; _Glycyrrhiza glabra_.[F79] It is a triterpene glycoside with glycyrrhetinic acid that possesses a wide range of pharmacological and biological activities. When extracted from the plant, it can be obtained in the form of ammonium glycyrrhizin and mono-ammonium glycyrrhizin.[T204] Glycyrrhizic acid has been developed in Japan and China as a hepatoprotective drug in cases of chronic hepatitis.[A33062] From January 2014, glycyrrhizic acid as part of the licorice extract was approved by the FDA as an existing food sweetener.[F80] It was approved by Health Canada to be used in over-the-counter products but all the products are currently on the status canceled post marketed.[L1113]","Alimentary Tract and Metabolism; Anti-Inflammatory Agents; Bile and Liver Therapy; BSEP/ABCB11 Substrates; Hydrocarbons; Liver Therapy; Liver Therapy, Lipotropics; Pentacyclic Triterpenes; Terpenes; Triterpenes",Corticosteroid 11-beta-dehydrogenase isozyme 1; Aldo-keto reductase family 1 member C4; Aldo-keto reductase family 1 member C3; Aldo-keto reductase family 1 member C2; Tumor necrosis factor; Caspase-3; Nuclear factor NF-kappa-B; Lipoprotein lipase; Serum albumin; Bile salt export pump,antagonist; substrate; translocation inhibitor; inducer; binder
ACHE; HTR2A; CYP3A4; CYP2D6; CYP2C9; BCHE; NOS1; TNFAIP6; IL1B; NFKB2; NFKB1; ABCG2; GRIN1; GRIN2A; GRIN2B; GRIN2C; GRIN2D; GRIN3A; GRIN3B,Donepezil,DB00843,N06DA52; N06DA53; N06DA02,"In 2016, the global burden of dementia was estimated to be 43.8 million, demonstrating a significant increase from a global prevalence of 20.2 million in 1990.[A182411] Donepezil, also known as Aricept, is a piperidine derivative acetylcholinesterase inhibitor used in the management of the dementia of Alzheimer's Disease, and in some cases, is used to manage other types of dementia. 

Donepezil was first approved by the FDA in 1996, and its extended-release form was approved in combination with [Memantine] in 2014 to manage moderate and severe forms of Alzheimer's dementia.[L7916,L7937] A donepezil transdermal delivery system, Adlarity, was approved by the FDA in March 2022 for the treatment of Alzheimer's dementia.[L41125] Though it does not alter the progression of Alzheimer's disease, donepezil is effective in managing the symptoms of its associated dementia.[T668]","Anti-Dementia Drugs; BCRP/ABCG2 Substrates; Bradycardia-Causing Agents; Central Nervous System Agents; Central Nervous System Depressants; Cholinergic Agents; Cholinesterase Inhibitors; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Indans; Indenes; Muscle Relaxants; Muscle Relaxants, Centrally Acting Agents; Nervous System; Neurotransmitter Agents; Nootropic Agents; Parasympathomemetic (Cholinergic) Agents; Piperidines; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Psychoanaleptics","Acetylcholinesterase; 5-hydroxytryptamine receptor 2A; Cytochrome P450 3A4; Cytochrome P450 2D6; Cytochrome P450 2C9; Cholinesterase; Nitric oxide synthase, brain; Tumor necrosis factor-inducible gene 6 protein; Interleukin-1 beta; Nuclear factor NF-kappa-B; ATP-binding cassette sub-family G member 2; NMDA receptor",inhibitor; inducer; substrate; downregulator
FOS; MYC; SELP; SERPINC1,Nadroparin,DB08813,B01AB06,"Nadroparin is a low molecular weight heparin (LMWH) which, when bound to antithrombin III (ATIII), accelerates the inactivation of factor II and factor Xa. Nadroparin halts the coagulation pathway by inhibiting the activation of thrombin (factor IIa) by factor Xa. The amplification of the fibrin clotting cascade is stopped once factors Xa and IIa are inactivated. It is derived from porcine sources and has a mean molecular size of 5000 daltons. Low molecular weight heparins are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin.",Agents causing hyperkalemia; Anticoagulants; Blood and Blood Forming Organs; Carbohydrates; Cardiovascular Agents; Fibrin Modulating Agents; Glycosaminoglycans; Hematologic Agents; Heparin (Low Molecular Weight); Heparin and similars; Polysaccharides,Proto-oncogene c-Fos; Myc proto-oncogene protein; P-selectin; Antithrombin-III,inhibitor; potentiator
TNF; IL5; RNASE3; NFKB1; MUC2; CYSLTR1; CYP3A4; ABCC2; CYP2C9; NFKB2; NFKB1,Pranlukast,DB01411,R03DC02,"Pranlukast is a cysteinyl leukotriene receptor-1 antagonist. It antagonizes or reduces bronchospasm caused, principally in asthmatics, by an allergic reaction to accidentally or inadvertently encountered allergens.","Agents to Treat Airway Disease; Anti-Asthmatic Agents; Benzopyrans; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs for Obstructive Airway Diseases; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hormone Antagonists; Hormones, Hormone Substitutes, and Hormone Antagonists; Leukotriene Antagonists; Pyrans; Respiratory System; Respiratory System Agents",Tumor necrosis factor; Interleukin-5; Eosinophil cationic protein; Nuclear factor NF-kappa-B p105 subunit; Mucin-2; Cysteinyl leukotriene receptor 1; Cytochrome P450 3A4; Canalicular multispecific organic anion transporter 1; Cytochrome P450 2C9; Nuclear factor NF-kappa-B,other/unknown; antagonist; substrate; inhibitor
BCR; ABL1; LYN; HCK; SRC; ABCB1; CYP3A4; CDK2; MAP2K1; MAP2K2; MAP3K2; CAMK2G; CYP2C8,Bosutinib,DB06616,L01XE14,"Bosutinib is a Bcr-Abl kinase inhibitor for the treatment of Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML). Compared to other tyrosine kinase inhibitors, it has a more favourable hematologic toxicity profile. FDA approved on September 4, 2012.","Amines; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Immunosuppressive Agents; Kinase Inhibitor; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; P-glycoprotein inhibitors; P-glycoprotein substrates; P-glycoprotein substrates with a Narrow Therapeutic Index; Protein Kinase Inhibitors; Tyrosine Kinase Inhibitors",Breakpoint cluster region protein; Tyrosine-protein kinase ABL1; Tyrosine-protein kinase Lyn; Tyrosine-protein kinase HCK; Proto-oncogene tyrosine-protein kinase Src; P-glycoprotein 1; Cytochrome P450 3A4; Cyclin-dependent kinase 2; Dual specificity mitogen-activated protein kinase kinase 1; Dual specificity mitogen-activated protein kinase kinase 2; Mitogen-activated protein kinase kinase kinase 2; Calcium/calmodulin-dependent protein kinase type II subunit gamma; Cytochrome P450 2C8,inhibitor; substrate
CDK2; CRK2; CDK4; MAPK1; MAPK3; SRPK2,Purvalanol,DB02733,"",,"",Cyclin-dependent kinase 2; Cell division control protein 2 homolog; Cyclin-dependent kinase 4; Mitogen-activated protein kinase 1; Mitogen-activated protein kinase 3; SRSF protein kinase 2,inhibitor
MAPK3; MAPK1,Ulixertinib,DB13930,"","Ulixertinib is a a novel, reversible, ATP-competitive ERK1/2 inhibitor with high potency and ERK1/2 selectivity [A31474]. It is currently in clinical trials for the treatment of a wide range of tumors.","Amines; Azoles; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Pyridines",Mitogen-activated protein kinase 3; Mitogen-activated protein kinase 1,inhibitor
CYP3A4; UGT1A9; RET; FLT1; KDR; FLT4; KIT; PDGFRA; PDGFRB; FGFR1; FGFR2; TEK; DDR2; NTRK1; EPHA2; RAF1; BRAF; CYP2C8; CYP2C9; CYP2B6; MAPK11; FRK; ABL1; ABCB1; ABCG2; UGT1A1; CYP2C19,Regorafenib,DB08896,L01XE21,"Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April 2017.","Amides; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; BCRP/ABCG2 Inhibitors; Benzene Derivatives; Bradycardia-Causing Agents; Cytochrome P-450 CYP2B6 Inhibitors; Cytochrome P-450 CYP2B6 Inhibitors (strength unknown); Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Hepatotoxic Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Kinase Inhibitor; Narrow Therapeutic Index Drugs; P-glycoprotein inhibitors; P-glycoprotein substrates; P-glycoprotein substrates with a Narrow Therapeutic Index; Protein Kinase Inhibitors; Tyrosine Kinase Inhibitors; UGT1A1 Inhibitors; UGT1A9 Inhibitors; UGT1A9 Substrates; UGT1A9 Substrates with a Narrow Therapeutic Index",Cytochrome P450 3A4; UDP-glucuronosyltransferase 1-9; Proto-oncogene tyrosine-protein kinase receptor Ret; Vascular endothelial growth factor receptor 1; Vascular endothelial growth factor receptor 2; Vascular endothelial growth factor receptor 3; Mast/stem cell growth factor receptor Kit; Platelet-derived growth factor receptor alpha; Platelet-derived growth factor receptor beta; Fibroblast growth factor receptor 1; Fibroblast growth factor receptor 2; Angiopoietin-1 receptor; Discoidin domain-containing receptor 2; High affinity nerve growth factor receptor; Ephrin type-A receptor 2; RAF proto-oncogene serine/threonine-protein kinase; Serine/threonine-protein kinase B-raf; Cytochrome P450 2C8; Cytochrome P450 2C9; Cytochrome P450 2B6; Mitogen-activated protein kinase 11; Tyrosine-protein kinase FRK; Tyrosine-protein kinase ABL1; P-glycoprotein 1; ATP-binding cassette sub-family G member 2; UDP-glucuronosyltransferase 1-1; Cytochrome P450 2C19,substrate; inhibitor
FGF1; EGFR; CSF2RA; IL1B; IL6; IFNG; FGFR2; PDGFRA; TGFBR2; TGFB1; TNF; VEGFA,Foreskin keratinocyte (neonatal),DB10772,"","Skin, the largest organ of the human body, plays the main role in protecting the body from mechanical damage. It is composed of epidermal, dermal and hypodermal layers. The barrier function of the skin owed to its avascular epidermal layer, which is made mainly of keratinocytes. The keratinocytes form a stratified epithelium, with growing basal cells at the innermost layer and the keratinized, and mostly impermeable outer stratum corneum layer on the surface [L2452].

Foreskin keratinocytes are a form of skin cells that are cultured as a skin cell replacement for wounds, to accelerate wound closure and healing [L2434], [L2460]. 

The defining moment in skin culture was in 1975 when Rheinwald and Green successfully grew human keratinocytes on lethally irradiated murine fibroblasts. In 1981, OConner and his group utilized cultured autologous epithelium to coat burn defects for the first time. To construct a ""living"" alternative, a dermal substitute based on collagen I gel was created with mesenchymal cells such as fibroblasts. When an epidermal layer was added, this approach became known as ""skin equivalent"", ""composite culture"" or ""organotypical culture"" [L2453].

Foreskin keratinocytes are an important ingredient in several skin substitutes [L2460], used for various indications. 
Keratinocytes are derived from neonatal foreskins and used to create a drug called _Apligraf_, a mixture of [DB10770] and keratinocytes. A gel made of bovine collagen is used as the matrix for cell growth and differentiation. Apligraf has been useful in the treatment of venous leg ulcers and diabetic foot ulcers, by increasing rates of wound healing and decreasing the time required for closure of wounds [L2452].

Orcel, another skin substitute,  is similar to Apligraf since it contains both fibroblasts and keratinocytes derived from neonatal foreskin, but in addition, utilizes a type I collagen sponge as its matrix. It is used for grafting onto partial-thickness wounds, where it offers a favorable matrix for host cell migration [L2452].",Allogeneic Cultured Cell Scaffold,Fibroblast growth factor 1; Epidermal growth factor receptor; Granulocyte-macrophage colony-stimulating factor receptor subunit alpha; Interleukin-1 beta; Interleukin-6; Interferon gamma; Fibroblast growth factor receptor 2; Platelet-derived growth factor receptor alpha; TGF-beta receptor type-2; Transforming growth factor beta-1; Tumor necrosis factor; Vascular endothelial growth factor A,agonist
TNF; IL1B; IL6,Dilmapimod,DB12140,"","Dilmapimod has been used in trials studying the treatment and diagnostic of Nerve Trauma, Inflammation, Pain, Neuropathic, Arthritis, Rheumatoid, and Coronary Heart Disease, among others. Dilmapimod (SB-681323) is a p38 MAP-kinase inhibitor that has potential uses in inflammatory conditions such as RA (Rheumatoid Arthritis). Previous p38 MAP-kinase inhibitors have been hindered in development by liver toxicity. Methotrexate (common treatment for RA patients) also has potential liver toxicity.}","Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; p38 Mitogen-Activated Protein Kinases, antagonists & inhibitors; Pyridines",Tumor necrosis factor; Interleukin-1 beta; Interleukin-6,""
MAPK14; MAPK1,SB220025,DB04338,"",,"Azoles; Calcium-Calmodulin-Dependent Protein Kinases, antagonists & inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring",Mitogen-activated protein kinase 14; Mitogen-activated protein kinase 1,""
MAPK14; MAPK1,4-[4-(4-Fluorophenyl)-2-[4-[(R)-methylsulfinyl]phenyl]-1H-imidazol-5-yl]pyridine,DB08521,"",,"",Mitogen-activated protein kinase 14; Mitogen-activated protein kinase 1,""
MMP2; MMP9; MMP12,AE-941,DB05387,"","AE-941 is a naturally occurring anti-angiogenic compound, extracted from cartilage, with multiple anti-angiogenic mechanisms of action that provide broad therapeutic potential for a number of diseases. It is currently in international Phase III trials for renal cell carcinoma and non-small-cell lung cancer.",Cartilage; Complex Mixtures,72 kDa type IV collagenase; Matrix metalloproteinase-9; Macrophage metalloelastase,""
ACE; ALB; MMP2; MMP9; ABCB1; SLC15A1; SLC22A6; LTA4H; BDKRB1,Captopril,DB01197,C09AA01; C09BA01,"Captopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Captopril may be used in the treatment of hypertension.","ACE Inhibitors and Diuretics; Agents Acting on the Renin-Angiotensin System; Agents causing angioedema; Agents causing hyperkalemia; Agents Causing Muscle Toxicity; Amino Acids; Amino Acids, Cyclic; Amino Acids, Peptides, and Proteins; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Antihypertensive Agents Indicated for Hypertension; Cardiovascular Agents; Cardiovascular System; Drugs causing inadvertant photosensitivity; Enzyme Inhibitors; Hypotensive Agents; Imino Acids; OAT1/SLC22A6 inhibitors; OAT1/SLC22A6 Substrates; OAT3/SLC22A8 Substrates; P-glycoprotein inhibitors; Photosensitizing Agents; Protease Inhibitors",Angiotensin-converting enzyme; Serum albumin; 72 kDa type IV collagenase; Matrix metalloproteinase-9; P-glycoprotein 1; Solute carrier family 15 member 1; Solute carrier family 22 member 6; Leukotriene A-4 hydrolase; B1 bradykinin receptor,inhibitor; other/unknown; substrate
BDKRB1; MGMT; ALDOA; EEF1A1; ENO1; GAPDHS; NME1; P4HB; PDIA3; PRDX1; PSPH; TPI1; TUFM; ESR1; IL3; MT2A; CCS; HDAC1; HDAC4; MPG; SEMG1; SOD1; HDAC8; SIVA1; GLRA1; MDM2; INS; UTRN; ASPA; S100A8; S100A9; MMP9; TP73; S100A2; TP53; MT3; PDCD6; DAND5; MT1A; A1BG; A2M; AGT; AHSG; APCS; APOA1; APOA2; APOA4; APOBR; APOE; APOL1; C1QB; C1QC; C1R; C1S; C3; C4B; C4BPA; C4BPB; C5; BRCC3; C8A; C8B; C8G; CFB; CFH; CFI; CLU; CP; CPN1; CPN2; DCD; DSP; F12; F13B; F2; FCN3; FGA; FN1; GSN; HBA1; HBB; HPR; HRNR; IGFALS; IGHA1; IGHM; IGKV1-17; ; IGLV3-21; ITIH1; ITIH2; ITIH3; ITIH4; JCHAIN; JUP; KLKB1; KNG1; KRT1; KRT10; KRT14; KRT16; KRT2; KRT5; KRT6A; KRT9; ORM2; PGLYRP2; PON1; PZP; S100A7; SEPP1; SERPINA1; SERPINA3; SERPINA4; SERPINA6; SERPIND1; SHBG; TF; TTR; VTN; APLP1; APLP2; APP; PARP1; CA1; CPE; ADH1C; IDE,Zinc acetate,DB14487,C05AX04; A16AX05,,"Acetates; Acids, Acyclic; Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use; Alimentary Tract and Metabolism; Carboxylic Acids; Cardiovascular System; Copper Absorption Inhibitor; Metal cations; Metal divalent cations; Minerals; Various Alimentary Tract and Metabolism Products; Vasoprotectives; Zinc Compounds","B1 bradykinin receptor; Methylated-DNA--protein-cysteine methyltransferase; Fructose-bisphosphate aldolase A; Elongation factor 1-alpha 1; Alpha-enolase; Glyceraldehyde-3-phosphate dehydrogenase, testis-specific; Nucleoside diphosphate kinase A; Protein disulfide-isomerase; Protein disulfide-isomerase A3; Peroxiredoxin-1; Phosphoserine phosphatase; Triosephosphate isomerase; Elongation factor Tu, mitochondrial; Estrogen receptor alpha; Interleukin-3; Metallothionein-2; Copper chaperone for superoxide dismutase; Histone deacetylase 1; Histone deacetylase 4; DNA-3-methyladenine glycosylase; Semenogelin-1; Superoxide dismutase [Cu-Zn]; Histone deacetylase 8; Apoptosis regulatory protein Siva; Glycine receptor subunit alpha-1; E3 ubiquitin-protein ligase Mdm2; Insulin; Utrophin; Aspartoacylase; Protein S100-A8; Protein S100-A9; Matrix metalloproteinase-9; Tumor protein p73; Protein S100-A2; Cellular tumor antigen p53; Metallothionein-3; Programmed cell death protein 6; DAN domain family member 5; Metallothionein-1A; Alpha-1B-glycoprotein; Alpha-2-macroglobulin; Angiotensinogen; Alpha-2-HS-glycoprotein; Serum amyloid P-component; Apolipoprotein A-I; Apolipoprotein A-II; Apolipoprotein A-IV; Apolipoprotein B receptor; Apolipoprotein E; Apolipoprotein L1; Complement C1q subcomponent subunit B; Complement C1q subcomponent subunit C; Complement C1r subcomponent; Complement C1s subcomponent; Complement C3; Complement C4-B; C4b-binding protein alpha chain; C4b-binding protein beta chain; Complement C5; Lys-63-specific deubiquitinase BRCC36; Complement component C8 alpha chain; Complement component C8 beta chain; Complement component C8 gamma chain; Complement factor B; Complement factor H; Complement factor I; Clusterin; Ceruloplasmin; Carboxypeptidase N catalytic chain; Carboxypeptidase N subunit 2; Dermcidin; Desmoplakin; Coagulation factor XII; Coagulation factor XIII B chain; Prothrombin; Ficolin-3; Fibrinogen alpha chain; Fibronectin; Gelsolin; Hemoglobin subunit alpha; Hemoglobin subunit beta; Haptoglobin-related protein; Hornerin; Insulin-like growth factor-binding protein complex acid labile subunit; Ig alpha-1 chain C region; Ig mu chain C region; Immunoglobulin kappa variable 1-17; Ig kappa chain V-III region GOL; Immunoglobulin lambda variable 3-21; Inter-alpha-trypsin inhibitor heavy chain H1; Inter-alpha-trypsin inhibitor heavy chain H2; Inter-alpha-trypsin inhibitor heavy chain H3; Inter-alpha-trypsin inhibitor heavy chain H4; Immunoglobulin J chain; Junction plakoglobin; Plasma kallikrein; Kininogen-1; Keratin, type II cytoskeletal 1; Keratin, type I cytoskeletal 10; Keratin, type I cytoskeletal 14; Keratin, type I cytoskeletal 16; Keratin, type II cytoskeletal 2 epidermal; Keratin, type II cytoskeletal 5; Keratin, type II cytoskeletal 6A; Keratin, type I cytoskeletal 9; Alpha-1-acid glycoprotein 2; N-acetylmuramoyl-L-alanine amidase; Serum paraoxonase/arylesterase 1; Pregnancy zone protein; Protein S100-A7; Selenoprotein P; Alpha-1-antitrypsin; Alpha-1-antichymotrypsin; Kallistatin; Corticosteroid-binding globulin; Heparin cofactor 2; Sex hormone-binding globulin; Serotransferrin; Transthyretin; Vitronectin; Amyloid-like protein 1; Amyloid-like protein 2; Amyloid beta A4 protein; Poly [ADP-ribose] polymerase 1; Carbonic anhydrase 1; Carboxypeptidase E; Alcohol dehydrogenase 1C; Insulin-degrading enzyme; Superoxide dismutase [Cu-Zn]",ligand; inhibitor
BDKRB1; MGMT; ALDOA; EEF1A1; ENO1; GAPDHS; NME1; P4HB; PDIA3; PRDX1; PSPH; TPI1; TUFM; ESR1; IL3; MT2A; CCS; HDAC1; HDAC4; MPG; SEMG1; SOD1; HDAC8; SIVA1; GLRA1; MDM2; INS; UTRN; ASPA; S100A8; S100A9; MMP9; TP73; S100A2; TP53; MT3; MT1A; A2M; AHSG; APOA1; APOBR; APOE; APOL1; C1QB; C1QC; C1R; C1S; C3; C4B; C4BPA; C4BPB; C5; BRCC3; CFH; CLU; CP; CPN1; CPN2; DCD; FGA; FN1; HBA1; HBB; HP; IGFALS; ITIH1; ITIH2; ITIH3; ITIH4; JCHAIN; KLKB1; KNG1; KRT9; ORM2; PGLYRP2; PON1; PZP; S100A7; SEPP1; SERPINA1; SERPINA3; SERPINA6; SERPIND1; SHBG; TF; TTR; VTN; APLP1; APLP2; APP; PARP1; CPE; ADH1C; IDE; CA2; ALB; SLC39A10; SLC30A7; SLC30A4; SLC39A6; SLC39A5; SLC39A2; SLC30A9; SLC30A1; SLC30A2; SLC39A7; SLC39A4; SLC30A3; SLC30A8; SLC39A12; SLC30A5; SLC30A10; SLC39A13; SLC39A8; SLC39A1; SLC39A14; SLC39A3; SLC39A9; SLC39A11; SLC30A6; APOB; HPX; HRG; F11; APOBEC1; SEMG2,Zinc chloride,DB14533,C05AX04; B05XA12,"Zinc chloride is a solution of ions indicated for use in total parenteral nutrition to maintain zinc levels and prevent deficiency syndromes.[L14189]

Zinc chloride was granted FDA approval before 26 June 1986.[L14189]","Acids; Acids, Noncarboxylic; Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use; Anions; Basic Ointments and Protectants; Blood and Blood Forming Organs; Blood Substitutes and Perfusion Solutions; Cardiovascular System; Chlorine Compounds; Compounds used in a research, industrial, or household setting; Copper Absorption Inhibitor; Cosmetics; Dental Agents; EENT Drugs, Miscellaneous; Electrolyte Solutions; Electrolytes; Household Products; I.V. Solution Additives; Ions; Manufactured Materials; Metal cations; Metal divalent cations; Mouthwashes; Skin Ulcer, drug therapy; Vasoprotectives; Zinc Compounds","B1 bradykinin receptor; Methylated-DNA--protein-cysteine methyltransferase; Fructose-bisphosphate aldolase A; Elongation factor 1-alpha 1; Alpha-enolase; Glyceraldehyde-3-phosphate dehydrogenase, testis-specific; Nucleoside diphosphate kinase A; Protein disulfide-isomerase; Protein disulfide-isomerase A3; Peroxiredoxin-1; Phosphoserine phosphatase; Triosephosphate isomerase; Elongation factor Tu, mitochondrial; Estrogen receptor alpha; Interleukin-3; Metallothionein-2; Copper chaperone for superoxide dismutase; Histone deacetylase 1; Histone deacetylase 4; DNA-3-methyladenine glycosylase; Semenogelin-1; Superoxide dismutase [Cu-Zn]; Histone deacetylase 8; Apoptosis regulatory protein Siva; Glycine receptor subunit alpha-1; E3 ubiquitin-protein ligase Mdm2; Insulin; Utrophin; Aspartoacylase; Protein S100-A8; Protein S100-A9; Matrix metalloproteinase-9; Tumor protein p73; Protein S100-A2; Cellular tumor antigen p53; Metallothionein-3; Metallothionein-1A; Alpha-2-macroglobulin; Alpha-2-HS-glycoprotein; Apolipoprotein A-I; Apolipoprotein B receptor; Apolipoprotein E; Apolipoprotein L1; Complement C1q subcomponent subunit B; Complement C1q subcomponent subunit C; Complement C1r subcomponent; Complement C1s subcomponent; Complement C3; Complement C4-B; C4b-binding protein alpha chain; C4b-binding protein beta chain; Complement C5; Lys-63-specific deubiquitinase BRCC36; Complement factor H; Clusterin; Ceruloplasmin; Carboxypeptidase N catalytic chain; Carboxypeptidase N subunit 2; Dermcidin; Fibrinogen alpha chain; Fibronectin; Hemoglobin subunit alpha; Hemoglobin subunit beta; Haptoglobin; Insulin-like growth factor-binding protein complex acid labile subunit; Inter-alpha-trypsin inhibitor heavy chain H1; Inter-alpha-trypsin inhibitor heavy chain H2; Inter-alpha-trypsin inhibitor heavy chain H3; Inter-alpha-trypsin inhibitor heavy chain H4; Immunoglobulin J chain; Plasma kallikrein; Kininogen-1; Keratin, type I cytoskeletal 9; Alpha-1-acid glycoprotein 2; N-acetylmuramoyl-L-alanine amidase; Serum paraoxonase/arylesterase 1; Pregnancy zone protein; Protein S100-A7; Selenoprotein P; Alpha-1-antitrypsin; Alpha-1-antichymotrypsin; Corticosteroid-binding globulin; Heparin cofactor 2; Sex hormone-binding globulin; Serotransferrin; Transthyretin; Vitronectin; Amyloid-like protein 1; Amyloid-like protein 2; Amyloid beta A4 protein; Poly [ADP-ribose] polymerase 1; Carboxypeptidase E; Alcohol dehydrogenase 1C; Insulin-degrading enzyme; Superoxide dismutase [Cu-Zn]; Carbonic anhydrase 2; Serum albumin; Zinc transporter ZIP10; Zinc transporter 7; Zinc transporter 4; Zinc transporter ZIP6; Zinc transporter ZIP5; Zinc transporter ZIP2; Zinc transporter 9; Zinc transporter 1; Zinc transporter 2; Zinc transporter SLC39A7; Zinc transporter ZIP4; Zinc transporter 3; Zinc transporter 8; Zinc transporter ZIP12; Zinc transporter 5; Zinc transporter 10; Zinc transporter ZIP13; Zinc transporter ZIP8; Zinc transporter ZIP1; Zinc transporter ZIP14; Zinc transporter ZIP3; Zinc transporter ZIP9; Zinc transporter ZIP11; Zinc transporter 6; Apolipoprotein B-100; Hemopexin; Histidine-rich glycoprotein; Coagulation factor XI; C->U-editing enzyme APOBEC-1; Semenogelin-2",agonist; stabilization; ligand; binder; inhibitor; cofactor; regulator; chaperone; inactivator; chelator; inducer; antagonist; modulator; component of; substrate; activator
PPP1CA; PPP2R1A; PPP2CA; PPP2R5C; PPP2R2A,"2,6,8-Trimethyl-3-Amino-9-Benzyl-9-Methoxynonanoic Acid",DB02506,"",,"",Serine/threonine-protein phosphatase PP1-alpha catalytic subunit; Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha isoform; Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform; Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit gamma isoform; Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B alpha isoform,""
PPP1CC,Calyculin A,DB02860,"",,"Azoles; Biological Factors; Carcinogens; Cardiovascular Agents; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Noxae; Phosphoprotein Phosphatases, antagonists & inhibitors; Toxic Actions; Toxins, Biological; Vasoconstrictor Agents",Serine/threonine-protein phosphatase PP1-gamma catalytic subunit,""
TNFRSF11A; HIF1A; STAT3,ENMD-1198,DB05959,"",,Estranes; Fused-Ring Compounds; Polycyclic Compounds; Steroids,Tumor necrosis factor receptor superfamily member 11A; Hypoxia-inducible factor 1-alpha; Signal transducer and activator of transcription 3,""
AR; CYP19A1; MAOB; MAOA; FOS; HTR2A; HTR2B; HTR2C; HTR1B; IGF1R; DRD1; DRD5; DRD2; DRD3; DRD4; UGT2B7; UGT1A4; UGT2B4; UGT1A3; UGT1A1; UGT1A10; SHBG,Nandrolone decanoate,DB08804,"","Nandrolone decanoate, also known as nandrolone caprinate, is an alkylated anabolic steroid indicated in the management of anemia of renal insufficiency and as an adjunct therapy in the treatment of senile and postmenopausal osteoporosis.[A233789,A233849,L32564,L9464] The process for creating esters of [nandrolone] was patented in Spain in 1959[L33244] and in 1960, it was described as having a long duration of action and strong anabolic effect compared to nandrolone and other esters.[A233849]

Nandrolone decanoate was granted FDA approval on 5 October 1962.[L32564]","Anabolic Agents; Androgens; Bone Density Conservation Agents; Estranes; Estrenes; Fused-Ring Compounds; Gonadal Hormones; Gonadal Steroid Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Monoamine Oxidase A Inhibitors  for interaction with Monoamine Oxidase A substrates; Nandrolone and esters; Polycyclic Compounds; Steroids; Testosterone Congeners; Thyroxine-binding globulin inhibitors; UGT1A1 Substrates; UGT1A3 substrates; UGT1A4 substrates; UGT2B7 substrates",Androgen receptor; Cytochrome P450 19A1; Amine oxidase [flavin-containing] B; Amine oxidase [flavin-containing] A; Proto-oncogene c-Fos; 5-hydroxytryptamine 2 receptor; 5-hydroxytryptamine receptor 1B; Insulin-like growth factor 1 receptor; Dopamine receptor; UDP-glucuronosyltransferase 2B7; UDP-glucuronosyltransferase 1-4; UDP-glucuronosyltransferase 2B4; UDP-glucuronosyltransferase 1-3; UDP-glucuronosyltransferase 1-1; UDP-glucuronosyltransferase 1-10; Sex hormone-binding globulin,agonist; inducer; inhibitor; modulator; substrate; binder
ACTG1; ALDH7A1; ANXA2; ATP5A1; ATP5L; ATP5O; CAST; CCT3; CFL1; CLIC1; CSRP1; DPYSL2; DSP; EEF1A1; ENO1; FLNA; FTO; G6PD; GAPDHS; GPI; HNRNPA2B1; HNRNPD; HNRNPK; HP1BP3; HSPB1; IQGAP1; KHSRP; LDHA; LDHB; LGALS1; MAP4; MDH1; NPEPPS; PFN1; PGK1; PKM; PPIA; PRDX1; RPL10; RPL14; RPL18; RPL23A; RPL35; RPL4; RPS13; RPS17; RPS18; RPS19; RPS28; RPS5; RPS6; RPS8; RPS9; SF1; SFPQ; SNRPD2; SRP14; SRSF4; TAGLN; TAGLN2; TPI1; TPM1; TUBA1A; VIM; ZYX; HSPA8; TUBB6; TUBB4A; TUBB; ALDOA; GAPDH; CYCS; PGAM1; MYH9; P4HB; DDX5; SHMT2; DDX39B; NPM1; TCTP; serca; OAT; MEF-1; MDR1; ; H45; LACZ; ENO; SERA5; GBP; ATP6; vapA; ACS3; CRT; MSP-1; HK; TPx1; Sec31p; RESA; UAP56; CPK4; PKAr; tlp1; pdx1; UGT1A9; UGT2B7; ALB; CYP2D6; CYP2C19,Artenimol,DB11638,P01BF05; P01BE05,Artenimol is an artemisinin derivative and antimalarial agent used in the treatment of uncomplicated *Plasmodium falciparum* infections [FDA Label]. It was first authorized for market by the European Medicines Agency in October 2011 in combination with [DB13941] as the product Eurartesim. Artemisinin combination therapy is highly effective against malaria and stongly recommended by the World Health Organization [L1156].,"Anti-Infective Agents; Antimalarials; Antiparasitic Agents; Antiparasitic Products, Insecticides and Repellents; Antiprotozoals; Artemisia; Artemisinin and derivatives; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 Inhibitors (weak); Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Free Radicals; Hydrocarbons; Peroxides; Sesquiterpenes; Terpenes; UGT1A9 Substrates; UGT2B7 substrates","Actin, cytoplasmic 2; Alpha-aminoadipic semialdehyde dehydrogenase; Annexin A2; ATP synthase subunit alpha, mitochondrial; ATP synthase subunit g, mitochondrial; ATP synthase subunit O, mitochondrial; Calpastatin; T-complex protein 1 subunit gamma; Cofilin-1; Chloride intracellular channel protein 1; Cysteine and glycine-rich protein 1; Dihydropyrimidinase-related protein 2; Desmoplakin; Elongation factor 1-alpha 1; Alpha-enolase; Filamin-A; Alpha-ketoglutarate-dependent dioxygenase FTO; Glucose-6-phosphate 1-dehydrogenase; Glyceraldehyde-3-phosphate dehydrogenase, testis-specific; Glucose-6-phosphate isomerase; Heterogeneous nuclear ribonucleoproteins A2/B1; Heterogeneous nuclear ribonucleoprotein D0; Heterogeneous nuclear ribonucleoprotein K; Heterochromatin protein 1-binding protein 3; Heat shock protein beta-1; Ras GTPase-activating-like protein IQGAP1; Far upstream element-binding protein 2; L-lactate dehydrogenase A chain; L-lactate dehydrogenase B chain; Galectin-1; Microtubule-associated protein 4; Malate dehydrogenase, cytoplasmic; Puromycin-sensitive aminopeptidase; Profilin-1; Phosphoglycerate kinase 1; Pyruvate kinase PKM; Peptidyl-prolyl cis-trans isomerase A; Peroxiredoxin-1; 60S ribosomal protein L10; 60S ribosomal protein L14; 60S ribosomal protein L18; 60S ribosomal protein L23a; 60S ribosomal protein L35; 60S ribosomal protein L4; 40S ribosomal protein S13; 40S ribosomal protein S17; 40S ribosomal protein S18; 40S ribosomal protein S19; 40S ribosomal protein S28; 40S ribosomal protein S5; 40S ribosomal protein S6; 40S ribosomal protein S8; 40S ribosomal protein S9; Splicing factor 1; Splicing factor, proline- and glutamine-rich; Small nuclear ribonucleoprotein Sm D2; Signal recognition particle 14 kDa protein; Serine/arginine-rich splicing factor 4; Transgelin; Transgelin-2; Triosephosphate isomerase; Tropomyosin alpha-1 chain; Tubulin alpha-1A chain; Vimentin; Zyxin; Heat shock cognate 71 kDa protein; Tubulin beta-6 chain; Tubulin beta-4A chain; Tubulin beta chain; Fructose-bisphosphate aldolase A; Glyceraldehyde-3-phosphate dehydrogenase; Cytochrome c; Phosphoglycerate mutase 1; Myosin-9; Protein disulfide-isomerase; Probable ATP-dependent RNA helicase DDX5; Serine hydroxymethyltransferase, mitochondrial; Spliceosome RNA helicase DDX39B; Nucleophosmin; Translationally-controlled tumor protein homolog; P-type Ca2+-transporting ATPase; Ornithine aminotransferase; Elongation factor 1-alpha; Multidrug resistance protein; Elongation factor 2; Actin-1; Glyceraldehyde-3-phosphate dehydrogenase; Fructose-bisphosphate aldolase; Cell division cycle protein 48 homologue,putative; Heat shock protein 90; Eukaryotic initiation factor 4A; Pyruvate kinase; L-lactate dehydrogenase; Protein disulfide-isomerase; Thioredoxin-related protein, putative; Spermidine synthase; Probable ATP-dependent 6-phosphofructokinase; Glutamate dehydrogenase; Endoplasmin homolog, putative; Hypoxanthine-guanine-xanthine phosphoribosyltransferase; Enolase; 40S ribosomal protein S3; Non-SERCA-type Ca2+-transporting P-ATPase; Tubulin alpha chain; Knob-associated histidine-rich protein; S-adenosylmethionine synthase; V-type H(+)-translocating pyrophosphatase, putative; 60S ribosomal protein L4; Phosphoethanolamine N-methyltransferase; 40S ribosomal protein S3a; Conserved Plasmodium membrane protein; 60S ribosomal protein L3; High molecular weight rhoptry protein 2; Serine repeat antigen 5; 40S ribosomal protein S19; Glycophorin-binding protein; Calcium-transporting ATPase; V-type proton ATPase catalytic subunit A; 60S ribosomal protein L2; Acyl-CoA synthetase; Plasmepsin IV; Plasmepsin-1; Chloroquine resistance transporter; 14-3-3 protein; Isoleucine--tRNA ligase, putative; Plasmodium exported protein; Tubulin beta chain; 60S ribosomal protein L27; Sec62, putative; Autophagy-related protein 18, putative; Mature parasite-infected erythrocyte surface antigen; Importin-7, putative; Importin subunit alpha; Peptidyl-prolyl cis-trans isomerase; DnaJ protein, putative; Merozoite surface protein 1; Glutamate--tRNA ligase; T-complex protein 1 subunit eta; Plasmepsin-2; Chaperone, putative; Rhoptry neck protein 3; 40S ribosomal protein S5, putative; Skeleton-binding protein 1; Purine nucleotide phosphorylase, putative; Adenosylhomocysteinase; Adenosine deaminase; Methionine--tRNA ligase; Carbamoyl phosphate synthetase; Aspartate carbamoyltransferase; Signal recognition particle receptor, beta subunit; Parasite-infected erythrocyte surface protein; Coatomer alpha subunit, putative; Hexokinase; Proteasome subunit alpha type; Haloacid dehalogenase-like hydrolase; Insulinase, putative; 40S ribosomal protein S21; Ubiquitin-conjugating enzyme E2; Eukaryotic translation initiation factor 3 subunit C; 60S ribosomal protein L24, putative; 60S ribosomal protein L23; 60S ribosomal protein L17, putative; HAP protein; Heat shock protein 110, putative; 60S ribosomal protein L10, putative; Lysophospholipase, putative; Polyadenylate-binding protein; Ubiquitin-60S ribosomal protein L40; Phosphoribosylpyrophosphate synthetase; Thioredoxin peroxidase 1; Protein transport protein SEC31; Dipeptidyl aminopeptidase 1; Ring-infected erythrocyte surface antigen; ATP-dependent RNA helicase UAP56; Calcium-dependent protein kinase 4; GTP-binding nuclear protein Ran; Nucleoside transporter 2; Anamorsin homolog; Glutamine synthetase, putative; 60S ribosomal protein L30e, putative; Casein kinase 2, alpha subunit; Threonine--tRNA ligase; cAMP-dependent protein kinase regulatory subunit; Elongation factor 1-gamma, putative; Thioredoxin-like protein; 60S ribosomal protein L21; 60S ribosomal protein L14, putative; Inner membrane complex sub-compartment protein 3; HSP40, subfamily A, putative; Pyridoxal 5'-phosphate synthase subunit Pdx1; UDP-glucuronosyltransferase 1-9; UDP-glucuronosyltransferase 2B7; Serum albumin; Cytochrome P450 2D6; Cytochrome P450 2C19",ligand; antagonist; substrate; inhibitor
ACTA2; ACTB; ATP5B; ATP5I; ATP5L; CYB5B; DIABLO; FBXO41; HNRNPF; HNRNPK; HSPA4; HSPB1; HSPE1; HSPH1; MT-ND1; NUDC; PAPPA; PSMA3; PSMC3; RANBP1; S100A10; SF3A3; SMARCE1; SUCLG2; TPD52L2; TPM1; TPM3; TPM4; TUBA1A; TUBA3C; TUBA4A; TUBB1; TUBB2A; TUBB3; TUBB4B; TXN; UCHL1; USP14; VCP; VIM; YWHAB; YWHAE; YWHAH; YWHAQ; YWHAZ,Phenethyl Isothiocyanate,DB12695,"","Phenethyl Isothiocyanate has been used in trials studying the prevention and treatment of Leukemia, Lung Cancer, Tobacco Use Disorder, and Lymphoproliferative Disorders.","Aldehyde Dehydrogenase, antagonists & inhibitors; Anticarcinogenic Agents; Antineoplastic Agents; Carcinogens; Compounds used in a research, industrial, or household setting; Enzyme Inhibitors; Isocyanates; Noxae; Protective Agents; Sulfur Compounds; Toxic Actions","Actin, aortic smooth muscle; Actin, cytoplasmic 1; ATP synthase subunit beta, mitochondrial; ATP synthase subunit e, mitochondrial; ATP synthase subunit g, mitochondrial; Cytochrome b5 type B; Diablo homolog, mitochondrial; F-box only protein 41; Heterogeneous nuclear ribonucleoprotein F; Heterogeneous nuclear ribonucleoprotein K; Heat shock 70 kDa protein 4; Heat shock protein beta-1; 10 kDa heat shock protein, mitochondrial; Heat shock protein 105 kDa; NADH-ubiquinone oxidoreductase chain 1; Nuclear migration protein nudC; Pappalysin-1; Proteasome subunit alpha type-3; 26S protease regulatory subunit 6A; Ran-specific GTPase-activating protein; Protein S100-A10; Splicing factor 3A subunit 3; SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily E member 1; Succinyl-CoA ligase [GDP-forming] subunit beta, mitochondrial; Tumor protein D54; Tropomyosin alpha-1 chain; Tropomyosin alpha-3 chain; Tropomyosin alpha-4 chain; Tubulin alpha-1A chain; Tubulin alpha-3C/D chain; Tubulin alpha-4A chain; Tubulin beta-1 chain; Tubulin beta-2A chain; Tubulin beta-3 chain; Tubulin beta-4B chain; Thioredoxin; Ubiquitin carboxyl-terminal hydrolase isozyme L1; Ubiquitin carboxyl-terminal hydrolase 14; Transitional endoplasmic reticulum ATPase; Vimentin; 14-3-3 protein beta/alpha; 14-3-3 protein epsilon; 14-3-3 protein eta; 14-3-3 protein theta; 14-3-3 protein zeta/delta",""
PPP1CC,"9,10-Deepithio-9,10-Didehydroacanthifolicin",DB02169,"",A specific inhibitor of phosphoserine/threonine protein phosphatase 1 and 2a. It is also a potent tumor promoter. (Thromb Res 1992;67(4):345-54 & Cancer Res 1993;53(2):239-41),"",Serine/threonine-protein phosphatase PP1-gamma catalytic subunit,""
MMP12; MMP1,CGS-27023,DB07556,"",,"Amides; Amines; Carboxylic Acids; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hydroxy Acids; Hydroxylamines; Matrix Metalloproteinase Inhibitors; Metalloendopeptidases, antagonists & inhibitors; Protease Inhibitors; Serine Protease Inhibitors; Sulfones; Sulfur Compounds",Macrophage metalloelastase; Interstitial collagenase,""
FNTA; FNTB; KRAS; ispF; FDPS; ispU; nisZ; GGPS1; ; RABGGTA; RABGGTB,Farnesyl diphosphate,DB07780,"",,Hydrocarbons; Organophosphates; Organophosphorus Compounds; Potential QTc-Prolonging Agents; QTc Prolonging Agents; Terpenes,"Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha; Protein farnesyltransferase subunit beta; GTPase KRas; 2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase; Farnesyl pyrophosphate synthase; Ditrans,polycis-undecaprenyl-diphosphate synthase ((2E,6E)-farnesyl-diphosphate specific); Lantibiotic nisin-Z; Geranylgeranyl pyrophosphate synthase; (2Z,6E)-farnesyl diphosphate synthase; Geranylgeranyl transferase type-2 subunit alpha; Geranylgeranyl transferase type-2 subunit beta",""
AKT2; GSK3B; PRKACA; PKIA,(2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE,DB08073,"",,"",RAC-beta serine/threonine-protein kinase; Glycogen synthase kinase-3 beta; cAMP-dependent protein kinase catalytic subunit alpha; cAMP-dependent protein kinase inhibitor alpha,""
STAT3,OPB-111077,DB16630,"",OPB-111077 is a novel inhibitor of STAT3 and mitochondrial oxidative phosphorylation. It has demonstrated promising anticancer activity in preclinical models.,"",Signal transducer and activator of transcription 3,inhibitor
HRAS; RHOA; TGM2; RAB11A; purA; ftsZ; TGM3; RAB8B; ARF6; ADSSL1; fusA; TUFM; der; gmm; engB; EIF2S3; GNAI1; ffh; GNAT1; tufB; RAB9A; NME1; RHEB; CDC42; tufA; ARF1; EEF2; relA; RAP2A; EFTUD1; ARL1; RAN; RAB7A; IRGC; GSPT1; RAB5A; EEF1A1; ARF4; GMDS; RALA; tuf; ARL5B; rab6; ARL3; NME2; gmd; RAC1; rsgA; SAR1B; Adss; ARL5A,Guanosine-5'-Diphosphate,DB04315,"",A guanine nucleotide containing two phosphate groups esterified to the sugar moiety. [PubChem],"","GTPase HRas; Transforming protein RhoA; Protein-glutamine gamma-glutamyltransferase 2; Ras-related protein Rab-11A; Adenylosuccinate synthetase; Cell division protein FtsZ; Protein-glutamine gamma-glutamyltransferase E; Ras-related protein Rab-8B; ADP-ribosylation factor 6; Adenylosuccinate synthetase isozyme 1; Elongation factor G; Elongation factor Tu, mitochondrial; GTPase Der; GDP-mannose mannosyl hydrolase; Probable GTP-binding protein EngB; Eukaryotic translation initiation factor 2 subunit 3; Guanine nucleotide-binding protein G(i) subunit alpha-1; Signal recognition particle protein; Guanine nucleotide-binding protein G(t) subunit alpha-1; Elongation factor Tu-B; Ras-related protein Rab-9A; Nucleoside diphosphate kinase A; GTP-binding protein Rheb; Cell division control protein 42 homolog; Elongation factor Tu; ADP-ribosylation factor 1; Elongation factor 2; Bifunctional (p)ppGpp synthase/hydrolase RelA; Ras-related protein Rap-2a; Elongation factor Tu GTP-binding domain-containing protein 1; ADP-ribosylation factor-like protein 1; GTP-binding nuclear protein Ran; Ras-related protein Rab-7a; Interferon-inducible GTPase 5; Eukaryotic peptide chain release factor GTP-binding subunit ERF3A; Ras-related protein Rab-5A; Elongation factor 1-alpha 1; ADP-ribosylation factor 4; GDP-mannose 4,6 dehydratase; Ras-related protein Ral-A; Elongation factor Tu; ADP-ribosylation factor-like protein 5B; GTPase (Rab6); ADP-ribosylation factor-like protein 3; Nucleoside diphosphate kinase B; GDP-mannose 4,6-dehydratase; Ras-related C3 botulinum toxin substrate 1; Putative ribosome biogenesis GTPase RsgA; GTP-binding protein SAR1b; Adenylosuccinate synthetase; ADP-ribosylation factor-like protein 5A",""
PPP1CC,Motuporin,DB04738,"",Motuporin is a toxin isolated from the marine sponge Thenonella swinhoie grey.,"Amino Acids, Peptides, and Proteins; Cytotoxins; Macrocyclic Compounds; Peptides; Polycyclic Compounds",Serine/threonine-protein phosphatase PP1-gamma catalytic subunit,""
RARA; RARB; RARG; JUN,LGD-1550,DB05785,"",LGD-1550 is an orally-active synthetic aromatic retinoic acid agent with potential antineoplastic and chemopreventive activities.,"Alkenes; Biological Factors; Carotenoids; Cyclohexanes; Cyclohexenes; Cycloparaffins; Hydrocarbons; Hydrocarbons, Acyclic; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Pigments, Biological; Polyenes; Receptors, Retinoic Acid, agonists; Terpenes",Retinoic acid receptor alpha; Retinoic acid receptor beta; Retinoic acid receptor gamma; Transcription factor AP-1,""
PRKACA; PKIA; AKT2; GSK3B,ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE,DB07947,"",,"",cAMP-dependent protein kinase catalytic subunit alpha; cAMP-dependent protein kinase inhibitor alpha; RAC-beta serine/threonine-protein kinase; Glycogen synthase kinase-3 beta,""
TNFRSF1A,"6-[3-(4-Morpholinyl)Propyl]-2-(3-Nitrophenyl)-5-Thioxo-5,6,-Dihydro-7h-Thienol[2',3':4,5]Pyrrolo[1,2-C]Imidazol-7-One",DB03507,"",,"",Tumor necrosis factor receptor superfamily member 1A,""
AKT2; GSK3B,"N-[(1S)-2-amino-1-phenylethyl]-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)thiophene-2-carboxamide",DB07812,"",,"",RAC-beta serine/threonine-protein kinase; Glycogen synthase kinase-3 beta,""
PRKACA; PKIA; AKT2; GSK3B,4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE,DB07859,"",,"",cAMP-dependent protein kinase catalytic subunit alpha; cAMP-dependent protein kinase inhibitor alpha; RAC-beta serine/threonine-protein kinase; Glycogen synthase kinase-3 beta,""
IL1R1,Anakinra,DB00026,L04AC03,"Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta.[L35415] Anakinra is indicated for the management of rheumatoid arthritis (RA) in patients 18 years of age or older who have failed one or more disease-modifying antirheumatic drugs (DMARDs), as well as the treatment of neonatal-onset multisystem inflammatory disease (NOMID) and deficiency of interleukin-1 receptor antagonist (DIRA).[L35415] Since IL-1 has an important role in inflammation and immunological responses, anakinra is also used for the off-label treatment of inflammatory diseases.[A247000]

A few studies have evaluated the use of anakinra for the treatment of COVID-19; however, further research is needed to validate the use of this drug in patients with COVID-19.[A247265] Anakinra is produced using the _E. Coli_ bacterial expression system. On November 14, 2001, it was approved by the FDA for the treatment of rheumatoid arthritis. It was later approved for the treatment of NOMID and DIRA on December 21, 2012, and December 18, 2020, respectively.","Agents reducing cytokine levels; Amino Acids, Peptides, and Proteins; Antineoplastic and Immunomodulating Agents; Antirheumatic Agents; Biological Factors; Biologics for Rheumatoid Arthritis Treatment; Cytokines; Disease-modifying Antirheumatic Agents; Immunosuppressive Agents; Immunotherapy; Intercellular Signaling Peptides and Proteins; Interleukin Inhibitors; Interleukin-1 Receptor Antagonist; Peptides; Proteins",Interleukin-1 receptor type 1,antagonist
MAP3K1,AZD-8330,DB06061,"","AZD-8330 is a potent, selective, orally active MEK inhibitor that blocks signal transduction pathways implicated in cancer cell proliferation and survival. AZD-8330 has shown tumor suppressive activity in multiple preclinical models of human cancer including melanoma, pancreatic, colon, lung, and breast cancers.","Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Protein Kinase Inhibitors; Pyridines",Mitogen-activated protein kinase kinase kinase 1,""
CSNK1G3; SLK; CAMK4; CLK3; ABL2,K-00546,DB07664,"",,"",Casein kinase I isoform gamma-3; STE20-like serine/threonine-protein kinase; Calcium/calmodulin-dependent protein kinase type IV; Dual specificity protein kinase CLK3; Abelson tyrosine-protein kinase 2,""
BRAF; RAF1,XL281,DB05190,"","XL281 is a novel anticancer compound designed to potently inhibit the RAS/RAF/MEK/ERK signaling pathway. Mutational activation of RAS occurs in about 30 percent of all human tumors, including non-small cell lung, pancreatic, and colon cancer. XL281 is a specific inhibitor of RAF kinases, including the mutant form of B-RAF, which is activated in 60 percent of melanomas, 24-44 percent of thyroid cancers, and 9 percent of colon cancers.
","",Serine/threonine-protein kinase B-raf; RAF proto-oncogene serine/threonine-protein kinase,""
RAF1,iCo-007,DB05268,"",iCo-007 (formerly known as ISIS 13650) is a second generation antisense compound being developed by iCo for the treatment of various eye diseases caused by the formation of new blood vessels (angiogenesis) such as age-related macular degeneration (AMD) and diabetic retinopathy(DR).,"",RAF proto-oncogene serine/threonine-protein kinase,""
MMP9,"5-(4-PHENOXYPHENYL)-5-(4-PYRIMIDIN-2-YLPIPERAZIN-1-YL)PYRIMIDINE-2,4,6(2H,3H)-TRIONE",DB07117,"",,"",Matrix metalloproteinase-9,""
MMP9,"(2R)-2-AMINO-3,3,3-TRIFLUORO-N-HYDROXY-2-{[(4-PHENOXYPHENYL)SULFONYL]METHYL}PROPANAMIDE",DB07246,"",,"",Matrix metalloproteinase-9,""
TTR; NQO2; PTGS1; CSNK2A1; PTGS2; SIRT1; CYP1A1; CYP3A4; CYP1A2; CYP1B1; ALOX15; ALOX5; AHR; PI4K2B; ITGA5; ITGB3; ALB; APP; SNCA; ESR1; MTNR1A; MTNR1B; CLEC14A; NR1I2; NR1I3; SLC2A1; CBR1; PPARA; PPARG; AKT1; KHSRP; YARS,Resveratrol,DB02709,"","Resveratrol (3,5,4'-trihydroxystilbene) is a polyphenolic phytoalexin. It is a stilbenoid, a derivate of stilbene, and is produced in plants with the help of the enzyme stilbene synthase. It exists as cis-(Z) and trans-(E) isomers. The trans- form can undergo isomerisation to the cis- form when heated or exposed to ultraviolet irradiation. In a 2004 issue of Science, Dr. Sinclair of Harvard University said resveratrol is not an easy molecule to protect from oxidation. It has been claimed that it is readily degraded by exposure to light, heat, and oxygen. However, studies find that Trans-resveratrol undergoes negligible oxidation in normal atmosphere at room temperature.","Angiogenesis Inhibitors; Anticarcinogenic Agents; Antioxidants; Antiplatelet agents; Antirheumatic Agents; Benzene Derivatives; Benzylidene Compounds; Biological Factors; Compounds used in a research, industrial, or household setting; Cytochrome P-450 CYP1A2 Inducers; Cytochrome P-450 CYP1A2 Inducers (strength unknown); Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Enzyme Inhibitors; Hematologic Agents; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Phenols; Polyphenols; Protective Agents; Stilbenes; Stilbestrols; Vasodilating Agents","Transthyretin; Ribosyldihydronicotinamide dehydrogenase [quinone]; Prostaglandin G/H synthase 1; Casein kinase II subunit alpha; Prostaglandin G/H synthase 2; NAD-dependent protein deacetylase sirtuin-1; Cytochrome P450 1A1; Cytochrome P450 3A4; Cytochrome P450 1A2; Cytochrome P450 1B1; Arachidonate 15-lipoxygenase; Arachidonate 5-lipoxygenase; Aryl hydrocarbon receptor; Phosphatidylinositol 4-kinase type 2-beta; Integrin alpha-5; Integrin beta-3; Serum albumin; Amyloid beta A4 protein; Alpha-synuclein; Estrogen receptor alpha; Melatonin receptor type 1A; Melatonin receptor type 1B; C-type lectin domain family 14 member A; Nuclear receptor subfamily 1 group I member 2; Nuclear receptor subfamily 1 group I member 3; Solute carrier family 2, facilitated glucose transporter member 1; Carbonyl reductase [NADPH] 1; Peroxisome proliferator-activated receptor alpha; Peroxisome proliferator-activated receptor gamma; RAC-alpha serine/threonine-protein kinase; Far upstream element-binding protein 2; Tyrosine--tRNA ligase, cytoplasmic",inhibitor; substrate; inducer
IL1B,VP025,DB05133,"","VP025, a novel drug formulation based on phospholipid microparticles incorporating phosphatidylglycerol, can inhibit neuroinflammation. VP025 may inhibit immune system activation and protect motoneurons from injury. It also shows the ability to reduce inflammation across the blood-brain barrier and improve correlates of memory and learning function. It is being developed to target the chronic inflammation within the central nervous system that is associated with a number of neurological diseases, including Alzheimers disease, Parkinsons disease, and amyotrophic lateral sclerosis (Lou Gehrigs disease). It is considered to be a systemic anti-inflammatory and neuroprotective agent.","",Interleukin-1 beta,""
AKT1,Archexin,DB05971,"",,"Nucleic Acids, Nucleotides, and Nucleosides; Nucleotides; Polynucleotides",RAC-alpha serine/threonine-protein kinase,""
AKT1; GSK3B,"N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine",DB07584,"",,"",RAC-alpha serine/threonine-protein kinase; Glycogen synthase kinase-3 beta,""
IL1B,Gevokizumab,DB12119,"","Gevokizumab has been used in trials studying the treatment of Acne Vulgaris, Osteoarthritis, Behcet's Uveitis, Pyoderma Gangrenosum, and Behcet's Disease Uveitis, among others. Gevokizumab acts as a modulator of cytokine imbalance in IL-1 mediated disease states. It has a very high binding affinity of 300fM and blocks the activation of IL-1 receptors.","Amino Acids, Peptides, and Proteins; Antibodies; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Blood Proteins; Globulins; Immunoglobulins; Immunoproteins; Proteins; Serum Globulins",Interleukin-1 beta,""
PTK2,"7-PYRIDIN-2-YL-N-(3,4,5-TRIMETHOXYPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-2-AMINE",DB07248,"",,"",Focal adhesion kinase 1,""
PTK2,2-({5-CHLORO-2-[(2-METHOXY-4-MORPHOLIN-4-YLPHENYL)AMINO]PYRIMIDIN-4-YL}AMINO)-N-METHYLBENZAMIDE,DB07460,"",,"",Focal adhesion kinase 1,""
SIGMAR1; CHRNA2; SLC6A4; GRIN3A; CYP2D6; CYP3A4; CYP3A7; CYP2C9; CYP2B6; CYP2C19; PGRMC1; CHRNA3; CHRNA4; CHRNB4; CHRNB2; CHRNA7; OPRM1; OPRD1; OPRK1; CYBB; CYBA; NCF1; NCF2; NCF4; RAC1; RAC2; SLC6A2; UGT2B4; UGT2B7; UGT2B15; UGT2B17,Dextromethorphan,DB00514,R05DA09; N07XX59,"Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse.[A215412] Although similar in structure to other opioids, it has minimal interaction with opioid receptors.[A215412]

Dextromethorphan was granted FDA approval before 3 December 1957.[A215412,L14997]","Alkaloids; Anticholinergic Agents; Antidepressive Agents; Antitussive Agents; Central Nervous System Agents; Central Nervous System Depressants; Combined Inhibitors of Serotonin/Norepinephrine Reuptake; Cough and Cold Preparations; Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Substrates; Excitatory Amino Acid Agents; Excitatory Amino Acid Antagonists; Heterocyclic Compounds; Heterocyclic Compounds with 4 or More Rings; Heterocyclic Compounds, Bridged-Ring; Heterocyclic Compounds, Fused-Ring; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Morphinans; Nervous System; Neurotransmitter Agents; Nicotinic Antagonists; NMDA Receptor Antagonists; Opiate Alkaloids; Opioids; Opium Alkaloids and Derivatives; Phenanthrene opioids; Phenanthrenes; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Respiratory System; Respiratory System Agents; Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome; Serotonin Agents; Serotonin Modulators; Sigma-1 Agonist; Sigma-1 Receptor Agonists; UGT2B17 substrates; UGT2B7 substrates; Uncompetitive N-methyl-D-aspartate Receptor Antagonist; Uncompetitive NMDA Receptor Antagonists","Sigma non-opioid intracellular receptor 1; Neuronal acetylcholine receptor subunit alpha-2; Sodium-dependent serotonin transporter; Glutamate receptor ionotropic, NMDA 3A; Cytochrome P450 2D6; Cytochrome P450 3A4; Cytochrome P450 3A7; Cytochrome P450 2C9; Cytochrome P450 2B6; Cytochrome P450 2C19; Membrane-associated progesterone receptor component 1; Neuronal acetylcholine receptor subunit alpha-3; Neuronal acetylcholine receptor subunit alpha-4; Neuronal acetylcholine receptor subunit beta-4; Neuronal acetylcholine receptor subunit beta-2; Neuronal acetylcholine receptor subunit alpha-7; Mu-type opioid receptor; Delta-type opioid receptor; Kappa-type opioid receptor; NADPH oxidase; Sodium-dependent noradrenaline transporter; UDP-glucuronosyltransferase 2B4; UDP-glucuronosyltransferase 2B7; UDP-glucuronosyltransferase 2B15; UDP-glucuronosyltransferase 2B17",agonist; antagonist; inhibitor; substrate; binder
MMP1,N-[3-(N'-HYDROXYCARBOXAMIDO)-2-(2-METHYLPROPYL)-PROPANOYL]-O-TYROSINE-N-METHYLAMIDE,DB07926,"",,"",Interstitial collagenase,""
MMP1; MMP8,METHYLAMINO-PHENYLALANYL-LEUCYL-HYDROXAMIC ACID,DB08403,"",,"",Interstitial collagenase; Neutrophil collagenase,""
MMP1,[[1-[N-HYDROXY-ACETAMIDYL]-3-METHYL-BUTYL]-CARBONYL-LEUCINYL]-ALANINE ETHYL ESTER,DB08482,"",,"",Interstitial collagenase,""
MMP1,N-HYDROXY-2-[4-(4-PHENOXY-BENZENESULFONYL)-TETRAHYDRO-PYRAN-4-YL]-ACETAMIDE,DB08491,"",,"",Interstitial collagenase,""
PIK3CA; PIK3CD; CYP3A4; CYP3A5; CYP3A7; ABCB1; ABCG2; SLC47A2; ALB; CYP1A1,Copanlisib,DB12483,L01XX61,"Copanlisib is a selective pan-Class I phosphoinositide 3-kinase (PI3K/Phosphatidylinositol-4,5-bisphosphate 3-kinase/phosphatidylinositide 3-kinase) inhibitor that was first developed by Bayer Healthcare Pharmaceuticals, Inc. The drug targets the enzyme that plays a role in regulating cell growth and survival. Copanlisib was granted accelerated approval on September 14, 2017 under the market name Aliqopa for the treatment of adult patients with relapsed follicular lymphoma and a treatment history of at least two prior systemic therapies. Follicular lymphoma is a slow-growing type of non-Hodgkin lymphoma that is caused by unregulated proliferation and growth of lymphocytes. The active ingredient in Aliquopa intravenous therapy is copanlisib dihydrochloride.","Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; BCRP/ABCG2 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 CYP3A7 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Kinase Inhibitor; MATE 2 Inhibitors; MATE inhibitors; Narrow Therapeutic Index Drugs; P-glycoprotein substrates; P-glycoprotein substrates with a Narrow Therapeutic Index","Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform; Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform; Cytochrome P450 3A4; Cytochrome P450 3A5; Cytochrome P450 3A7; P-glycoprotein 1; ATP-binding cassette sub-family G member 2; Multidrug and toxin extrusion protein 2; Serum albumin; Cytochrome P450 1A1",inhibitor; substrate
ADORA1; PDE4B; ADORA2A; CYP1A2; RYR1; CYP3A4; CYP2E1; CYP2C8; CYP2C9; CYP1A1; CYP1B1; CYP2D6; PDE1A; PDE1B; PDE1C; PDE10A; PDE4A; PDE4B; PDE4C; PDE4D; PDE7B; PDE2A; PDE3A; PDE3B; PDE5A; PDE6C; PDE11A; PDE7A; PDE8A; PDE8B; PDE9A; PDE6A; PDE6B; PRKDC; PIK3CD; PIK3CA; PIK3CB; ITPR1; ITPR2; ITPR3; ATM; ABCG2; ADORA2B; ADORA3; PDE1B; PDE4D; PDE3B; PDE5A,Caffeine,DB00201,R03DA20; V04CG30; N06BC01,"Caffeine is a drug of the methylxanthine class used for a variety of purposes, including certain respiratory conditions of the premature newborn, pain relief, and to combat drowsiness. Caffeine is similar in chemical structure to [Theophylline] and [Theobromine].[A187691,L9851] It can be sourced from coffee beans, but also occurs naturally in various teas and cacao beans, which are different than coffee beans.[T716] Caffeine is also used in a variety of cosmetic products and can be administered topically, orally, by inhalation, or by injection.[T716]

The caffeine citrate injection, used for apnea of the premature newborn, was initially approved by the FDA in 1999.[L9863] According to an article from 2017, more than 15 million babies are born prematurely worldwide. This correlates to about 1 in 10 births. Premature birth can lead to apnea and bronchopulmonary dysplasia, a condition that interferes with lung development and may eventually cause asthma or early onset emphysema in those born prematurely.[A187694] Caffeine is beneficial in preventing and treating apnea and bronchopulmonary dysplasia in newborns, improving the quality of life of premature infants.[T716]","Alkaloids; Anorexigenic Agents & Respiratory and CNS Stimulants; BCRP/ABCG2 Inhibitors; Caffeine and Caffeine Containing Products; Carboxylic Acids; Central Nervous System Agents; Central Nervous System Stimulants; Central Nervous System Stimulation; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (moderate); Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP2E1 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Diagnostic Agents; Drugs for Obstructive Airway Diseases; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Nervous System; Neurotransmitter Agents; Phosphodiesterase Inhibitors; Psychoanaleptics; Psychostimulants, Agents Used for ADHD and Nootropics; Purinergic Agents; Purinergic Antagonists; Purines; Purinones; Respiratory and CNS Stimulants; Respiratory System; Tests for Gastric Secretion; Tricarboxylic Acids; Xanthine derivatives","Adenosine receptor A1; cAMP-specific 3',5'-cyclic phosphodiesterase 4B; Adenosine receptor A2a; Cytochrome P450 1A2; Ryanodine receptor 1; Cytochrome P450 3A4; Cytochrome P450 2E1; Cytochrome P450 2C8; Cytochrome P450 2C9; Cytochrome P450 1A1; Cytochrome P450 1B1; Cytochrome P450 2D6; Cyclic nucleotide phosphodiesterase; DNA-dependent protein kinase catalytic subunit; Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform; Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform; Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform; Inositol 1,4,5-trisphosphate receptor; Serine-protein kinase ATM; ATP-binding cassette sub-family G member 2; Adenosine receptor A2b; Adenosine receptor A3; Phosphodiesterase enzymes",antagonist; inhibitor; substrate
NFKB2; NFKB1,P54,DB05451,"","P54 reduces the inflammation associated with cancer/tumors, Crohn's disease, inflammatory bowel disease, osteoarthritis, and ulcerative colitis. It inhibits the induction of the enzyme NFkB, thereby inhibiting downstream inflammatory genes such as COX II and iNOS.","",Nuclear factor NF-kappa-B p100 subunit; Nuclear factor NF-kappa-B p105 subunit,""
NFKB2; NFKB1,NF-kappaB Decoy,DB05559,"",,"Nucleic Acids, Nucleotides, and Nucleosides; Nucleotides; Oligonucleotides; Polynucleotides",Nuclear factor NF-kappa-B,inhibitor
PTGS1; NFKB1; NOS2; PDE10A; ALB,Triflusal,DB08814,B01AC18,"Triflusal is a 2-acetoxy-4-trifluoromethylbenzoic acid and it is an aspirin chemically-related molecule but not a derivative. The benefits of this agent are the lack of action over the arachidonic acid pathway, the driven production of nitric oxide and the increase of cyclic nucleotide concentration on endothelial cells. The latest translates into the expansion of peripheral blood vessels.[A31675] It is very important as a secondary prevention of ischemic stroke by offering a lower risk of bleeding.[A31676] It was developed by  J. Uriach and Company and even though it is commercialized in different countries it is not approved by the FDA, EMA or HealthCanada.","Acids, Carbocyclic; Anticoagulants; Antiplatelet agents; Benzene Derivatives; Benzoates; Blood and Blood Forming Organs; Carboxylic Acids; Hematologic Agents; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydroxy Acids; Hydroxybenzoates; Phenols; Platelet Aggregation Inhibitors Excl. Heparin","Prostaglandin G/H synthase 1; Nuclear factor NF-kappa-B p105 subunit; Nitric oxide synthase, inducible; cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A; Serum albumin",antagonist; agonist; substrate
DGAT2; PTGS2; FFAR4; CACNA1C; CACNA1D; CACNA1F; CACNA1S; CACNB1; CACNB2; CACNB3; CACNB4; SCN1A; SCN10A; SCN11A; SCN2A; SCN3A; SCN4A; SCN5A; SCN7A; SCN8A; SCN9A; SCN1B; SCN2B; SCN3B; SCN4B; ; NFKB2; NFKB1; SREBF1; PPARA; PPARG; PPARD; CYP3A4,Fish oil,DB13961,"","Fish oil is a component of SMOFLIPID, which was FDA approved in July 2016. It is indicated in adults as a source of calories and essential fatty acids for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated.

More commonly, fish oil refers to the omega-3-fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) [FDA Label]. In general, dietary or pharmaceutical intake of these acids is primarily the only way to increase their levels in the human body where they are overall an essential element to dietary health as they have demonstrated abilities in minimizing or preventing hypertriglyceridemia when taken as an adjunct to a healthy diet [FDA Label].

Such fish oils are available in both non-prescription and prescription-only varieties at different concentrations. For many individuals, taking non-prescription fish oils as part of their multivitamin regimen is an effective way to supplement their diets with the healthy fatty acids. However, prescription-only fish oil products are sometimes prescribed for individuals who demonstrate severe (>= 500 mg/dL) hypertriglyceridemia [FDA Label].

Furthermore, a variety of studies regarding additional potential actions of fish oil omega-3-fatty acids EPA and DHA are ongoing. Such experimental actions include inflammation modulation, cardioprotective effects, the attenuation of oxidative stress, and more. Regardless, the specific mechanisms of action for these effects have yet to be formally elucidated.",Agents causing hyperkalemia; Antiarrhythmic agents; Bradycardia-Causing Agents; Calcium Channel Blockers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Fish Oils; Lipids; Oils; Vasodilating Agents,Diacylglycerol O-acyltransferase 2; Prostaglandin G/H synthase 2; Free fatty acid receptor 4; Voltage gated L-type calcium channel; Sodium channel protein; Free radicals; Nuclear factor NF-kappa-B; Sterol regulatory element-binding protein 1; Peroxisome proliferator-activated receptor alpha; Peroxisome proliferator-activated receptor gamma; Peroxisome proliferator-activated receptor delta; Cytochrome P450 3A4,agonist; inhibitor; inhibits downstream inflammation cascades; regulator; substrate
TPMT; XDH; GSTA1; GSTA2; GSTM1; RAC1; CYP1A2; HPRT1; NUDT15; SLC29A2; SLC28A3; ABCB1; SLC43A3; ALB; IMPDH1; IMPDH2; GMPS; ITPA,Azathioprine,DB00993,L04AX01,"Azathioprine is a prodrug of 6-mercaptopurine, first synthesized in 1956 by Gertrude Elion, William Lange, and George Hitchings in an attempt to produce a derivative of 6-mercaptopurine with a better therapeutic index.[A189678,A189687,A189690] Azathioprine is used to treat inflammatory conditions like rheumatoid arthritis and as an immunosuppressant in the prevention of renal transplant rejection.[L11214]

Azathiprine was granted FDA approval on 20 March 1968.[L11214]","Antimetabolites; Antineoplastic and Immunomodulating Agents; Antirheumatic Agents; Carbohydrates; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Glycosides; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Immunologic Factors; Immunosuppressive Agents; Immunotherapy; Noxae; Nucleic Acid Synthesis Inhibitors; Nucleic Acids, Nucleotides, and Nucleosides; Nucleosides; P-glycoprotein substrates; Purine Antimetabolite; Purines; Sulfhydryl Compounds; Sulfur Compounds; Thionucleosides; Thiopurine Analogs; Toxic Actions",Thiopurine S-methyltransferase; Xanthine dehydrogenase/oxidase; Glutathione S-transferase A1; Glutathione S-transferase A2; Glutathione S-transferase Mu 1; Ras-related C3 botulinum toxin substrate 1; Cytochrome P450 1A2; Hypoxanthine-guanine phosphoribosyltransferase; Nucleotide triphosphate diphosphatase NUDT15; Equilibrative nucleoside transporter 2; Solute carrier family 28 member 3; P-glycoprotein 1; Solute carrier family 43 member 3; Serum albumin; Inosine-5'-monophosphate dehydrogenase 1; Inosine-5'-monophosphate dehydrogenase 2; GMP synthase [glutamine-hydrolyzing]; Inosine triphosphate pyrophosphatase,substrate; modulator; binder
PIK3CA; PIK3CG; PIK3CD; PIK3CB; MTOR,XL765,DB05241,"","XL765 is an orally available small molecule that has been shown in preclinical studies to selectively inhibit the activity of phosphoinositide-3 kinase (PI3K) and mammalian target of rapamycin (mTOR). It is being developed by Exelixis, Inc.","Amides; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Phosphatidylinositol 3-Kinase, antagonists & inhibitors; Sulfones; Sulfur Compounds","Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform; Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform; Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform; Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform; Serine/threonine-protein kinase mTOR",""
BRAF; FLT3; RAF1; FLT4; PDGFRB; KIT; KDR; CYP3A4; UGT1A9; CYP2B6; CYP2C8; CYP3A5; CYP3A7; CYP2C9; ABCC4; ABCB1; ABCC2; ABCG2; CYP1A2; CYP2C19; CYP2D6; UGT1A1; RALBP1; FGFR1; RET; FLT1; SLCO1B1,Sorafenib,DB00398,L01XE05,"Sorafenib (rINN), marketed as Nexavar by Bayer, is a drug approved for the treatment of advanced renal cell carcinoma (primary kidney cancer). It has also received ""Fast Track"" designation by the FDA for the treatment of advanced hepatocellular carcinoma (primary liver cancer), and has since performed well in Phase III trials.
Sorafenib is a small molecular inhibitor of Raf kinase, PDGF (platelet-derived growth factor), VEGF receptor 2 & 3 kinases and c Kit the receptor for Stem cell factor. A growing number of drugs target most of these pathways. The originality of Sorafenib lays in its simultaneous targeting of the Raf/Mek/Erk pathway.","Acids, Heterocyclic; Amides; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; BCRP/ABCG2 Inhibitors; BCRP/ABCG2 Substrates; Benzene Derivatives; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2B6 Inhibitors; Cytochrome P-450 CYP2B6 Inhibitors (moderate); Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Cytochrome P-450 CYP2C8 Inhibitors (strong); Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strong); Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 CYP3A7 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Immunosuppressive Agents; Kinase Inhibitor; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; Nicotinic Acids; OATP1B1/SLCO1B1 Inhibitors; P-glycoprotein inhibitors; P-glycoprotein substrates; P-glycoprotein substrates with a Narrow Therapeutic Index; Phenylurea Compounds; Potential QTc-Prolonging Agents; Protein Kinase Inhibitors; Pyridines; QTc Prolonging Agents; Tyrosine Kinase Inhibitors; UGT1A1 Inhibitors; UGT1A9 Inhibitors; UGT1A9 Substrates; UGT1A9 Substrates with a Narrow Therapeutic Index",Serine/threonine-protein kinase B-raf; Receptor-type tyrosine-protein kinase FLT3; RAF proto-oncogene serine/threonine-protein kinase; Vascular endothelial growth factor receptor 3; Platelet-derived growth factor receptor beta; Mast/stem cell growth factor receptor Kit; Vascular endothelial growth factor receptor 2; Cytochrome P450 3A4; UDP-glucuronosyltransferase 1-9; Cytochrome P450 2B6; Cytochrome P450 2C8; Cytochrome P450 3A5; Cytochrome P450 3A7; Cytochrome P450 2C9; Multidrug resistance-associated protein 4; P-glycoprotein 1; Canalicular multispecific organic anion transporter 1; ATP-binding cassette sub-family G member 2; Cytochrome P450 1A2; Cytochrome P450 2C19; Cytochrome P450 2D6; UDP-glucuronosyltransferase 1-1; RalA-binding protein 1; Fibroblast growth factor receptor 1; Proto-oncogene tyrosine-protein kinase receptor Ret; Vascular endothelial growth factor receptor 1; Solute carrier organic anion transporter family member 1B1,inhibitor; antagonist; substrate
PIK3CA; CYP3A4; CYP2C9; CYP2C8; CYP2C19; ABCG2; ABCB1,Alpelisib,DB12015,L01XX65,"Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110 [A179203], which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metabolism. Alpelisib was designed to target this enzyme that appears to be mutated at a rate of nearly 30% in human cancers, leading to hyperactivation.[A179209] 

There are several isoform-specific PI3K inhibitors that are under clinical development or currently approved, such as [idelalisib] used for chronic lymphocytic leukemia (CLL).[A179209] Approved by the FDA in May 2019, alpelisib is the first approved PI3K inhibitor indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer in combination with [fulvestrant] for postmenopausal women and male patients. To initiate alpelisib therapy, it is required that the presence of a PIK3CA mutation in the tissue and/or liquid biopsy sample collection should be confirmed via FDA-approved diagnostic tests. Alpelisib is marketed under the trade name Piqray and is available as oral tablets. Studies evaluating the therapeutic effectiveness of alpelisib in other cancers, such as ovarian cancer [A179200] and colorectal cancer [A179203], are under ongoing investigations.

Alpelisib was granted FDA approval on 24 May 2019.[L6652] In April 2022, the FDA granted the use of alpelisib in the treatment of PIK3CA-Related Overgrowth Spectrum (PROS) in adults and children who require systemic therapy.[L41384]","Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Azoles; BCRP/ABCG2 Inhibitors; BCRP/ABCG2 Substrates; Breast Neoplasms; Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inducers (moderate); Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP2C9 Inducers (moderate); Cytochrome P-450 CYP2C9 Inducers (strength unknown); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (weak); Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (weak); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates (strength unknown); Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Kinase Inhibitor; Narrow Therapeutic Index Drugs; P-glycoprotein inhibitors; Phosphatidylinositol 3-Kinases, antagonists & inhibitors; Sulfur Compounds","Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform; Cytochrome P450 3A4; Cytochrome P450 2C9; Cytochrome P450 2C8; Cytochrome P450 2C19; ATP-binding cassette sub-family G member 2; P-glycoprotein 1",inhibitor; substrate; inducer
NFKB1; NFKB2; CYP3A4,HE3286,DB05212,"",,"17-Ketosteroids; Adrenal Cortex Hormones; Androstanes; Androstenes; Androstenols; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Substrates; Fused-Ring Compounds; Gonadal Hormones; Gonadal Steroid Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Ketosteroids; Polycyclic Compounds; Steroids",Nuclear factor NF-kappa-B p105 subunit; Nuclear factor NF-kappa-B p100 subunit; Cytochrome P450 3A4,substrate
NFKB2; NFKB1,NOX-700,DB05464,"","NOX-700, an new orally active dithiocarbamate-based nitric oxide (NO) blocking agent that is in development for the treatment of diabetes mellitus (type 2 diabetes). In animal studies, NOX-700 lowered serum glucose, improved glucose tolerance, and reduced the percentage of total glycated hemoglobin. Immunohistochemical studies on
pancreatic tissue also showed that NOX-700 therapy effectively preserved islet structure and increased insulin immunoreactivity. It has since been found that oxidative signaling of the redox-sensitive transcription factor, NF-B, and inhibiting protein glycation are responsible for the drug's therapeutic effects.
","Acids, Acyclic; Carbamates; Carboxylic Acids; Sulfur Compounds",Nuclear factor NF-kappa-B p100 subunit; Nuclear factor NF-kappa-B p105 subunit,""
ESR1; NFKB2; NFKB1,Custirsen,DB05487,"","Custirsen is a benzopyran with potential antineoplastic activity. Custirsen acts as a selective estrogen receptor modulator (SERM), inhibiting the proliferation of estrogen-sensitive breast cancer cells. This agent also inhibits growth and induces apoptosis of glioblastoma cells via a mechanism independent of estrogen receptor-related mechanisms. Custirsen is also being investigated in the treatment of primary brain tumors.","Antisense Oligonucleotides; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Nucleic Acids, Nucleotides, and Nucleosides; Nucleotides; Pyrans; Sulfur Compounds",Estrogen receptor alpha; Nuclear factor NF-kappa-B p100 subunit; Nuclear factor NF-kappa-B p105 subunit,""
PTGS2; NFKB2; NFKB1; RELA,SC-236,DB14059,"","SC-236 is a potent, selective, orally active inhibitor of cyclooxygenase-2 (COX-2) [L2964] that has been studied in cancer therapy [A33375], lower back pain [A33376], and inflammation [A33373], [A33374],[L2962], [A33377].","Agents causing hyperkalemia; Agents that produce hypertension; Amides; Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Azoles; Cyclooxygenase Inhibitors; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Nephrotoxic agents; Peripheral Nervous System Agents; Sensory System Agents; Sulfones; Sulfur Compounds",Cyclooxygenase 2; Nuclear factor NF-kappa-B complex,inhibitor
FGA; PLG; SERPINE1,Reteplase,DB00015,B01AD07,"Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells. Retavase is considered a ""third-generation"" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA. Retavase is a deletion mutein of human tPA formed by deleting various amino acids present in endogenous human tPA. Retavase contains 355 of the 527 amino acids of native human tPA (amino acids 1-3 and 176-527), and retains the activity-related kringle-2 and serine protease domains of human tPA. Three domains are deleted from retavase - kringle-1, finger, and epidermal growth factor (EGF).","Agents causing angioedema; Amino Acids, Peptides, and Proteins; Anticoagulants; Biological Factors; Blood and Blood Forming Organs; Blood Proteins; Cardiovascular Agents; Endopeptidases; Enzymes; Enzymes and Coenzymes; Fibrin Modulating Agents; Fibrinolytic Agents; Hematologic Agents; Hydrolases; Peptide Hydrolases; Plasminogen Activators; Proteins; Serine Endopeptidases; Serine Proteases; Tissue Plasminogen Activator",Fibrinogen alpha chain; Plasminogen; Plasminogen activator inhibitor 1,activator
FGA; PLG; SERPINE1,Anistreplase,DB00029,B01AD03,"Human tissue plasminogen activator, purified, glycosylated, 527 residues purified from CHO cells. Eminase is a lyophilized (freeze-dried) formulation of anistreplase, the p-anisoyl derivative of the primary Lys-plasminogen-streptokinase activator complex (a complex of Lys-plasminogen and streptokinase). A p-anisoyl group is chemically conjugated to a complex of bacterial-derived streptokinase and human Plasma-derived Lys-plasminogen proteins.","Agents causing angioedema; Amino Acids, Peptides, and Proteins; Anticoagulants; Blood and Blood Forming Organs; Blood Proteins; Cardiovascular Agents; Endopeptidases; Enzymes; Enzymes and Coenzymes; Fibrin Modulating Agents; Fibrinolytic Agents; Hematologic Agents; Hydrolases; Peptide Hydrolases; Plasminogen Activators; Proteins; Serine Endopeptidases; Serine Proteases",Fibrinogen alpha chain; Plasminogen; Plasminogen activator inhibitor 1,activator
MAP2K1,"(5S)-4,5-difluoro-6-[(2-fluoro-4-iodophenyl)imino]-N-(2-hydroxyethoxy)cyclohexa-1,3-diene-1-carboxamide",DB06892,"",,"",Dual specificity mitogen-activated protein kinase kinase 1,""
MAP2K1,PD-0325901,DB07101,"","PD-0325901 has been used in trials studying the treatment and basic science of Melanoma, Solid Tumour, Solid Tumors, Advanced Cancer, and Breast Neoplasms, among others.","Acids, Carbocyclic; Amides; Amines; Aniline Compounds; Benzene Derivatives; Benzoates; Carboxylic Acids; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic",Dual specificity mitogen-activated protein kinase kinase 1,""
MAPK8IP1; MAPK8,"5-CYANO-N-(2,5-DIMETHOXYBENZYL)-6-ETHOXYPYRIDINE-2-CARBOXAMIDE",DB07276,"",,"",C-Jun-amino-terminal kinase-interacting protein 1; Mitogen-activated protein kinase 8,""
KRAS; FNTA; FNTB,"[(3,7,11-TRIMETHYL-DODECA-2,6,10-TRIENYLOXYCARBAMOYL)-METHYL]-PHOSPHONIC ACID",DB07771,"",,"",GTPase KRas; Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha; Protein farnesyltransferase subunit beta,""
PIK3CG; PLK1; PIK3R1; PIK3CA,Wortmannin,DB08059,"","Wortmannin is a steroid metabolite of _Penicillium funiculosum_ and _Talaromyces wortmannii_ fungi. This drug acts as a nonspecific, covalent inhibitor of phosphoinositide 3-kinase enzymes (PI3Ks).","Androstadienes; Androstanes; Androstenes; Anti-Infective Agents; Antidepressive Agents; Antifungal Agents; Central Nervous System Depressants; Enzyme Inhibitors; Fused-Ring Compounds; Hormone Antagonists; Hormones, Hormone Substitutes, and Hormone Antagonists; Immunologic Factors; Immunosuppressive Agents; Insulin Antagonists; Polycyclic Compounds; Protein Kinase Inhibitors; Radiation-Sensitizing Agents; Serotonin Agents; Serotonin Receptor Antagonists; Steroids","Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform; Serine/threonine-protein kinase PLK1; Phosphatidylinositol 3-kinase regulatory subunit alpha; Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform",""
PIK3CA,Pilaralisib,DB11772,"","Pilaralisib is an orally available small molecule that selectively inhibits the activity of phosphoinositide-3 kinase (PI3K). Pilaralisib has been used in trials studying the treatment of Cancer, Lymphoma, Solid Tumors, Glioblastoma, and Breast Cancer, among others.","Amides; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Phosphatidylinositol 3-Kinase, antagonists & inhibitors; Sulfones; Sulfur Compounds","Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform",""
KRAS,Adagrasib,DB15568,"","Adagrasib (MRTX849) is a KRAS inhibitor developed by Mirati and is currently undergoing trials for KRAS G12C mutant cancers. This mutation makes up >50% of all KRAS mutations.[A187559]

The drug [AMG-510] is also currently being developed and has the same target.[A187547]","Antineoplastic Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Nitriles",GTPase KRas,inhibitor
MAPK10; MAPK8; MAPK9,Halicin,DB15624,"",,"Azoles; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Sulfur Compounds; Thiazoles",c-Jun N-terminal kinases,inhibitor
SERPINE1; PLAU,Fibrinolysin,DB05254,B01AD05; B06AA02,"Fibrinolysin consists of two polypeptide chains, one light and one heavy, linked by a disulfide bond. The light chain has a molecular weight of approximately 27,000 Da and contains the active center of Fibrinolysin; the heavy chain has a molecular weight of approximately 57,000 Da. Fibrinolysin is used as a local healing ointment when combined together with the enzyme deoxyribonuclease I (extracted from bovine pancreas). Fibrinolysin and deoxyribonuclease both act as lytic enzymes. The combination is available as ointment containing 1 BU (Biological Unit) Fibrinolysin and 666 BUs desoxyribonuclease per gram. The ointment is marketed by Pfizer under the brand name Fibrolan in a variety of countries (e.g. Switzerland). It is currently not approved in the USA.","Anticoagulants; Blood and Blood Forming Organs; Cardiovascular Agents; Endopeptidases; Enzymes; Enzymes and Coenzymes; Fibrin Modulating Agents; Fibrinolysin, antagonists & inhibitors; Fibrinolytic Agents; Hematologic Agents; Hydrolases; Peptide Hydrolases; Serine Endopeptidases; Serine Proteases",Plasminogen activator inhibitor 1; Urokinase-type plasminogen activator,""
CYP2C8; CYP3A4; MAP2K1; MAP2K2,Trametinib,DB08911,L01XE25,"Trametinib dimethyl sulfoxide is a kinase inhibitor. Each 1-mg tablet contains 1.127 mg trametinib dimethyl sulfoxide equivalent to 1 mg of trametinib non-solvated parent. FDA approved on May 29, 2013 [L2727].

The U.S. Food and Drug Administration approved [DB08912](Tafilnar) and Mekinist (trametinib), administered together, for the treatment of anaplastic thyroid cancer (ATC) that cannot be removed by surgery or has spread to other parts of the body (metastatic), and has a type of abnormal gene, BRAF V600E (BRAF V600E mutation-positive) [L2726].

Thyroid cancer is a disease in which cancer cells form in the tissues of the thyroid. Anaplastic thyroid cancer is a rare, aggressive type of thyroid cancer. The National Institutes of Health (NIH) estimates there will be 53,990 new cases of thyroid cancer and an estimated 2,060 deaths from the disease in the United States in 2018. Anaplastic thyroid cancer accounts for approximately 1 to 2 percent of all thyroid cancers [L2726].","Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strong); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Drugs that are Mainly Renally Excreted; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Kinase Inhibitor; MAP Kinase Kinase 1, antagonists & inhibitors; MAP Kinase Kinase 2, antagonists & inhibitors; MAP Kinase, antagonists & inhibitors; Narrow Therapeutic Index Drugs; Protein Kinase Inhibitors; Pyridines; Pyrimidines",Cytochrome P450 2C8; Cytochrome P450 3A4; Dual specificity mitogen-activated protein kinase kinase 1; Dual specificity mitogen-activated protein kinase kinase 2,inhibitor; inducer; antagonist
KRAS; CYP3A4; CYP3A43; CYP3A5; CYP3A7; CYP2C8; CYP2C9; CYP2B6; ABCG2; ABCB1,Sotorasib,DB15569,"","Sotorasib, also known as AMG-510, is an acrylamide-derived KRAS inhibitor developed by Amgen.[A187547,A187556] It is indicated in the treatment of adult patients with KRAS G12C mutant non-small cell lung cancer.[L34288] This mutation makes up >50% of all KRAS mutations.[A187550] Mutant KRAS discovered in 1982 but was not considered a druggable target until the mid-2010s.[A235168] It is the first experimental KRAS inhibitor.[A187547] The drug [MRTX849] is also currently being developed and has the same target.[A187547]

Sotorasib was granted FDA approval on May 28, 2021,[L34288] followed by the European Commission's approval on January 10, 2022.[L39675]","Antineoplastic Agents; Antineoplastic Agents, Immunological; BCRP/ABCG2 Inhibitors; Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inducers (strength unknown); Cytochrome P-450 CYP2C8 Inducers; Cytochrome P-450 CYP2C8 Inducers (strength unknown); Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP2C9 Inducers (strength unknown); Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Immune Checkpoint Inhibitors; P-glycoprotein inhibitors",GTPase KRas; Cytochrome P450 3A Subfamily; Cytochrome P450 2C8; Cytochrome P450 2C9; Cytochrome P450 2B6; ATP-binding cassette sub-family G member 2; P-glycoprotein 1,inhibitor; substrate; inducer
PLAUR; PLG; SERPINB2; SERPINE1; SERPINA5; NID1; LRP2; ST14; MMP12,Urokinase,DB00013,B01AD04,"Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and isoleucine 159 to yield active urokinase.[A191943] Urokinase remains connected between these 2 chains by a sulfhydryl bond.[A191943]

Urokinase was granted FDA approval on 16 January 1978.[L12138]","Agents causing angioedema; Amino Acids, Peptides, and Proteins; Anticoagulants; Biological Factors; Blood and Blood Forming Organs; Blood Proteins; Endopeptidases; Enzymes; Enzymes and Coenzymes; Fibrinolytic Agents; Hydrolases; Increased Thrombolysis; Peptide Hydrolases; Plasminogen Activators; Proteins; Serine Endopeptidases; Serine Proteases; Urokinase-Type Plasminogen Activator, antagonists & inhibitors",Urokinase plasminogen activator surface receptor; Plasminogen; Plasminogen activator inhibitor 2; Plasminogen activator inhibitor 1; Plasma serine protease inhibitor; Nidogen-1; Low-density lipoprotein receptor-related protein 2; Suppressor of tumorigenicity 14 protein; Macrophage metalloelastase,inducer; modulator; activator; substrate; ligand
F8; F5; SERPINE1; THBD; PROS1; F2; PF4; SERPINA5; SERPINB6; PROCR,Drotrecogin alfa,DB00055,B01AD10,"Drotrecogin alfa is activated human protein C that is synthesized by recombinant DNA technology. It is a glycoprotein of approximately 55 kilodalton molecular weight, consisting of a heavy chain and a light chain linked by a disulfide bond. Drotrecogin alfa was withdrawn from the market after a major study indicated that it was not effective in improving outcomes in patients with sepsis.","Amino Acids, Peptides, and Proteins; Anti-Infective Agents; Anticoagulants; Biological Factors; Blood and Blood Forming Organs; Blood Coagulation Factor Inhibitors; Blood Proteins; Enzyme Precursors; Enzymes; Enzymes and Coenzymes; Fibrinolytic Agents; Glycoproteins; Protein Precursors; Proteins; Recombinant Activated Protein C",Coagulation factor VIII; Coagulation factor V; Plasminogen activator inhibitor 1; Thrombomodulin; Vitamin K-dependent protein S; Prothrombin; Platelet factor 4; Plasma serine protease inhibitor; Serpin B6; Endothelial protein C receptor,inhibitor
PPARG; ACSL4; SERPINE1; SLC29A1; CYP3A4; CYP2C19; UGT1A1; CYP2C8; ABCB11; SLCO1B1; ESRRG; ESRRA; CYP19A1; CYP1A1; CYP2B6; CYP2C9; CYP3A5; CYP3A7; UGT1A3; UGT1A4; UGT1A6; UGT1A7; UGT1A8; UGT1A9; UGT1A10; UGT2B7; UGT2B15; PPARD; PPARA; GSTP1,Troglitazone,DB00197,A10BG01,Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone].,"Alimentary Tract and Metabolism; Azoles; Benzopyrans; Blood Glucose Lowering Agents; BSEP/ABCB11 Inhibitors; Chromans; Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inducers (strength unknown); Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (moderate); Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (moderate); Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A5 Inhibitors; Cytochrome P-450 CYP3A5 Inhibitors (strength unknown); Cytochrome P-450 CYP3A7 Inhibitors; Cytochrome P-450 CYP3A7 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs Used in Diabetes; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; OATP1B1/SLCO1B1 Inhibitors; Oral Hypoglycemics; Pyrans; Sulfur Compounds; Thiazoles; Thiazolidinediones; UGT1A1 Substrates; UGT1A3 substrates; UGT1A4 substrates; UGT1A6 Inhibitors; UGT1A6 substrate; UGT1A9 Substrates; UGT2B7 substrates",Peroxisome proliferator-activated receptor gamma; Long-chain-fatty-acid--CoA ligase 4; Plasminogen activator inhibitor 1; Equilibrative nucleoside transporter 1; Cytochrome P450 3A4; Cytochrome P450 2C19; UDP-glucuronosyltransferase 1-1; Cytochrome P450 2C8; Bile salt export pump; Solute carrier organic anion transporter family member 1B1; Estrogen-related receptor gamma; Steroid hormone receptor ERR1; Cytochrome P450 19A1; Cytochrome P450 1A1; Cytochrome P450 2B6; Cytochrome P450 2C9; Cytochrome P450 3A5; Cytochrome P450 3A7; UDP-glucuronosyltransferase 1-3; UDP-glucuronosyltransferase 1-4; UDP-glucuronosyltransferase 1-6; UDP-glucuronosyltransferase 1-7; UDP-glucuronosyltransferase 1-8; UDP-glucuronosyltransferase 1-9; UDP-glucuronosyltransferase 1-10; UDP-glucuronosyltransferase 2B7; UDP-glucuronosyltransferase 2B15; Peroxisome proliferator-activated receptor delta; Peroxisome proliferator-activated receptor alpha; Glutathione S-transferase P,agonist; regulator; inhibitor; antagonist; inducer; substrate; inverse agonist
MET; MAP2K1,K-252a,DB02152,"",,"Alkaloids; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, Fused-Ring; Indoles; Indolizidines; Indolizines; Protein Kinase C, antagonists & inhibitors",Hepatocyte growth factor receptor; Dual specificity mitogen-activated protein kinase kinase 1,""
MAP2K1,"2-[(4-ETHYNYL-2-FLUOROPHENYL)AMINO]-3,4-DIFLUORO-N-(2-HYDROXYETHOXY)BENZAMIDE",DB08208,"",,"",Dual specificity mitogen-activated protein kinase kinase 1,""
PLAUR; SERPINE1; FGA; SERPINB2; CLEC3B; KRT8; ANXA2; CALR; CANX; LRP1; PLG,Tenecteplase,DB00031,B01AD11,"Tenecteplase is a tissue plasminogen activator (tPA) developed from modifications of natural human tPA complementary DNA (cDNA). It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 117 with glutamine within the kringle 1 domain, and a tetra-alanine substitution at amino acids 296-299 in the protease domain.","Agents causing angioedema; Amino Acids, Peptides, and Proteins; Anticoagulants; Biological Factors; Blood and Blood Forming Organs; Blood Proteins; Cardiovascular Agents; Endopeptidases; Enzymes; Enzymes and Coenzymes; Fibrin Modulating Agents; Fibrinolytic Agents; Hematologic Agents; Hydrolases; Peptide Hydrolases; Plasminogen Activators; Proteins; Serine Endopeptidases; Serine Proteases; Tissue Plasminogen Activator","Urokinase plasminogen activator surface receptor; Plasminogen activator inhibitor 1; Fibrinogen alpha chain; Plasminogen activator inhibitor 2; Tetranectin; Keratin, type II cytoskeletal 8; Annexin A2; Calreticulin; Calnexin; Prolow-density lipoprotein receptor-related protein 1; Plasminogen",activator
MAP2K1; CYP3A4; ABCB1; SLCO1B1; SLCO1B3; ABCG2,Cobimetinib,DB05239,L01XE38,"Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of patients with unresectable or metastatic BRAF V600 mutation-positive melanoma.","Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Azetines; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates (strength unknown); Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Substrates; Drugs causing inadvertant photosensitivity; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Kinase Inhibitor; MAP Kinase Kinase 1, antagonists & inhibitors; MAP Kinase, antagonists & inhibitors; Narrow Therapeutic Index Drugs; OATP1B1/SLCO1B1 Substrates; OATP1B3 inhibitors; OATP1B3 substrates; P-glycoprotein substrates; P-glycoprotein substrates with a Narrow Therapeutic Index; Photosensitizing Agents; Protein Kinase Inhibitors",Dual specificity mitogen-activated protein kinase kinase 1; Cytochrome P450 3A4; P-glycoprotein 1; Solute carrier organic anion transporter family member 1B1; Solute carrier organic anion transporter family member 1B3; ATP-binding cassette sub-family G member 2; P-glycoprotein 1,inhibitor; substrate; weak inhibitor
TF; RRM2; PPI; IL1B; ; BGLAP; ATP6V1B2,Gallium nitrate,DB05260,"","Gallium nitrate is a drug that is used to treat hyper-calcemia, or too much calcium in the blood. This condition may occur when individuals develop various types of cancer. Gallium nitrate is also known by the common brand name Ganite.","Antineoplastic Agents; Bone Resorption Inhibition; Calcium Resorption Inhibitor; Calcium-Regulating Hormones and Agents; Elements; Immunosuppressive Agents; Medications that reduce magnesium levels; Metals; Metals, Heavy; Narrow Therapeutic Index Drugs","Serotransferrin; Ribonucleoside-diphosphate reductase subunit M2; Protein-tyrosine-phosphatase; Interleukin-1 beta; Hydroxylapatite; Osteocalcin; V-type proton ATPase subunit B, brain isoform",binder; inhibitor; antagonist; modulator
IL1B,Etiprednol dicloacetate,DB05442,"",Etiprednol dicloacetate (BNP-166) is a soft corticosteroid with anti-inflammatory properties that has been indicated in the treatment of asthma and Chron's disease. Anti-asthmatic effects were associated with decreased cytokine production in lipopolysaccharide-stimulated lymphocytes and attenuated lectin-induced proliferation of blood mononuclear cells in tissue culture.,"Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists",Interleukin-1 beta,""
MAP2K1,"5-Bromo-N-[(2S)-2,3-dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide",DB03115,"",,"",Dual specificity mitogen-activated protein kinase kinase 1,""
MAP2K1,"2-[(2-chloro-4-iodophenyl)amino]-N-{[(2R)-2,3-dihydroxypropyl]oxy}-3,4-difluorobenzamide",DB07046,"",,"",Dual specificity mitogen-activated protein kinase kinase 1,""
MAP2K1,"N-(5-{3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}-1,3,4-oxadiazol-2-yl)ethane-1,2-diamine",DB08130,"",,"",Dual specificity mitogen-activated protein kinase kinase 1,""
MAP2K1; MAP2K2; ALB; ORM1; ORM2; ABCB1; ABCG2; CYP2C19; UGT1A1; CYP2C9; CYP3A4; CYP1A2; CYP2C8; UGT1A3; CYP2E1; CYP3A5,Selumetinib,DB11689,"","Activation of the Raf-MEK-ERK signaling pathway is known to be implemented in several types of malignancies, thus, mitogen-activated protein kinase kinase (MEK) inhibitors such as selumetinib are important tools that can target the problematic overactivity of this pathway.[A193611]
Results from clinical trials investigating earlier developed MEK inhibitors were underwhelming.[A193611] However, selumetinib demonstrated impressive efficacy and tolerability in Phase I trials, leading to its continued investigation for the treatment of various types of tumors in Phase II trials.[A193611]

Currently, the novel MEK 1 / 2 inhibitor, selumetinib, is approved solely for the treatment of Neurofibromatosis type 1 (NF-1) in a limited age group. NF-1 is considered rare with an estimated incidence of 1/3000 individuals.[A193608] It is a genetic, autosomal dominant condition resulting from mutations of the NF1 gene, which can lead to various complications including the development of multiple tumors in the nervous system.[A193533,A193608] Some patients with this disorder develop plexiform neurofibromas (PN); however, this is considered to be relatively uncommon compared to other variants of NF-1.[A193608] Luckily, the use of selumetinib in patients with NF-1 has shown efficacy in shrinking associated tumors and is linked to other positive clinical outcomes.[A193533]","BCRP/ABCG2 Substrates; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2E1 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Kinase Inhibitor; Mitogen-Activated Protein Kinase Kinase 1 Inhibitors; Mitogen-Activated Protein Kinase Kinase 2 Inhibitors; P-glycoprotein substrates; Tyrosine Kinase Inhibitors; UGT1A1 Substrates",Dual specificity mitogen-activated protein kinase kinase 1; Dual specificity mitogen-activated protein kinase kinase 2; Serum albumin; alpha1-acid glycoprotein; P-glycoprotein 1; ATP-binding cassette sub-family G member 2; Cytochrome P450 2C19; UDP-glucuronosyltransferase 1-1; Cytochrome P450 2C9; Cytochrome P450 3A4; Cytochrome P450 1A2; Cytochrome P450 2C8; UDP-glucuronosyltransferase 1-3; Cytochrome P450 2E1; Cytochrome P450 3A5,inhibitor; carrier; substrate
PLAUR; FGA; PLG; SERPINE1,Alteplase,DB00009,B01AD02; S01XA13,"Human tissue plasminogen activator, purified, glycosylated, 527 residues purified from CHO cells","Agents causing angioedema; Amino Acids, Peptides, and Proteins; Anticoagulants; Blood and Blood Forming Organs; Blood Proteins; Cardiovascular Agents; Endopeptidases; Enzymes; Enzymes and Coenzymes; Fibrin Modulating Agents; Fibrinolytic Agents; Hematologic Agents; Hydrolases; Ophthalmologicals; Peptide Hydrolases; Plasminogen Activators; Proteins; Sensory Organs; Serine Endopeptidases; Serine Proteases; Tissue Plasminogen Activator; Tissue Plasminogen Activator, antagonists & inhibitors",Urokinase plasminogen activator surface receptor; Fibrinogen alpha chain; Plasminogen; Plasminogen activator inhibitor 1,activator
RAF1,LErafAON,DB04973,"","NeoPharm is developing liposome-encapsulated, c-Raf antisense oligodeoxynucleotides (LErafAON) for the potential treatment of various solid tumors, including those that have become resistant to radiation or chemotherapy. Phase I/II trials commenced in March 2001 and were ongoing as of June 2003.","Nucleic Acids, Nucleotides, and Nucleosides; Nucleotides; Oligonucleotides; Polynucleotides",RAF proto-oncogene serine/threonine-protein kinase,""
CYP3A4; CYP2C8; ABCB1; ABCG2; SLCO1B1; SLCO1B3; SLC22A6; SLC22A8; BRAF; RAF1; SIK1; NEK11; LIMK1; CYP2B6; CYP2C9; CYP2C19; CYP1A2; ALB; SLCO1A2; SLC22A2; UGT1A1,Dabrafenib,DB08912,L01XE23,"Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation [L41955]. It was also used for metastatic non-small cell lung cancer with the same mutation.[L41955]

In May 2018, Tafinlar (dabrafenib) and Mekinist ([DB08911]) in combination have been approved to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene [L41955].","Amines; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Azoles; BCRP/ABCG2 Inhibitors; BCRP/ABCG2 Substrates; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (strength unknown); Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inducers (strength unknown); Cytochrome P-450 CYP2B6 Inhibitors; Cytochrome P-450 CYP2B6 Inhibitors (strength unknown); Cytochrome P-450 CYP2C19 Inducers; Cytochrome P-450 CYP2C19 Inducers (strength unknown); Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2C8 Inducers; Cytochrome P-450 CYP2C8 Inducers (strength unknown); Cytochrome P-450 CYP2C8 Inducers (weak); Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strong); Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP2C9 Inducers (strength unknown); Cytochrome P-450 CYP2C9 Inducers (strong); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs causing inadvertant photosensitivity; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hydroxylamines; Hyperglycemia-Associated Agents; Kinase Inhibitor; Narrow Therapeutic Index Drugs; OAT1/SLC22A6 inhibitors; OAT3/SLC22A8 Inhibitors; OATP1B1/SLCO1B1 Inhibitors; OATP1B1/SLCO1B1 Substrates; OATP1B3 inhibitors; OATP1B3 substrates; OCT2 Inhibitors; Organic Anion Transporter 1 Inhibitors; Organic Anion Transporting Polypeptide 1B1 Inhibitors; Organic Anion Transporting Polypeptide 1B3 Inhibitors; P-glycoprotein substrates; P-glycoprotein substrates with a Narrow Therapeutic Index; Photosensitizing Agents; Potential QTc-Prolonging Agents; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf, antagonists & inhibitors; QTc Prolonging Agents; UGT1A1 Inhibitors",Cytochrome P450 3A4; Cytochrome P450 2C8; P-glycoprotein 1; ATP-binding cassette sub-family G member 2; Solute carrier organic anion transporter family member 1B1; Solute carrier organic anion transporter family member 1B3; Solute carrier family 22 member 6; Solute carrier family 22 member 8; Serine/threonine-protein kinase B-raf; RAF proto-oncogene serine/threonine-protein kinase; Serine/threonine-protein kinase SIK1; Serine/threonine-protein kinase Nek11; LIM domain kinase 1; Cytochrome P450 2B6; Cytochrome P450 2C9; Cytochrome P450 2C19; Cytochrome P450 1A2; Serum albumin; Solute carrier organic anion transporter family member 1A2; Solute carrier family 22 member 2; UDP-glucuronosyltransferase 1-1,substrate; inhibitor; inducer; binder
MMP2,SC-74020,DB01630,"","",Amides; Amines; Carboxylic Acids; Hydroxy Acids; Hydroxylamines; Sulfones; Sulfur Compounds,72 kDa type IV collagenase,""
ESR2; TOP2A; PTK2B; ABCB1; ABCC1; ABCG2; CYP1A2; NCOA1; ESR1; NCOA2; TTR; ESRRB; ESRRA; NR1I2; AKT1; GPER1; CYP1B1; SHBG; Cyp1a1; SLCO1B1; SLCO2B1; CYP2C8; CYP2C9; Cyp3a1; Cyp3a2; CYP3A4; CFTR,Genistein,DB01645,"","An isoflavonoid derived from soy products. It inhibits protein-tyrosine kinase and topoisomerase-II (DNA topoisomerases, type II) activity and is used as an antineoplastic and antitumor agent. Experimentally, it has been shown to induce G2 phase arrest in human and murine cell lines.

Additionally, genistein has antihelmintic activity. It has been determined to be the active ingredient in <I>Felmingia vestita</I>, which is a plant traditionally used against worms. It has shown to be effective in the treatment of common liver fluke, pork trematode and poultry cestode.

Further, genistein is a phytoestrogen which has selective estrogen receptor modulator properties. It has been investigated in clinical trials as an alternative to classical hormone therapy to help prevent cardiovascular disease in postmenopausal women [A14417].  

Natural sources of genistein include tofu, fava beans, soybeans, kudzu, and lupin.","Anticarcinogenic Agents; Antineoplastic Agents; BCRP/ABCG2 Inhibitors; Benzopyrans; Chromones; Compounds used in a research, industrial, or household setting; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors (weak); Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (moderate); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (weak); Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Enzyme Inhibitors; Estrogens, Non-Steroidal; Flavonoids; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Isoflavones; OATP1B1/SLCO1B1 Inhibitors; Organic Anion Transporting Polypeptide 2B1 Inhibitors; P-glycoprotein inhibitors; Phytoestrogens; Protective Agents; Protein Kinase Inhibitors; Pyrans; Tyrosine Kinase Inhibitors",Estrogen receptor beta; DNA topoisomerase 2-alpha; Protein-tyrosine kinase 2-beta; P-glycoprotein 1; Multidrug resistance-associated protein 1; ATP-binding cassette sub-family G member 2; Cytochrome P450 1A2; Nuclear receptor coactivator 1; Estrogen receptor alpha; Nuclear receptor coactivator 2; Transthyretin; Steroid hormone receptor ERR2; Steroid hormone receptor ERR1; Nuclear receptor subfamily 1 group I member 2; RAC-alpha serine/threonine-protein kinase; G-protein coupled estrogen receptor 1; Cytochrome P450 1B1; Sex hormone-binding globulin; Cytochrome P450 1A1; Solute carrier organic anion transporter family member 1B1; Solute carrier organic anion transporter family member 2B1; Cytochrome P450 2C8; Cytochrome P450 2C9; Cytochrome P450 3A1; Cytochrome P450 3A2; Cytochrome P450 3A4; Cystic fibrosis transmembrane conductance regulator,inhibitor; substrate; agonist; inducer; activator
AKT1; PLEKHA4; BTK; DAPP1; ITPKA; CYTH2; CYTH3; PDPK1,"Inositol 1,3,4,5-Tetrakisphosphate",DB01863,"",,Alcohols; Carbohydrates; Sugar Alcohols; Sugar Phosphates,RAC-alpha serine/threonine-protein kinase; Pleckstrin homology domain-containing family A member 4; Tyrosine-protein kinase BTK; Dual adapter for phosphotyrosine and 3-phosphotyrosine and 3-phosphoinositide; Inositol-trisphosphate 3-kinase A; Cytohesin-2; Cytohesin-3; 3-phosphoinositide-dependent protein kinase 1,inhibitor
COL1A1; MMP2,Halofuginone,DB04866,"","Halofuginone is a low molecular weight quinazolinone alkaloid, and a potent inhibitor of collagen alpha1(I) and matrix metalloproteinase 2 (MMP-2) gene expression. Halofuginone also effectively suppresses tumor progression and metastasis in mice. Collgard Biopharmaceuticals is developing halofuginone for the treatment of scleroderma and received orphan drug designation from the U.S. Food and Drug Administration in March, 2000.","Angiogenesis Inhibitors; Angiogenesis Modulating Agents; Anti-Infective Agents; Antineoplastic Agents; Antiparasitic Agents; Antiprotozoals; Coccidiostats; Enzyme Inhibitors; Growth Inhibitors; Growth Substances; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Protein Synthesis Inhibitors; Quinazolines",Collagen alpha-1(I) chain; 72 kDa type IV collagenase,""
PRKCB; AURKB; AURKA; CDK15; CHEK1; CHEK2; AKT1; PIK3R1,Enzastaurin,DB06486,"","Enzastaurin, an investigational, targeted, oral agent, will be evaluated at more than 100 sites worldwide for the treatment of relapsed glioblastoma multiforme (GBM), an aggressive and malignant form of brain cancer.","Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring",Protein kinase C beta type; Aurora kinase B; Aurora kinase A; Cyclin-dependent kinase 15; Serine/threonine-protein kinase Chk1; Serine/threonine-protein kinase Chk2; RAC-alpha serine/threonine-protein kinase; Phosphatidylinositol 3-kinase regulatory subunit alpha,""
AKT1; GSK3B,"5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine",DB07585,"",,"",RAC-alpha serine/threonine-protein kinase; Glycogen synthase kinase-3 beta,""
MAPK10; MAPK8IP1; MAPK8; TTK,Pyrazolanthrone,DB01782,"",,"Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic",Mitogen-activated protein kinase 10; C-Jun-amino-terminal kinase-interacting protein 1; Mitogen-activated protein kinase 8; Dual specificity protein kinase TTK,""
CYP2C9; PPARA; PPARG; SREBF1; RXRA; RXRB; RXRG; MYC,Doconexent,DB03756,"","A mixture of fish oil and primrose oil, doconexent is used as a high-docosahexaenoic acid (DHA) supplement. DHA is a 22 carbon chain with 6 cis double bonds with anti-inflammatory effects. It can be biosythesized from alpha-linolenic acid or commercially manufactured from microalgae. It is an omega-3 fatty acid and primary structural component of the human brain, cerebral cortex, skin, and retina thus plays an important role in their development and function. The amino-phospholipid DHA is found at a high concentration across several brain subcellular fractions, including nerve terminals, microsomes, synaptic vesicles, and synaptosomal plasma membranes [A19436].","Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Dietary Fats; Dietary Fats, Unsaturated; Fats; Fatty Acids; Fatty Acids, Omega-3; Fatty Acids, Unsaturated; Fish Oils; Lipids; Oils",Cytochrome P450 2C9; Peroxisome proliferator-activated receptor alpha; Peroxisome proliferator-activated receptor gamma; Sterol regulatory element-binding protein 1; Retinoic acid receptor RXR-alpha; Retinoic acid receptor RXR-beta; Retinoic acid receptor RXR-gamma; Myc proto-oncogene protein,substrate; inhibitor; activator
MAPK8IP1; MAPK8,"6-CHLORO-9-HYDROXY-1,3-DIMETHYL-1,9-DIHYDRO-4H-PYRAZOLO[3,4-B]QUINOLIN-4-ONE",DB07218,"",,"",C-Jun-amino-terminal kinase-interacting protein 1; Mitogen-activated protein kinase 8,""
MAPK8,2-({2-[(3-HYDROXYPHENYL)AMINO]PYRIMIDIN-4-YL}AMINO)BENZAMIDE,DB07268,"",,"",Mitogen-activated protein kinase 8,""
MAPK8IP1; MAPK8,"N-(4-AMINO-5-CYANO-6-ETHOXYPYRIDIN-2-YL)-2-(4-BROMO-2,5-DIMETHOXYPHENYL)ACETAMIDE",DB07272,"",,"",C-Jun-amino-terminal kinase-interacting protein 1; Mitogen-activated protein kinase 8,""
MAPK8,"2-fluoro-6-{[2-({2-methoxy-4-[(methylsulfonyl)methyl]phenyl}amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino}benzamide",DB07845,"",,"",Mitogen-activated protein kinase 8,""
ESR1; ESR2; CYP2C9; CYP3A4; CYP2D6; CYP2C8; CYP2B6; CES1; CYP3A5; CYP1A1; CYP1B1; CYP2C19; FMO1; FMO3; CYP3A7; ABCB1; ABCG2; CYP19A1; CYP2A6; CYP2E1; UGT1A10; SULT1A1; ABCC2; EBP; PRKCA; PRKCB; PRKCD; PRKCE; PRKCG; PRKCI; PRKCQ; PRKCZ; AR; KCNH2; NR1I2; ESRRG; SHBG; ABCB11; SERPINA7; SULT2A1; CYP1A2; UGT2B7; UGT2B17; SULT1E1; ABCA1; MAPK8; ALB,Tamoxifen,DB00675,L02BA01,"Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment for these types of cancers as patients generally have better survival, side effect profiles, and compliance with [anastrozole].[A1026]

Tamoxifen was granted FDA approval on 30 December 1977.[L7799]","Anti-Estrogens; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic and Immunomodulating Agents; BCRP/ABCG2 Substrates; Benzene Derivatives; Benzylidene Compounds; BSEP/ABCB11 Inhibitors; Cardiotoxic antineoplastic agents; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2A6 Substrates; Cytochrome P-450 CYP2A6 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2B6 Inhibitors; Cytochrome P-450 CYP2B6 Inhibitors (moderate); Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 CYP2B6 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (moderate); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2E1 Substrates; Cytochrome P-450 CYP2E1 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 CYP3A7 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Endocrine Therapy; Estrogen Agonist/Antagonist; Estrogen Antagonists; Estrogen Receptor Modulators; Hormone Antagonists; Hormone Antagonists and Related Agents; Hormones, Hormone Substitutes, and Hormone Antagonists; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Medications that reduce magnesium levels; Narrow Therapeutic Index Drugs; P-glycoprotein inducers; P-glycoprotein inhibitors; P-glycoprotein substrates; P-glycoprotein substrates with a Narrow Therapeutic Index; Potential QTc-Prolonging Agents; QTc Prolonging Agents; Selective Estrogen Receptor Modulators; Stilbenes; Thyroxine-binding globulin inducers; UGT2B17 substrates; UGT2B7 substrates; UGT2B7 Substrates with a Narrow Therapeutic Index","Estrogen receptor alpha; Estrogen receptor beta; Cytochrome P450 2C9; Cytochrome P450 3A4; Cytochrome P450 2D6; Cytochrome P450 2C8; Cytochrome P450 2B6; Liver carboxylesterase 1; Cytochrome P450 3A5; Cytochrome P450 1A1; Cytochrome P450 1B1; Cytochrome P450 2C19; Dimethylaniline monooxygenase [N-oxide-forming] 1; Dimethylaniline monooxygenase [N-oxide-forming] 3; Cytochrome P450 3A7; P-glycoprotein 1; ATP-binding cassette sub-family G member 2; Cytochrome P450 19A1; Cytochrome P450 2A6; Cytochrome P450 2E1; UDP-glucuronosyltransferase 1-10; Sulfotransferase 1A1; Canalicular multispecific organic anion transporter 1; 3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase; Protein kinase C; Androgen receptor; Potassium voltage-gated channel subfamily H member 2; Nuclear receptor subfamily 1 group I member 2; Estrogen-related receptor gamma; Sex hormone-binding globulin; Bile salt export pump; Thyroxine-binding globulin; Bile salt sulfotransferase; Cytochrome P450 1A2; UDP-glucuronosyltransferase 2B7; UDP-glucuronosyltransferase 2B17; Estrogen sulfotransferase; ATP-binding cassette sub-family A member 1; Mitogen-activated protein kinase 8; Serum albumin",antagonist; agonist; substrate; inhibitor; inducer; modulator
PLAUR; FGA; KLK1; LAMA5; F10; FN1; SERPINB2; CLEC3B; KRT8; ANXA2; LAMB1; LAMC1; LAMA1; CALR; CANX; LRP1; LAMA3,Lanoteplase,DB06245,"",,"Agents causing angioedema; Amino Acids, Peptides, and Proteins; Biological Factors; Blood Proteins; Endopeptidases; Enzymes; Enzymes and Coenzymes; Hydrolases; Peptide Hydrolases; Plasminogen Activators; Proteins; Serine Endopeptidases; Serine Proteases","Urokinase plasminogen activator surface receptor; Fibrinogen alpha chain; Kallikrein-1; Laminin subunit alpha-5; Coagulation factor X; Fibronectin; Plasminogen activator inhibitor 2; Tetranectin; Keratin, type II cytoskeletal 8; Annexin A2; Laminin subunit beta-1; Laminin subunit gamma-1; Laminin subunit alpha-1; Calreticulin; Calnexin; Prolow-density lipoprotein receptor-related protein 1; Laminin subunit alpha-3",""
MAPK1,"N,N-DIMETHYL-4-(4-PHENYL-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE",DB06877,"",,"",Mitogen-activated protein kinase 1,""
MAPK1; MAPK10,N-BENZYL-4-[4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL]-1H-PYRROLE-2-CARBOXAMIDE,DB07010,"",,"",Mitogen-activated protein kinase 1; Mitogen-activated protein kinase 10,""
MAPK1,(S)-N-(1-(3-CHLORO-4-FLUOROPHENYL)-2-HYDROXYETHYL)-4-(4-(3-CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE,DB07264,"",,"",Mitogen-activated protein kinase 1,""
MAPK1,"(3R,5Z,8S,9S,11E)-8,9,16-TRIHYDROXY-14-METHOXY-3-METHYL-3,4,9,10-TETRAHYDRO-1H-2-BENZOXACYCLOTETRADECINE-1,7(8H)-DIONE",DB07788,"",,"",Mitogen-activated protein kinase 1,""
MAPK1,Turpentine,DB11120,"","Turpentine, also known as spirit of turpentine, oil of turpentine, and wood turpentine, is a liquid extracted from live trees, mainly pine, through distillation of resin. It is used as a solvent and base material in organic synthesis reactions. Turpentine is composed of terpenes, mainly the monoterpenes alpha-pinene and beta-pinene with lesser amounts of carene, camphene, dipentene, and terpinolene.","Biological Products; Complex Mixtures; Compounds used in a research, industrial, or household setting; Irritants; Lipids; Noxae; Oils; Oils, Volatile; Plant Exudates; Resins, Plant; Solvents; Toxic Actions",Mitogen-activated protein kinase 1,""
A2M; SERPINF2; FN1,Ocriplasmin,DB08888,S01XA22,"Ocriplasmin is a recombinant truncated form of human plasmin with a molecular weight of 27.2 kDa produced by recombinant DNA technology in a Pichia pastoris expression system. Ocriplasmin is a protein made up of 249 amino acids and has two peptide chains.  Agent for pharmacologic vitreolysis; thrombolytic agent. FDA approved in October 17, 2012.","Amino Acids, Peptides, and Proteins; EENT Drugs, Miscellaneous; Endopeptidases; Enzymes; Enzymes and Coenzymes; Hydrolases; Ophthalmics; Ophthalmologicals; Peptide Hydrolases; Peptides; Sensory Organs; Serine Endopeptidases; Serine Proteases",Alpha-2-macroglobulin; Alpha-2-antiplasmin; Fibronectin,ligand; cleavage
CDK2; CDK5; CDK1; MAPK1,Olomoucine,DB02116,"",,"Cyclin-Dependent Kinases, antagonists & inhibitors; Cytokinins; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Purines",Cyclin-dependent kinase 2; Cyclin-dependent kinase 5; Cyclin-dependent kinase 1; Mitogen-activated protein kinase 1,inhibitor; binder
ABL; ABL1,N-[4-Methyl-3-[[4-(3-Pyridinyl)-2-Pyrimidinyl]Amino]Phenyl]-3-Pyridinecarboxamide,DB03878,"",,"",Tyrosine-protein kinase transforming protein Abl; Tyrosine-protein kinase ABL1,""
MAPK1,"5-(2-PHENYLPYRAZOLO[1,5-A]PYRIDIN-3-YL)-1H-PYRAZOLO[3,4-C]PYRIDAZIN-3-AMINE",DB07794,"",,"",Mitogen-activated protein kinase 1,""
MAPK1,Hypothemycin,DB07905,"",,"Benzene Derivatives; Biological Factors; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Lactones; Mycotoxins; Phenols; Resorcinols; Toxins, Biological",Mitogen-activated protein kinase 1,""
ABL1,PD-166326,DB08339,"",,"Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring",Tyrosine-protein kinase ABL1,""
CYP3A4; UGT2B7; UGT2B17; ABL1; ABCG2; UGT1A1; CYP2C19; ABCB1; SLCO1B1; SLCO1B3; SLC22A1; CYP2C9,Asciminib,DB12597,"","Asciminib is a tyrosine kinase inhibitor (TKI) used in the treatment of chronic-phase Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). More specifically, it is an inhibitor of the ABL1 kinase activity of the BCR-ABL1 fusion protein[L38995] which serves as a driver of CML proliferation in most patients with the disease.[L39005] It has also shown benefit in Ph+ CML with the T315I mutation, which produces a mutant BCR-ABL1 which is typically treatment-resistant as compared to wild-type BCR-ABL1.

Existing inhibitors of ABL compete at the ATP binding sites of these proteins and can be classified into those that target the active conformation of the kinase domain ([dasatinib], [bosutinib]) and those that target the inactive kinase domain ([imatinib], [nilotinib], [ponatinib]).[A241065] Asciminib is unique in that it acts as an allosteric inhibitor, binding at the myristoyl pocket of the BCR-ABL1 protein and locking it into an inactive conformation.[L38995,A241055]

Asciminib received FDA approval on October 29, 2021 (Scemblix, Novartis AG).[L39000]","Acids, Heterocyclic; Azoles; BCRP/ABCG2 Inhibitors; BCRP/ABCG2 Substrates; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Nicotinic Acids; OATP1B1/SLCO1B1 Inhibitors; OATP1B3 inhibitors; OCT1 inhibitors; P-glycoprotein inhibitors; P-glycoprotein substrates; Pyridines; UGT1A1 Inhibitors; UGT2B17 substrates; UGT2B7 substrates",Cytochrome P450 3A4; UDP-glucuronosyltransferase 2B7; UDP-glucuronosyltransferase 2B17; Tyrosine-protein kinase ABL1; ATP-binding cassette sub-family G member 2; UDP-glucuronosyltransferase 1-1; Cytochrome P450 2C19; P-glycoprotein 1; Solute carrier organic anion transporter family member 1B1; Solute carrier organic anion transporter family member 1B3; Solute carrier family 22 member 1; Cytochrome P450 2C9,substrate; inhibitor; allosteric modulator
ABCB1; CYP2C9; CYP1A2; CYP3A4; CSNK1E; PIK3CD; ABL1,Umbralisib,DB14989,"","Marginal zone lymphoma is a rare, slowly progressing type of non-Hodgkin lymphoma initially treated with [rituximab] (an anti-CD20 drug), either alone or in combination with chemotherapy. Unfortunately, many patients experience a relapse or develop resistance to these drugs. Treatment options then become limited, and alternate treatments for the lymphoma are required to control disease progression.[A229363] Follicular lymphoma is also treated with rituximab and other chemotherapeutic agents, but may show similar progression.[A229668]

On February 5, 2021, the Food and Drug Administration granted accelerated approval to umbralisib, a kinase inhibitor for PI3K-delta and casein kinase CK1-epsilon, based on promising results from clinical trials. It was marketed as Ukoniq by TG Therapeutics and has been approved for the treatment of relapsing and refractory marginal cell lymphoma and follicular lymphoma in adults.[L31863] Umbralisib inhibits casein kinase, a primary regulator of protein translation, kinase-1, distinguishing it from other lymphoma treatments. While it initially offered a promising therapy for patients experiencing relapsing or refractory disease,[A229363] umbralisib was withdrawn from the market due to safety concerns as the drug was associated with a possible increased risk of death outweighing the benefits.[L41930]","Antineoplastic Agents; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates (strength unknown); Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, Fused-Ring; Kinase Inhibitor; P-glycoprotein inhibitors; Protein Kinase Inhibitors","P-glycoprotein 1; Cytochrome P450 2C9; Cytochrome P450 1A2; Cytochrome P450 3A4; Casein kinase I isoform epsilon; Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform; Tyrosine-protein kinase ABL1; Tyrosine-protein kinase ABL1",inhibitor; substrate
RARB; RARG; RXRA; RXRB; RXRG; JUN; RARA; GOT1; TLR2,Adapalene,DB00210,D10AD03; D10AD53,"Acne vulgaris is a multifactorial disorder of the pilosebaceous unit involving increased sebum production, inflammation, and hyperproliferation/hyperkeratinization of the follicular infundibulum. It is also associated with _Cutibacterium acnes_ (also known as _Propionibacterium acnes_). Adapalene is a third-generation topical retinoid used for the treatment of acne vulgaris.[A193518] Adapalene has similar efficacy but a superior safety profile compared to tretinoin.[A193521] [Tazarotene] is more efficacious than adapalene but is designated as pregnancy category X and hence is contraindicated in pregnant women.[A193518] Adapalene can also be combined with benzoyl peroxide (BPO), which possesses bactericidal properties[A193524], and either adapalene alone, or adapalene BPO combination products, are commonly used to treat mild-to-severe acne.[A193518]

Differin, produced by Galderma Labs, was first granted FDA approval on May 31st, 1996, as a 0.1% adapalene topical solution. Differin was later made available as 0.1% gel, cream, or lotion, or 0.3% gel products. On December 8th, 2008, Galderma Labs gained FDA approval for Epiduo, a 0.1% adapalene, 2.5% BPO combination gel.[L12873]","Anti-Acne Preparations; Anti-Acne Preparations for Topical Use; Anti-Inflammatory Agents; Dermatologicals; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Misc. Skin and Mucous Membrane Agents; Naphthalenes; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Retinoids; Retinoids for Topical Use in Acne","Retinoic acid receptor beta; Retinoic acid receptor gamma; Retinoic acid receptor RXR-alpha; Retinoic acid receptor RXR-beta; Retinoic acid receptor RXR-gamma; Transcription factor AP-1; Retinoic acid receptor alpha; Aspartate aminotransferase, cytoplasmic; Toll-like receptor 2",agonist; antagonist; inhibitor
TUBB; JUN; CYP3A4; ABCB1; ABCC1; ABCC2; ABCC6; ABCB11; TUBA1A; TUBD1; TUBE1; TUBG1; CYP2D6; SLCO1B1,Vinblastine,DB00570,L01CA01,"Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)","ABVD chemotherapy regimen; Alkaloids; Antimitotic Agents; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic and Immunomodulating Agents; BSEP/ABCB11 Inhibitors; BSEP/ABCB11 Substrates; BSEP/ABCB11 Substrates with a Narrow Therapeutic Index; Cardiotoxic antineoplastic agents; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (weak); Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Immunosuppressive Agents; Indole Alkaloids; Indoles; Indolizidines; Indolizines; Mitosis Modulators; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; OATP1B1/SLCO1B1 Inhibitors; P-glycoprotein inducers; P-glycoprotein inhibitors; P-glycoprotein substrates; P-glycoprotein substrates with a Narrow Therapeutic Index; Secologanin Tryptamine Alkaloids; Tubulin Modulators; Vinca Alkaloids",Tubulin beta chain; Transcription factor AP-1; Cytochrome P450 3A4; P-glycoprotein 1; Multidrug resistance-associated protein 1; Canalicular multispecific organic anion transporter 1; Multidrug resistance-associated protein 6; Bile salt export pump; Tubulin alpha-1A chain; Tubulin delta chain; Tubulin epsilon chain; Tubulin gamma-1 chain; Cytochrome P450 2D6; Solute carrier organic anion transporter family member 1B1,binder; other/unknown; substrate; inhibitor; inducer
NFKB1; NFKB2,SGN-30,DB05471,"","SGN-30 is an  engineered monoclonal antibody (mAb) that reacts with significant affinity to the CD30 antigen, which is highly expressed on a variety of hematologic malignancies as compared to on normal cells. SGN-30 has been shown to induce direct anti-cancer activity towards tumor cells expressing CD30 and is undergoing phase II trials for cancer therapy.  SGN-30 has demonstrated objective antitumor responses as a single agent in phase II clinical trials. We are collaborating with the National Cancer Institute (NCI) on three clinical trials of SGN-30 in combination with chemotherapy for the treatment of relapsed Hodgkin lymphoma, front-line ALCL and pediatric ALCL.

SGN-30 received orphan drug designation from the FDA in July 2003 for Hodgkin lymphoma and in February 2004 for T-cell lymphomas. ","",Nuclear factor NF-kappa-B p105 subunit; Nuclear factor NF-kappa-B p100 subunit,""
PRKCQ; AURKA; MAPK1; PRKACA; PRKACB; CDK7; cobD; RHO; S100A11; MAPK12,Phosphonothreonine,DB02482,"","The phosphoric acid ester of threonine. Used as an identifier in the analysis of peptides, proteins, and enzymes. [PubChem]","",Protein kinase C theta type; Aurora kinase A; Mitogen-activated protein kinase 1; cAMP-dependent protein kinase catalytic subunit alpha; cAMP-dependent protein kinase catalytic subunit beta; Cyclin-dependent kinase 7; Threonine-phosphate decarboxylase; Rhodopsin; Protein S100-A11; Mitogen-activated protein kinase 12,""
MAPK1; INSR; IRS1,[4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID,DB08513,"",,"",Mitogen-activated protein kinase 1; Insulin receptor; Insulin receptor substrate 1,""
AGTR1; JUN; CYP2C9; CYP2C8; UGT1A3; PTGS1; CYP3A4; ALB; ORM1; ORM2,Irbesartan,DB01029,C09CA04; C09DB05; C09DA04; C09DX07,"Irbesartan is an angiotensin receptor blocker (ARB) indicated to treat hypertension or diabetic nephropathy.[L7456,L7459] It can also be used as part of a combination product with [hydrochlorothiazide] for patients not well controlled or not expected to be well controlled on monotherapy.[L7459] Unlike angiotensin converting enzyme inhibitors, ARBs are not associated with a dry cough.[L7456,L7459]

Irbesartan was granted FDA approval on 30 September 1997.[L7456,L7459]","Agents Acting on the Renin-Angiotensin System; Agents causing hyperkalemia; Angiotensin 2 Receptor Blocker; Angiotensin II receptor antagonists; Angiotensin II receptor blockers (ARBs) and calcium channel blockers; Angiotensin II receptor blockers (ARBs) and diuretics; Angiotensin II receptor blockers (ARBs), plain; Angiotensin II Type 2 Receptor Blockers; Angiotensin Receptor Antagonists; Antihypertensive Agents; Antihypertensive Agents Indicated for Hypertension; Azoles; Benzene Derivatives; Biphenyl Compounds; Cardiovascular Agents; Cardiovascular System; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (moderate); Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hypotensive Agents; Polycyclic Compounds; Spiro Compounds; Tetrazoles; UGT1A3 substrates",Type-1 angiotensin II receptor; Transcription factor AP-1; Cytochrome P450 2C9; Cytochrome P450 2C8; UDP-glucuronosyltransferase 1-3; Prostaglandin G/H synthase 1; Cytochrome P450 3A4; Serum albumin; alpha1-acid glycoprotein,antagonist; other/unknown; substrate; inhibitor; binder
TNF; PDE3A; PDE3B; PDE4A; PDE4B; PDE4C; PDE4D; ,Amrinone,DB01427,C01CE01,Amrinone (or inamrinone) is a type 3 pyridine phosphodiesterase inhibitor. It is used in the treatment of congestive heart failure.,"Amines; Aminopyridines; Calcium-Regulating Hormones and Agents; Cardiac Stimulants Excl. Cardiac Glycosides; Cardiac Therapy; Cardiotonic Agents; Cardiovascular Agents; Cardiovascular System; Compounds used in a research, industrial, or household setting; Drugs that are Mainly Renally Excreted; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Membrane Transport Modulators; Phosphodiesterase 3 Inhibitors; Phosphodiesterase Inhibitors; Protective Agents; Pyridines; Tumor Necrosis Factor Blockers; Vasodilating Agents","Tumor necrosis factor; cGMP-inhibited 3',5'-cyclic phosphodiesterase A; cGMP-inhibited 3',5'-cyclic phosphodiesterase B; cAMP-specific 3',5'-cyclic phosphodiesterase 4 (PDE4); cAMP-specific 3',5'-cyclic phosphodiesterase 3",inhibitor
TNF; IL6,YSIL6,DB05017,"","YSIL6 is a small-molecule drug in development for the treatment of inflammatory diseases, including rheumatoid arthritis and psoriasis. The molecule works by inhibiting TNF-alpha and IL-6 production in T-cells and macrophages, and by inhibiting T-cell proliferation and migration.","",Tumor necrosis factor; Interleukin-6,""
TNF,PN0621,DB05218,"","PN0621 is an anti-TNF, domain antibody (dAb) based therapeutic. It targets tumour necrosis factor (TNF) to treat auto-immune inflammatory diseases such as rheumatoid arthritis. It is being developed by Peptech.","",Tumor necrosis factor,""
TNF; IL6; CRP; IL10,CRx-139,DB05744,"","CRx-139 is an oral synergistic combination drug candidates with novel mechanisms of action targeting multiple biological pathways simultaneously. It is a dissociated steroid designed to enhance the immuno-modulatory activity of a low-dose glucocorticoid steroid without a comparable increase in steroid-related side effects. The synergistic combination containing low doses of the glucocorticoid steroid prednisolone and the antidepressant paroxetine. This novel synergistic combination is developed for the treatment of immuno-inflammatory diseases.

","",Tumor necrosis factor; Interleukin-6; C-reactive protein; Interleukin-10,""
TNF,AME-527,DB05879,"",AME-527 is a humanized monoclonal antibody that recognizes human TNF-alpha (hTNF-alpha) with high affinity and specificity. AME-527 was generated by protein engineering and identified from a library of antibody variants based on its improved binding properties. ,"",Tumor necrosis factor,""
TNF,Golimumab,DB06674,L04AB06,"Golimumab is a human IgG1 monoclonal antibody derived from immunizing genetically engineered mice with human TNF. Golimumab binds and inhibits soluble and transmembrane human TNF. Increased TNF is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications. In the U.S. and Canada, golimumab is marketed under the brand name Simponi. The FDA label includes a black box warning of serious infections and malignancy. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed.","Agents reducing cytokine levels; Amino Acids, Peptides, and Proteins; Anti-Inflammatory Agents; Antibodies; Antibodies, Monoclonal; Antineoplastic and Immunomodulating Agents; Antirheumatic Agents; Biologics for Rheumatoid Arthritis Treatment; Blood Proteins; Disease-modifying Antirheumatic Agents; Globulins; Immunoglobulins; Immunologic Factors; Immunoproteins; Immunosuppressive Agents; Proteins; Serum Globulins; Tumor Necrosis Factor Blockers; Tumor Necrosis Factor Receptor Blocking Activity",Tumor necrosis factor,antibody
CSNK1G2; GSG2; MAPK3,5-iodotubercidin,DB04604,"","","Adenosine Kinase, antagonists & inhibitors; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Nucleic Acids, Nucleotides, and Nucleosides; Nucleosides; Purine Nucleosides; Purines; Ribonucleosides",Casein kinase I isoform gamma-2; Serine/threonine-protein kinase haspin; Mitogen-activated protein kinase 3,""
PTGS2; AKR1B1; PTGS1; MAPK3; PPARD; PTGDR2; ALB; SLC22A6; CYP1A1; AKR1B10,Sulindac,DB00605,M01AB02,"Sulindac is a nonsteroidal anti-inflammatory drug (NSAID) of the arylalkanoic acid class that is marketed by Merck under the brand name Clinoril. Like other NSAIDs, it may be used in the treatment of acute or chronic inflammatory conditions. Sulindac is a prodrug, derived from sulfinylindene, that is converted _in vivo_ to an active sulfide compound by liver enzymes. There is evidence from some studies that sulindac may be associated with fewer gastrointestinal side effects than other NSAIDs, except for the cyclooxygenase-2 (COX-2) inhibitor drug class. This may be due to the sulfide metabolite undergoing enterohepatic circulation thus maintaining constant blood levels of the compound without inducing gastrointestinal effects, where the drug is excreted in the bile and then reabsorbed from the intestines. While its full mechanism of action is not fully understood, sulindac is thought to primarily mediate its action by inhibiting prostaglandin synthesis by inhibiting COX-1 and COX-2.","Acetic Acid Derivatives and Related Substances; Agents causing hyperkalemia; Agents that produce hypertension; Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Inflammatory Agents, Non-Steroidal (Non-Selective); Antiinflammatory and Antirheumatic Products; Antiinflammatory and Antirheumatic Products, Non-Steroids; Antirheumatic Agents; Cyclooxygenase Inhibitors; Drugs causing inadvertant photosensitivity; Enzyme Inhibitors; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Indenes; Musculo-Skeletal System; Nephrotoxic agents; Non COX-2 selective NSAIDS; OAT1/SLC22A6 inhibitors; Other Nonsteroidal Anti-inflammatory Agents; Peripheral Nervous System Agents; Photosensitizing Agents; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Sensory System Agents",Prostaglandin G/H synthase 2; Aldose reductase; Prostaglandin G/H synthase 1; Mitogen-activated protein kinase 3; Peroxisome proliferator-activated receptor delta; Prostaglandin D2 receptor 2; Serum albumin; Solute carrier family 22 member 6; Cytochrome P450 1A1; Aldo-keto reductase family 1 member B10,inhibitor; negative modulator; antagonist
TNF,Plinabulin,DB05992,"",,"Deuterium; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Piperazines",Tumor necrosis factor,""
TNF; LTA; FCGR3B; FCGR3A; FCGR1A; FCGR2A; FCGR2B; FCGR2C; C1QA; C1QB; C1QC,Etanercept,DB00005,L04AB01,"Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.[L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of IgG1. Etanercept is produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell expression system. It consists of 934 amino acids. It is used to treat or manage a variety of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis (AS), and juvenile idiopathic poly-articular arthritis (JIA).","Agents reducing cytokine levels; Amino Acids, Peptides, and Proteins; Anti-Inflammatory Agents; Antibodies; Antirheumatic Agents; Biological Products; Biologics for Rheumatoid Arthritis Treatment; Dermatologicals; Disease-modifying Antirheumatic Agents; Immunoglobulin Constant Regions; Immunoglobulin Fc Fragments; Immunoglobulin Fragments; Immunoglobulin Isotypes; Immunologic Factors; Immunoproteins; Immunosuppressive Agents; Membrane Proteins; Peptides; Proteins; Tumor Necrosis Factor Blockers",Tumor necrosis factor; Lymphotoxin-alpha; Low affinity immunoglobulin gamma Fc region receptor III-B; Low affinity immunoglobulin gamma Fc region receptor III-A; High affinity immunoglobulin gamma Fc receptor I; Low affinity immunoglobulin gamma Fc region receptor II-a; Low affinity immunoglobulin gamma Fc region receptor II-b; Low affinity immunoglobulin gamma Fc region receptor II-c; Complement component 1q (C1q),antibody; ligand
TNF,Adalimumab,DB00051,L04AB04,"Adalimumab is a subcutaneously administered biological disease modifier for the treatment of rheumatoid arthritis and other chronic debilitating diseases mediated by tumor necrosis factor [A39984], [A39999]. It was originally launched by Abbvie in the U.S. and approved in 2002 by the FDA [A39983]. This drug is frequently known as _Humira_. It is produced by recombinant DNA technology using a mammalian cell expression system. This drug is available in a prefilled syringe form and convenient pen form for subcutaneous self-administered doses [A39983]. A new biosimilar to adalimumab, named _adalimumab-adaz_, was approved by the FDA on October 31, 2018. This biosimilar is known as _Hyrimoz_, and is a trademark of Novartis AG [L4799].","Agents reducing cytokine levels; Amino Acids, Peptides, and Proteins; Anti-Inflammatory Agents; Antibodies; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic and Immunomodulating Agents; Antirheumatic Agents; Biological Products; Biologics for Rheumatoid Arthritis Treatment; Blood Proteins; Complex Mixtures; Disease-modifying Antirheumatic Agents; Globulins; Immunoglobulins; Immunomodulatory Agents; Immunoproteins; Immunosuppressive Agents; Miscellaneous GI Drugs; Proteins; Serum Globulins; Tumor Necrosis Factor Blockers; Tumor Necrosis Factor Receptor Blocking Activity",Tumor necrosis factor,antibody
TNF; AKR1A1,Certolizumab pegol,DB08904,L04AB05,"Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha).[A176585] It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent complement fixation and antibody-mediated cytotoxicity as well as to markedly increase its half-life.[A176606] 

Certolizumab does not require glycosylation for active function and hence, its production is significantly more affordable when compared to other existing TNF-alpha therapies as it can be done directly in bacterial hosts such as _E. coli_.[A176606] It was developed and manufactured by UCB Pharma, first FDA approved in 2008[L4894] and updated for a new indication on March 28, 2019.[L5819]","Agents reducing cytokine levels; Alcohols; Amino Acids, Peptides, and Proteins; Anti-Inflammatory Agents; Antibodies; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic and Immunomodulating Agents; Antirheumatic Agents; Biologics for Rheumatoid Arthritis Treatment; Blood Proteins; Disease-modifying Antirheumatic Agents; Drugs that are Mainly Renally Excreted; Ethylene Glycols; Globulins; Glycols; Immunoglobulin Fab Fragments; Immunoglobulin Fragments; Immunoglobulins; Immunologic Factors; Immunoproteins; Immunosuppressive Agents; Immunotherapy; Macromolecular Substances; Pegylated agents; Peptide Fragments; Peptides; Polyethylene Glycols; Polymers; Proteins; Serum Globulins; Tumor Necrosis Factor Blockers; Tumor Necrosis Factor Receptor Blocking Activity",Tumor necrosis factor; Alcohol dehydrogenase [NADP(+)],neutralizer; substrate
TNF; TLR9; GSTA2; CYP2D6; CYP3A4; CYP1A1; CYP2C8; CYP3A5; GST; ABCB1; ALB; ORM1; ORM2; HMGB1; GSTM1; ACE2,Chloroquine,DB00608,P01BA01,"Chloroquine is an aminoquinolone derivative first developed in the 1940s for the treatment of malaria.[A191655] It was the drug of choice to treat malaria until the development of newer antimalarials such as [pyrimethamine], [artemisinin], and [mefloquine].[A191787] Chloroquine and its derivative [hydroxychloroquine] have since been repurposed for the treatment of a number of other conditions including HIV, systemic lupus erythematosus, and rheumatoid arthritis.[A192432]

**The FDA emergency use authorization for [hydroxychloroquine] and chloroquine in the treatment of COVID-19 was revoked on 15 June 2020.[L14312]**

Chloroquine was granted FDA Approval on 31 October 1949.[L12054]","Agents Causing Muscle Toxicity; Agents that produce neuromuscular block (indirect); Agents that reduce seizure threshold; alpha-Galactosidase, antagonists & inhibitors; Amebicides; Aminoquinolines; Analgesics; Analgesics, Non-Narcotic; Anti-Infective Agents; Anti-Inflammatory Agents; Antimalarials; Antinematodal Agents; Antiparasitic Agents; Antiparasitic Products, Insecticides and Repellents; Antiprotozoals; Antirheumatic Agents; Central Nervous System Agents; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (moderate); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs causing inadvertant photosensitivity; Drugs that are Mainly Renally Excreted; Experimental Unapproved Treatments for COVID-19; Filaricides; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Methemoglobinemia Associated Agents; Moderate Risk QTc-Prolonging Agents; P-glycoprotein inhibitors; P-glycoprotein substrates; Peripheral Nervous System Agents; Photosensitizing Agents; QTc Prolonging Agents; Quinolines; Sensory System Agents; Tumor Necrosis Factor Blockers",Tumor necrosis factor; Toll-like receptor 9; Glutathione S-transferase A2; Cytochrome P450 2D6; Cytochrome P450 3A4; Cytochrome P450 1A1; Cytochrome P450 2C8; Cytochrome P450 3A5; Glutathione S-transferase; P-glycoprotein 1; Serum albumin; alpha1-acid glycoprotein; High mobility group protein B1; Glutathione S-transferase Mu 1; Angiotensin-converting enzyme 2,inhibitor; substrate; binder; modulator
CYP1A2; CYP3A4; ABCB1; CRBN; TNF; PTGS2,Pomalidomide,DB08910,L04AX06,"Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.","Acids, Carbocyclic; Angiogenesis Inhibitors; Angiogenesis Modulating Agents; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Cancer immunotherapy; Carboxylic Acids; Central Nervous System Depressants; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Growth Inhibitors; Growth Substances; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Imides; Immunologic Factors; Immunosuppressive Agents; Immunotherapy; Isoindoles; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; P-glycoprotein substrates; P-glycoprotein substrates with a Narrow Therapeutic Index; Phthalic Acids; Phthalimides; Piperidines; Piperidones; Thalidomide Analog; Tumor Necrosis Factor Blockers",Cytochrome P450 1A2; Cytochrome P450 3A4; P-glycoprotein 1; Protein cereblon; Tumor necrosis factor; Prostaglandin G/H synthase 2,substrate; inhibitor
ABL1,"2-{[(6-OXO-1,6-DIHYDROPYRIDIN-3-YL)METHYL]AMINO}-N-[4-PROPYL-3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE",DB07831,"",,"",Tyrosine-protein kinase ABL1,""
ABL1,1-[4-(PYRIDIN-4-YLOXY)PHENYL]-3-[3-(TRIFLUOROMETHYL)PHENYL]UREA,DB08043,"",,"",Tyrosine-protein kinase ABL1,""
; ALB; PKIA; PRKACA; fadR; ECI2; FABP2; RCVRN; CALM1; luxF; ABL1; lpxC; HNF4A; NCOA1; nef; fhuA; FKBP1A; PPP3R1; PPP3CA; pks18; gag-pol; TRAPPC3; INS; GM2A; ARF6; LY96; tonB; gag; ARF1; GUCA1A; APOM; nrdB; PVR; TLR4; PPARA,Myristic acid,DB08231,"",,Fatty Acids; Lipids; Myristic Acids,"Genome polyprotein; Genome polyprotein; Genome polyprotein; Genome polyprotein; Serum albumin; cAMP-dependent protein kinase inhibitor alpha; cAMP-dependent protein kinase catalytic subunit alpha; Genome polyprotein; Genome polyprotein; Genome polyprotein; Genome polyprotein; Genome polyprotein; Fatty acid metabolism regulator protein; Enoyl-CoA delta isomerase 2, mitochondrial; Fatty acid-binding protein, intestinal; Recoverin; Calmodulin; Non-fluorescent flavoprotein; Genome polyprotein; Tyrosine-protein kinase ABL1; UDP-3-O-[3-hydroxymyristoyl] N-acetylglucosamine deacetylase; Genome polyprotein; Hepatocyte nuclear factor 4-alpha; Nuclear receptor coactivator 1; Protein Nef; Ferrichrome-iron receptor; Peptidyl-prolyl cis-trans isomerase FKBP1A; Calcineurin subunit B type 1; Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform; Alpha-pyrone synthesis polyketide synthase-like Pks18; Gag-Pol polyprotein; Trafficking protein particle complex subunit 3; Insulin; Genome polyprotein; Polyprotein; Ganglioside GM2 activator; ADP-ribosylation factor 6; Lymphocyte antigen 96; Protein TonB; Gag polyprotein; Gag-Pol polyprotein; ADP-ribosylation factor 1; Guanylyl cyclase-activating protein 1; Apolipoprotein M; R2-like ligand binding oxidase; Poliovirus receptor; Toll-like receptor 4; Peroxisome proliferator-activated receptor alpha",""
ABL1,"5-[3-(2-METHOXYPHENYL)-1H-PYRROLO[2,3-B]PYRIDIN-5-YL]-N,N-DIMETHYLPYRIDINE-3-CARBOXAMIDE",DB08350,"",,"",Tyrosine-protein kinase ABL1,""
CKB; ABL1; ATP5D; ADCY1; GUCY1A2; PFKFB1; ATP1A1,Magnesium gluconate,DB13749,A12CC03,"Magnesium gluconate is a magnesium salt of gluconate. It demonstrates the highest oral bioavailability of magnesium salts [L2608] and is used as a mineral supplement. Magnesium is ubiquitous in the human body, and is naturally present in many foods, added to other food products, available as a dietary supplement and used as an ingredient in some medicines (such as antacids and laxatives) [L2601].

Although magnesium is available in the form of sulphates, lactate, hydroxide, oxide and chloride, only magnesium gluconate is recommended for magnesium supplementation as it appears to be better absorbed and causes less diarrha [A32821].

This drug has been studied in the prevention of pregnancy-induced hypertension, and has displayed promising results [A32807]. In addition, it has been studied for its effects on premature uterine contractions [A32808].","Acids, Acyclic; Agents that produce neuromuscular block (indirect); Alimentary Tract and Metabolism; Carbohydrates; Carboxylic Acids; Hydroxy Acids; Magnesium Compounds; Metal cations; Metal divalent cations; Mineral Supplements; Sugar Acids","Creatine kinase B-type; Tyrosine-protein kinase ABL1; ATP synthase subunit delta, mitochondrial; Adenylate cyclase type 1; Guanylate cyclase soluble subunit alpha-2; 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 1; Sodium/potassium-transporting ATPase subunit alpha-1",substrate; inducer
ABL1; BCR; KIT; RET; TEK; FLT3; CYP3A4; CYP2C8; CYP2D6; CYP3A5; ABCB1; ABCG2; FGFR1; FGFR2; FGFR3; FGFR4; LCK; SRC; LYN; KDR; PDGFRA,Ponatinib,DB08901,L01XE24,"Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.","Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Azoles; BCRP/ABCG2 Inhibitors; BCRP/ABCG2 Substrates; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Substrates; Enzyme Inhibitors; Hepatotoxic Agents; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Immunosuppressive Agents; Kinase Inhibitor; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; P-glycoprotein inhibitors; P-glycoprotein substrates; P-glycoprotein substrates with a Narrow Therapeutic Index; Protein Kinase Inhibitors; Tyrosine Kinase Inhibitors",Tyrosine-protein kinase ABL1; Breakpoint cluster region protein; Mast/stem cell growth factor receptor Kit; Proto-oncogene tyrosine-protein kinase receptor Ret; Angiopoietin-1 receptor; Receptor-type tyrosine-protein kinase FLT3; Cytochrome P450 3A4; Cytochrome P450 2C8; Cytochrome P450 2D6; Cytochrome P450 3A5; P-glycoprotein 1; ATP-binding cassette sub-family G member 2; Fibroblast growth factor receptor 1; Fibroblast growth factor receptor 2; Fibroblast growth factor receptor 3; Fibroblast growth factor receptor 4; Tyrosine-protein kinase Lck; Proto-oncogene tyrosine-protein kinase Src; Tyrosine-protein kinase Lyn; Vascular endothelial growth factor receptor 2; Platelet-derived growth factor receptor alpha,inhibitor; substrate
CASP1; IL1B,VX-765,DB05507,"","VX-765 is the orally available prodrug of a potent and selective competitive inhibitor of ICE/caspase-1 (VRT-043198). VX-765 is currently under clinical development for the treatment of inflammatory and autoimmune conditions, as it blocks the hypersensitive response to an inflammatory stimulus.","Acids, Carbocyclic; Amino Acids, Peptides, and Proteins; Aminobenzoates; Benzene Derivatives; Benzoates; Carboxylic Acids; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Oligopeptides; Peptides",Caspase-1; Interleukin-1 beta,""
IL1B,Canakinumab,DB06168,L04AC08,"Canakinumab is a recombinant, human anti-human-IL-1 monoclonal antibody that belongs to the IgG1/ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. Both heavy chains of canakinumab contain oligosaccharide chains linked to the protein backbone at asparagine 298 (Asn 298). Canakinumab binds to human IL-1 and neutralizes its inflammatory activity by blocking its interaction with IL-1 receptors, but it does not bind IL-1alpha or IL-1 receptor antagonist (IL-1ra). Canakinumab is marketed under the brand name Ilaris and indicated for patients 4 years of age and older to treat Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), which are both part of the Cryopyrin-Associated Periodic Syndromes (CAPS) as well as for patients 2 years of age and older to treat systemic juvenile idiopathic arthritis (SJIA). Clinical trials have established the administration of canakinumab every 2 weeks to be safe and effective, offering a considerable advantage over the existing treatment with the human IL-1 receptor antagonist, anakinra, which must be injected daily and which is often poorly tolerated by patients.","Agents reducing cytokine levels; Amino Acids, Peptides, and Proteins; Antibodies; Antibodies, Monoclonal; Antineoplastic and Immunomodulating Agents; Blood Proteins; Globulins; Immunoglobulins; Immunoproteins; Immunosuppressive Agents; Interleukin Inhibitors; Interleukin-1beta, antagonists & inhibitors; Proteins; Serum Globulins",Interleukin-1 beta,binder
ABL1,"2-amino-5-[3-(1-ethyl-1H-pyrazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,N-dimethylbenzamide",DB08583,"",,"",Tyrosine-protein kinase ABL1,""
ABL1,Radotinib,DB12323,"","Radotinib is under investigation for the treatment of Leukemia, Myelogenous, Chronic, BCR-ABL Positive.","Acids, Carbocyclic; Amides; Benzene Derivatives; Benzoates; Carboxylic Acids; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Tyrosine Kinase Inhibitors",Tyrosine-protein kinase ABL1,antagonist
PDGFRB; ABL1; KIT; RET; NTRK1; CSF1R; PDGFRA; DDR1; CYP3A4; BCR; CYP1A2; CYP2D6; CYP2C9; CYP2C19; CYP3A5; CYP3A7; SLC22A1; ABCB1; SLC22A2; ABCG2; ABCA3; ALB; ORM1; ABCB11; CYP2C8; ABCC2,Imatinib,DB00619,L01XE01,"Imatinib is a small molecule kinase inhibitor used to treat certain types of cancer. It is currently marketed by Novartis as Gleevec (USA) or Glivec (Europe/Australia) as its mesylate salt, imatinib mesilate (INN). It is occasionally referred to as CGP57148B or STI571 (especially in older publications). It is used in treating chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies.

It is the first member of a new class of agents that act by inhibiting particular tyrosine kinase enzymes, instead of non-specifically inhibiting rapidly dividing cells.","Acids, Carbocyclic; Amides; Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; BCRP/ABCG2 Inhibitors; BCRP/ABCG2 Substrates; Benzamides and benzamide derivatives; Benzene Derivatives; Benzoates; BSEP/ABCB11 Substrates; Cancer immunotherapy; Carboxylic Acids; Cardiotoxic antineoplastic agents; Cytochrome P-450 CYP1A2 Substrates; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (moderate); Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (weak); Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Inhibitors; Cytochrome P-450 CYP3A5 Inhibitors (strength unknown); Cytochrome P-450 CYP3A5 Substrates; Cytochrome P-450 CYP3A7 Inhibitors; Cytochrome P-450 CYP3A7 Inhibitors (strength unknown); Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs causing inadvertant photosensitivity; Enzyme Inhibitors; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Highest Risk QTc-Prolonging Agents; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Immunosuppressive Agents; Immunotherapy; Kinase Inhibitor; Myelosuppressive Agents; OCT1 substrates; OCT2 Inhibitors; P-glycoprotein inhibitors; P-glycoprotein substrates; Photosensitizing Agents; Piperazines; Protein Kinase Inhibitors; Pyrimidines; QTc Prolonging Agents; Tyrosine Kinase Inhibitors; UDP Glucuronosyltransferases Inhibitors; UGT2B17 Inhibitors",Platelet-derived growth factor receptor beta; Tyrosine-protein kinase ABL1; Mast/stem cell growth factor receptor Kit; RET proto-oncogene; High affinity nerve growth factor receptor; Macrophage colony-stimulating factor 1 receptor; Platelet-derived growth factor receptor alpha; Epithelial discoidin domain-containing receptor 1; Cytochrome P450 3A4; Breakpoint cluster region protein; Cytochrome P450 1A2; Cytochrome P450 2D6; Cytochrome P450 2C9; Cytochrome P450 2C19; Cytochrome P450 3A5; Cytochrome P450 3A7; Solute carrier family 22 member 1; P-glycoprotein 1; Solute carrier family 22 member 2; ATP-binding cassette sub-family G member 2; ATP-binding cassette sub-family A member 3; Serum albumin; Alpha-1-acid glycoprotein 1; Bile salt export pump; Cytochrome P450 2C8; Canalicular multispecific organic anion transporter 1,antagonist; inhibitor; substrate; binder
ABL1; KIT; CYP2D6; CYP2C8; CYP2C9; CYP3A4; ABCB1; ABCG2; UGT1A1; CYP2B6; SLCO1B1,Nilotinib,DB04868,L01XE08,"Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec), another tyrosine kinase inhibitor used as a first-line treatment for CML.","Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; Bcr-Abl Tyrosine Kinase Inhibitors; BCRP/ABCG2 Inhibitors; BCRP/ABCG2 Substrates; Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2B6 Inducers (strength unknown); Cytochrome P-450 CYP2C8 Inducers; Cytochrome P-450 CYP2C8 Inducers (strength unknown); Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (moderate); Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (moderate); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Inhibitors (strong); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Substrates; Drugs causing inadvertant photosensitivity; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Highest Risk QTc-Prolonging Agents; Hyperglycemia-Associated Agents; Immunosuppressive Agents; Kinase Inhibitor; Myelosuppressive Agents; Narrow Therapeutic Index Drugs; OATP1B1/SLCO1B1 Inhibitors; P-glycoprotein inhibitors; P-glycoprotein substrates; P-glycoprotein substrates with a Narrow Therapeutic Index; Photosensitizing Agents; Protein Kinase Inhibitors; QTc Prolonging Agents; Tyrosine Kinase Inhibitors; UGT1A1 Inhibitors",Tyrosine-protein kinase ABL1; Mast/stem cell growth factor receptor Kit; Cytochrome P450 2D6; Cytochrome P450 2C8; Cytochrome P450 2C9; Cytochrome P450 3A4; P-glycoprotein 1; ATP-binding cassette sub-family G member 2; UDP-glucuronosyltransferase 1-1; Cytochrome P450 2B6; Solute carrier organic anion transporter family member 1B1,inhibitor; antagonist; inducer; substrate
ALK; EGFR; ABL1; IGF1R; FLT3; CYP2C8; CYP3A4; INSR; MET; ERBB4; ERBB2; ABCB5; ABCG2; SLC22A1; SLC47A1; SLC47A2; CYP3A4; CYP3A43; CYP3A5; CYP3A7,Brigatinib,DB12267,L01XE43,"Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type.[A31311] It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the EML4-ALK fusion gene, which is a pivotal player in the transformation of susceptible lung parenchyma.[A31313] Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and FDA-approved on April 28, 2017.[L1026]","Antineoplastic Agents; Antineoplastic and Immunomodulating Agents; BCRP/ABCG2 Inhibitors; BCRP/ABCG2 Substrates; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Kinase Inhibitor; MATE 1 Inhibitors; MATE 2 Inhibitors; MATE inhibitors; Narrow Therapeutic Index Drugs; Protein Kinase Inhibitors; Tyrosine Kinase Inhibitors",ALK tyrosine kinase receptor; Epidermal growth factor receptor; Tyrosine-protein kinase ABL1; Insulin-like growth factor 1 receptor; Receptor-type tyrosine-protein kinase FLT3; Cytochrome P450 2C8; Cytochrome P450 3A4; Insulin receptor; Hepatocyte growth factor receptor; Receptor tyrosine-protein kinase erbB-4; Receptor tyrosine-protein kinase erbB-2; ATP-binding cassette sub-family B member 5; ATP-binding cassette sub-family G member 2; Solute carrier family 22 member 1; Multidrug and toxin extrusion protein 1; Multidrug and toxin extrusion protein 2; Cytochrome P450 3A Subfamily,inhibitor; substrate; binding; inducer
MAPK14,6((S)-3-Benzylpiperazin-1-Yl)-3-(Naphthalen-2-Yl)-4-(Pyridin-4-Yl)Pyrazine,DB01988,"",,"",Mitogen-activated protein kinase 14,""
MAPK14,"3-(4-Fluorophenyl)-1-Hydroxy-2-(Pyridin-4-Yl)-1h-Pyrrolo[3,2-B]Pyridine",DB02195,"",,"",Mitogen-activated protein kinase 14,""
MAPK14,2-Chlorophenol,DB03110,"",,"Benzene Derivatives; Chlorobenzenes; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Phenols",Mitogen-activated protein kinase 14,""
MAPK14,4-(2-HYDROXYBENZYLAMINO)-N-(3-(4-FLUOROPHENOXY)PHENYL)PIPERIDINE-1-SULFONAMIDE,DB04632,"",,"",Mitogen-activated protein kinase 14,""
MAPK14; MAPK11; MAPK12; MAPK13,KC706,DB05157,"","KC706 is a novel anti-inflammatory drug that works by inhibiting the activity of p38 MAP kinase. KC706 holds potential to treat inflammatory conditions such as rheumatoid arthritis, psoriasis, inflammatory bowel disease and cardiovascular disease.","",Mitogen-activated protein kinase 14; Mitogen-activated protein kinase 11; Mitogen-activated protein kinase 12; Mitogen-activated protein kinase 13,""
MAPK14,4-[5-(3-IODO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-1H-IMIDAZOL-4-YL]-PYRIDINE,DB07607,"",,"",Mitogen-activated protein kinase 14,""
MAPK14,"N-cyclopropyl-2',6-dimethyl-4'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-3-carboxamide",DB07811,"",,"",Mitogen-activated protein kinase 14,""
MAPK14,4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDINE,DB07829,"",,"",Mitogen-activated protein kinase 14,""
MAPK14,"N~3~-cyclopropyl-N~4~'-(cyclopropylmethyl)-6-methylbiphenyl-3,4'-dicarboxamide",DB07835,"",,"",Mitogen-activated protein kinase 14,""
MAPK14,SD-0006,DB07943,"",,"Azoles; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring",Mitogen-activated protein kinase 14,""
MAPK14,3-fluoro-N-1H-indol-5-yl-5-morpholin-4-ylbenzamide,DB08092,"",3-fluoro-N-1H-indol-5-yl-5-morpholin-4-ylbenzamide is a solid. This compound belongs to the phenylmorpholines. These are aromatic compounds containing a morpholine ring and a benzene ring linked to each other through a CC or a CN bond. This drug targets mitogen-activated protein kinase 14.,"",Mitogen-activated protein kinase 14,""
MAPK14,"3-(2-CHLOROPHENYL)-1-(2-{[(1S)-2-HYDROXY-1,2-DIMETHYLPROPYL]AMINO}PYRIMIDIN-4-YL)-1-(4-METHOXYPHENYL)UREA",DB08095,"",,"",Mitogen-activated protein kinase 14,""
MAPK14,"6-[4-(2-fluorophenyl)-1,3-oxazol-5-yl]-N-(1-methylethyl)-1,3-benzothiazol-2-amine",DB08352,"",,"",Mitogen-activated protein kinase 14,""
MAPK14,"[5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL](3-{[(2R)-2,3-DIHYDROXYPROPYL]OXY}PHENYL)METHANONE",DB08424,"",,"",Mitogen-activated protein kinase 14,""
ADRB2; NGF; TNF; ADRB1; ADRB3; CYP1A1,Clenbuterol,DB01407,R03CC13; R03AC14; R03CC63,A substituted phenylaminoethanol that has beta-2 adrenomimetic properties at very low doses. It is used as a bronchodilator in asthma.,"Adrenergic Agents; Adrenergic Agonists; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Agonists; Adrenergics for Systemic Use; Adrenergics, Inhalants; Agents producing tachycardia; Agents that produce hypertension; Agents to Treat Airway Disease; Alcohols; Amines; Amino Alcohols; Anti-Asthmatic Agents; Autonomic Agents; Bronchodilator Agents; Drugs for Obstructive Airway Diseases; Ethanolamines; Long-acting beta-adrenoceptor agonists; Neurotransmitter Agents; Peripheral Nervous System Agents; Respiratory System; Respiratory System Agents; Selective Beta 2-adrenergic Agonists; Sympathomimetics",Beta-2 adrenergic receptor; Beta-nerve growth factor; Tumor necrosis factor; Beta-1 adrenergic receptor; Beta-3 adrenergic receptor; Cytochrome P450 1A1,agonist; stimulator; other/unknown; substrate
MAPK14,"1-(2,6-Dichlorophenyl)-5-(2,4-Difluorophenyl)-7-Piperidin-4-Yl-3,4-Dihydroquinolin-2(1h)-One",DB01948,"",,"",Mitogen-activated protein kinase 14,""
MAPK14,1-(5-Tert-Butyl-2-Methyl-2h-Pyrazol-3-Yl)-3-(4-Chloro-Phenyl)-Urea,DB02277,"",,"",Mitogen-activated protein kinase 14,""
MAPK14,"1-(2,6-Dichlorophenyl)-5-(2,4-Difluorophenyl)-7-Piperazin-1-Yl-3,4-Dihydroquinazolin-2(1h)-One",DB02873,"",,"",Mitogen-activated protein kinase 14,""
MAPK14,Doramapimod,DB03044,"",Doramapimod is a P38 MAP kinase inhibitor.,"Amides; Azoles; Benzene Derivatives; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Polycyclic Compounds; Polycyclic Hydrocarbons, Aromatic; Protein Kinase Inhibitors",Mitogen-activated protein kinase 14,""
MAPK14,4-(Fluorophenyl)-1-Cyclopropylmethyl-5-(2-Amino-4-Pyrimidinyl)Imidazole,DB03980,"",,"",Mitogen-activated protein kinase 14,""
MAPK14,Triazolopyridine,DB04797,"","","",Mitogen-activated protein kinase 14,""
TNF,Afelimomab,DB04956,L04AB03,Afelimomab (also known as Fab 2 or MAK 195F) is an anti-TNF- monoclonal antibody. Administration of 195F reduces the concentration of interleukin-6 in patients with sepsis.,"Agents reducing cytokine levels; Amino Acids, Peptides, and Proteins; Antibodies; Antineoplastic and Immunomodulating Agents; Blood Proteins; Globulins; Immunoglobulins; Immunologic Factors; Immunoproteins; Immunosuppressive Agents; Proteins; Serum Globulins; Tumor Necrosis Factor Blockers",Tumor necrosis factor,""
IL6; TNF,Atiprimod,DB05513,"",,"Hydrocarbons; Hydrocarbons, Cyclic; Polycyclic Compounds",Interleukin-6; Tumor necrosis factor,""
TNF,CYT007-TNFQb,DB05758,"","CYT007-TNFQb is an active immunization therapy that aims at
providing a novel treatment to people suffering from RA or psoriasis. The vaccine should allow for administration of low
amounts of drug to individual patients (in the microgram range) and for convenient dosing schedules.","",Tumor necrosis factor,""
TNF; HMGB1,Ethyl pyruvate,DB05869,"","CTI-01 (ethyl pyruvate) is a novel anti-inflammatory agent for the treatment of critical inflammatory conditions. CTI-01 shows a  potent anti-inflammatory and tissue protection activity in multiple animal models of disease including pancreatitis, ischemia-reperfusion injury, sepsis, renal injury and endotoxemia.",Carboxylic Acids; Keto Acids,Tumor necrosis factor; High mobility group protein B1,""
TNF,PR-104,DB05968,"",,"Hydrocarbons; Hydrocarbons, Halogenated; Mustard Compounds",Tumor necrosis factor,""
TNF,Dexanabinol,DB06444,"",,"Antiemetics; Autonomic Agents; Cannabinoids and similars; Cardiovascular Agents; Central Nervous System Agents; Compounds used in a research, industrial, or household setting; Excitatory Amino Acid Agents; Excitatory Amino Acid Antagonists; Gastrointestinal Agents; Hydrocarbons; Neuroprotective Agents; Neurotransmitter Agents; Peripheral Nervous System Agents; Protective Agents; Terpenes",Tumor necrosis factor,""
TNF,Onercept,DB06495,"",,"Amino Acids, Peptides, and Proteins; Membrane Proteins; Polyethylene Glycols; Proteins; Receptors, Death Domain; Recombinant Proteins",Tumor necrosis factor,""
SRC; MAPK14,1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea,DB06882,"",,"",Proto-oncogene tyrosine-protein kinase Src; Mitogen-activated protein kinase 14,""
MAPK14,"N-ethyl-4-{[5-(methoxycarbamoyl)-2-methylphenyl]amino}-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide",DB06940,"","N-ethyl-4-{[5-(methoxycarbamoyl)-2-methylphenyl]amino}-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide is a solid. This compound belongs to the pyrrolotriazines. These are compounds containing a pyrrolotriazine moiety, which consists of a pyrrole ring fused to a triazine ring. N-ethyl-4-{[5-(methoxycarbamoyl)-2-methylphenyl]amino}-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide is known to target mitogen-activated protein kinase 14.","",Mitogen-activated protein kinase 14,""
MAPK14,"N-[2-methyl-5-(methylcarbamoyl)phenyl]-2-{[(1R)-1-methylpropyl]amino}-1,3-thiazole-5-carboxamide",DB06991,"",,"",Mitogen-activated protein kinase 14,""
MAPK14,Neflamapimod,DB07138,"",Neflamapimod has been used in trials studying the treatment of Alzheimer's Disease and Mild Cognitive Impairment.,"Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring",Mitogen-activated protein kinase 14,""
MAPK14,4-PHENOXY-N-(PYRIDIN-2-YLMETHYL)BENZAMIDE,DB07459,"",,"",Mitogen-activated protein kinase 14,""
MAPK14,"N-(cyclopropylmethyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-carboxamide",DB07834,"",,"",Mitogen-activated protein kinase 14,""
MAPK14,2-fluoro-4-[4-(4-fluorophenyl)-1H-pyrazol-3-yl]pyridine,DB07942,"",,"",Mitogen-activated protein kinase 14,""
MAPK14,3-FLUORO-5-MORPHOLIN-4-YL-N-[3-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-5-YL]BENZAMIDE,DB08091,"",,"",Mitogen-activated protein kinase 14,""
MAPK14,"8-(2-CHLOROPHENYLAMINO)-2-(2,6-DIFLUOROPHENYLAMINO)-9-ETHYL-9H-PURINE-1,7-DIIUM",DB08096,"",,"",Mitogen-activated protein kinase 14,""
MAPK14,"2-(2,6-DIFLUOROPHENOXY)-N-(2-FLUOROPHENYL)-9-ISOPROPYL-9H-PURIN-8-AMINE",DB08097,"",,"",Mitogen-activated protein kinase 14,""
MAPK14,"N,4-dimethyl-3-[(1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino]benzamide",DB08242,"",,"",Mitogen-activated protein kinase 14,""
MAPK14,"N-cyclopropyl-3-{[1-(2,4-difluorophenyl)-7-methyl-6-oxo-6,7-dihydro-1H-pyrazolo[3,4-b]pyridin-4-yl]amino}-4-methylbenzamide",DB08349,"",,"",Mitogen-activated protein kinase 14,""
MAPK14,N-cyclopropyl-4-methyl-3-{2-[(2-morpholin-4-ylethyl)amino]quinazolin-6-yl}benzamide,DB08351,"",,"",Mitogen-activated protein kinase 14,""
MAPK14,4-(4-FLUOROPHENYL)-1-CYCLOROPROPYLMETHYL-5-(4-PYRIDYL)-IMIDAZOLE,DB08522,"",,"",Mitogen-activated protein kinase 14,""
TNF; IL6; IL3; SOD1; HMOX1; SOD2; GSTT1; GPX1; PRDX1; PRDX5; FLT1; NGF; PDGFRB; HSP90AA1; HSP90AB1,Polaprezinc,DB09221,"","Polaprezinc is a chelated form of zinc and L-carnosine. It is a zinc-related medicine approved for the first time in Japan, which has been clinically used to treat gastric ulcers [L1307, L1308].  It was determined that polaprezinc may be effective in pressure ulcer treatment [A31856]. A study in 2013 showed that CO-administration of polaprezinc may be effective against small intestine mucosal injury associated with long-term aspirin therapy [A7840].","Amino Acids, Peptides, and Proteins; Anti-Ulcer Agents; Dipeptides; Gastrointestinal Agents; Metal cations; Metal divalent cations; Nerve Tissue Proteins; Neuropeptides; Oligopeptides; Peptides; Proteins; Tumor Necrosis Factor Blockers; Zinc Compounds","Tumor necrosis factor; Interleukin-6; Interleukin-3; Superoxide dismutase [Cu-Zn]; Heme oxygenase 1; Superoxide dismutase [Mn], mitochondrial; Glutathione S-transferase theta-1; Glutathione peroxidase 1; Peroxiredoxin-1; Peroxiredoxin-5, mitochondrial; Vascular endothelial growth factor receptor 1; Beta-nerve growth factor; Platelet-derived growth factor receptor beta; Heat shock protein HSP 90-alpha; Heat shock protein HSP 90-beta",inhibitor; inducer; agonist
CYP3A4; PRKCA; PRKCE; CASP8; Unc13b; PRKD1; CD86; PTGS2; CCND1; TNF,Bryostatin 1,DB11752,"",Bryostatin 1 has been investigated for the treatment of HIV Infection and Alzheimer's Disease.,"Adjuvants, Immunologic; Anti-Bacterial Agents; Antineoplastic Agents; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Enzyme Activation; Immunologic Factors; Lactones; Macrocyclic Compounds; Macrolides; Polycyclic Compounds",Cytochrome P450 3A4; Protein kinase C alpha type; Protein kinase C epsilon type; Caspase-8; Protein unc-13 homolog B; Serine/threonine-protein kinase D1; T-lymphocyte activation antigen CD86; Prostaglandin G/H synthase 2; G1/S-specific cyclin-D1; Tumor necrosis factor,inhibitor; activator; ligand; inducer
TNF,Infliximab,DB00065,L04AB02,"Infliximab is a tumor necrosis factor (TNF-alpha or TNF-) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions [A31469]. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-) is a key proinflammatory cytokine involved in chronic inflammatory diseases [A31469]. Its hyperactivity and enhanced signalling pathways can be observed in inflammatory diseases where it activates further pro-inflammatory cascades. By binding to both the soluble subunit and the membrane-bound precursor of TNF- [A106], infliximab disrupts the interaction of TNF- with its receptors and may also cause lysis of cells that produce TNF- [A106].

Infliximab was first approved by the FDA in 1998 under the market name Remicade as an intravenous injection. It is indicated for the treatment of various inflammatory disorders such as adult or pediatric Chron's disease, adult or pediatric ulcerative colitis, rheumatoid arthritis in combination with methotrexate, ankylosing spondyliti, psoriatic arthritis, and plaque psoriasis [FDA Label]. In clinical trials, multiple infusions of infliximab displayed in a reduction of signs and symptoms of inflammatory diseases and induction of remission in patients who have had an inadequate response to alternative first-line therapies for that disorder [FDA Label]. 

There are currently two biosilimars of infliximab available in the US market that demonstrate a high degree of similarity to the reference product, Remicade. They are approved for all eligible indications of the reference product. Inflectra, a first biosimilar drug product, was approved in 2016. In December 2017, Ixifi, a second biosimilar that was developed by Pfizer, was granted approval by the FDA.","Agents Causing Muscle Toxicity; Agents reducing cytokine levels; Amino Acids, Peptides, and Proteins; Anti-Inflammatory Agents; Antibodies; Antibodies, Monoclonal; Antineoplastic and Immunomodulating Agents; Antirheumatic Agents; Biological Products; Biologics for Rheumatoid Arthritis Treatment; Blood Proteins; Complex Mixtures; Dermatologicals; Disease-modifying Antirheumatic Agents; Gastrointestinal Agents; Globulins; Immunoglobulins; Immunoproteins; Immunosuppressive Agents; Proteins; Serum Globulins; Tumor Necrosis Factor Blockers; Tumor Necrosis Factor Receptor Blocking Activity",Tumor necrosis factor,inhibitor
ADRA1A; ADRB1; ADRB2; SLC22A2; SLC22A1; CYP2C9; CYP3A4; ADRA1B; ADRA1D; ADRA2A; ADRA2B; TNF; COMT; MAOA; MAOB,Epinephrine,DB00668,A01AD01; R03AK01; B02BC09; C01CA24; S01EA01; R01AA14; R03AA01; S01EA51,"Epinephrine, also known as _adrenaline_, is a hormone and neurotransmitter and produced by the adrenal glands that can also be used as a drug due to its various important functions. Though it has long been used in the treatment of hypersensitivity reactions, epinephrine in the auto-injector form (EpiPen) has been available since 1987 in the USA. Many new products/biosimilars and dosage routes have been approved under various names over the last several decades [L4355], [L4356], [L4358].  On August 16, 2018, Teva Pharmaceuticals USA gained approval to market its generic epinephrine auto-injector in 0.3 mg and 0.15 mg strengths [L4353]. Dosage delivery routes for epinephrine include intravenous, inhalation, nebulization, intramuscular injection, and subcutaneous injection.

In general, the most common uses of parenteral epinephrine are to relieve respiratory distress due to bronchospasm, to provide rapid relief of hypersensitivity (anaphylactic or anaphylactoid) reactions to drugs, animal serums and other allergens, and to prolong the action of infiltration anesthetics [F2136]. In addition to the above functions, epinephrine is the primary drug administered during cardiopulmonary resuscitation (CPR) to reverse cardiac arrest [A37697], [A37699].  It can be used in severe cases of croup [L4824].","Adrenergic Agents; Adrenergic Agonists; Adrenergic alpha-1 Receptor Agonists; Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Adrenergic and Dopaminergic Agents; Adrenergic beta-1 Receptor Agonists; Adrenergic beta-2 Receptor Agonists; Adrenergic beta-3 Receptor Agonists; Adrenergic beta-Agonists; Adrenergics, Inhalants; Agents producing tachycardia; Agents that produce hypertension; Alpha-and Beta-adrenergic Agonists; Amines; Anti-Asthmatic Agents; Antiglaucoma Preparations and Miotics; Autonomic Agents; Benzene Derivatives; Biogenic Amines; Biogenic Monoamines; Bronchodilator Agents; Cardiac Stimulants Excl. Cardiac Glycosides; Cardiac Therapy; Cardiovascular Agents; Cardiovascular System; Catecholamines; Catechols; COMT Substrates; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 Enzyme Inhibitors; Dental Agents; Drugs for Obstructive Airway Diseases; Epinephrine and similars; Hemostatics; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hyperglycemia-Associated Agents; Local Hemostatics; Mydriatics; Nasal Preparations; Neurotransmitter Agents; OCT1 substrates; OCT2 Inhibitors; OCT2 Substrates; Ophthalmologicals; Peripheral Nervous System Agents; Phenols; Respiratory System; Respiratory System Agents; Stomatological Preparations; Sympathomimetic (Adrenergic) Agents; Sympathomimetics; Sympathomimetics in Glaucoma Therapy; Sympathomimetics, Plain; Vasoconstrictor Agents",Alpha-1A adrenergic receptor; Beta-1 adrenergic receptor; Beta-2 adrenergic receptor; Solute carrier family 22 member 2; Solute carrier family 22 member 1; Cytochrome P450 2C9; Cytochrome P450 3A4; Alpha-1B adrenergic receptor; Alpha-1D adrenergic receptor; Alpha-2A adrenergic receptor; Alpha-2B adrenergic receptor; Tumor necrosis factor; Catechol O-methyltransferase; Monoamine oxidase,agonist; substrate; inhibitor; antagonist
MAPK14,4-[5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1-methyl-4-(3-trifluoromethylphenyl)-1H-imidazol-2-yl]-piperidine,DB01761,"",,"",Mitogen-activated protein kinase 14,""
MAPK14,"N-[(3Z)-5-Tert-butyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-ylidene]-N'-(4-chlorophenyl)urea",DB01807,"",,"",Mitogen-activated protein kinase 14,""
MAPK14,Inhibitor of P38 Kinase,DB01953,"","Inhibitor of P38 Kinase is a solid. This compound belongs to the indoles. These are compounds containing an indole moiety, which consists of a pyrrole ring fused to benzene to form 2,3-benzopyrrole. This drug is known to target mitogen-activated protein kinase 14.","",Mitogen-activated protein kinase 14,""
MAPK14; LTA4H,3-(Benzyloxy)Pyridin-2-Amine,DB02352,"",,"",Mitogen-activated protein kinase 14; Leukotriene A-4 hydrolase,""
MAPK14,"4-[3-Methylsulfanylanilino]-6,7-Dimethoxyquinazoline",DB02984,"",,"",Mitogen-activated protein kinase 14,""
MAPK14,R-1487,DB06518,"",,"Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Mitogen-Activated Protein Kinase 14, antagonists & inhibitors; Pyridines",Mitogen-activated protein kinase 14,""
MAPK14,N-cyclopropyl-4-methyl-3-[1-(2-methylphenyl)phthalazin-6-yl]benzamide,DB07307,"",,"",Mitogen-activated protein kinase 14,""
MAPK14,"4-{4-[(5-hydroxy-2-methylphenyl)amino]quinolin-7-yl}-1,3-thiazole-2-carbaldehyde",DB07832,"",,"",Mitogen-activated protein kinase 14,""
MAPK14,"N-(3-cyanophenyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)-4-biphenylcarboxamide",DB07833,"",,"",Mitogen-activated protein kinase 14,""
MAPK14,PH-797804,DB07941,"",PH-797804 has been investigated for the treatment of Osteoarthritis.,"Acids, Carbocyclic; Amides; Benzene Derivatives; Benzoates; Carboxylic Acids; Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; p38 Mitogen-Activated Protein Kinases, antagonists & inhibitors; Pyridines",Mitogen-activated protein kinase 14,""
MAPK14,N-(3-TERT-BUTYL-1H-PYRAZOL-5-YL)-N'-{4-CHLORO-3-[(PYRIDIN-3-YLOXY)METHYL]PHENYL}UREA,DB08064,"",,"",Mitogen-activated protein kinase 14,""
MAPK14,N-[4-CHLORO-3-(PYRIDIN-3-YLOXYMETHYL)-PHENYL]-3-FLUORO-,DB08068,"",,"",Mitogen-activated protein kinase 14,""
MAPK14,3-(1-NAPHTHYLMETHOXY)PYRIDIN-2-AMINE,DB08093,"",,"",Mitogen-activated protein kinase 14,""
MAPK14,2-(ETHOXYMETHYL)-4-(4-FLUOROPHENYL)-3-[2-(2-HYDROXYPHENOXY)PYRIMIDIN-4-YL]ISOXAZOL-5(2H)-ONE,DB08395,"",,"",Mitogen-activated protein kinase 14,""
MAPK14,[5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL][3-(PIPERIDIN-4-YLOXY)PHENYL]METHANONE,DB08423,"",,"",Mitogen-activated protein kinase 14,""
MAPK14,3-FLUORO-5-MORPHOLIN-4-YL-N-[1-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-6-YL]BENZAMIDE,DB08730,"",,"",Mitogen-activated protein kinase 14,""
GSR; GSS; GSTM1; GSTK1; GSTA3; GSTM3; GSTA4; GSTM4; GSTA5; GSTP1; GSTO1; GPX1; GPX2; GSTT1; GSTZ1; GPX5; GPX3; GLO1; LTC4S; MGST3; HPGDS; GSTA1; GSTA2; MGST1; ESD; GGT1; GSTM2; GLRX; GPX4; GSTM5; GPX6; HAGH; GPX7; MGST2; GSTO2; GLRX2; ABCC1; ABCC2; ABCC3; ABCC4; ABCC5; AKR1B1; MMP9; CYP3A4; GPX5; GPX1; GPX2; GPX3; GPX6; GPX7; GPX4; GPX8,Glutathione,DB00143,V03AB32,"A tripeptide with many roles in cells. It conjugates to drugs to make them more soluble for excretion, is a cofactor for some enzymes, is involved in protein disulfide bond rearrangement and reduces peroxides.","Amino Acids, Peptides, and Proteins; Antidotes; Dietary Supplements; Glutathione, antagonists & inhibitors; Oligopeptides; Peptides; Supplements","Glutathione reductase, mitochondrial; Glutathione synthetase; Glutathione S-transferase Mu 1; Glutathione S-transferase kappa 1; Glutathione S-transferase A3; Glutathione S-transferase Mu 3; Glutathione S-transferase A4; Glutathione S-transferase Mu 4; Glutathione S-transferase A5; Glutathione S-transferase P; Glutathione S-transferase omega-1; Glutathione peroxidase 1; Glutathione peroxidase 2; Glutathione S-transferase theta-1; Maleylacetoacetate isomerase; Epididymal secretory glutathione peroxidase; Glutathione peroxidase 3; Lactoylglutathione lyase; Leukotriene C4 synthase; Microsomal glutathione S-transferase 3; Hematopoietic prostaglandin D synthase; Glutathione S-transferase A1; Glutathione S-transferase A2; Microsomal glutathione S-transferase 1; S-formylglutathione hydrolase; Gamma-glutamyltranspeptidase 1; Glutathione S-transferase Mu 2; Glutaredoxin-1; Phospholipid hydroperoxide glutathione peroxidase, mitochondrial; Glutathione S-transferase Mu 5; Glutathione peroxidase 6; Hydroxyacylglutathione hydrolase, mitochondrial; Glutathione peroxidase; Glutathione peroxidase 7; Microsomal glutathione S-transferase 2; Glutathione S-transferase omega-2; Glutaredoxin-2, mitochondrial; Glutathione S-transferase A2; Glutathione S-transferase A1; Multidrug resistance-associated protein 1; Canalicular multispecific organic anion transporter 1; Canalicular multispecific organic anion transporter 2; Multidrug resistance-associated protein 4; Multidrug resistance-associated protein 5; Aldose reductase; Matrix metalloproteinase-9; Cytochrome P450 3A4; Glutathione peroxidase",cofactor; substrate; inhibitor
MMP9,"2-Amino-N,3,3-Trimethylbutanamide",DB01949,"",,"",Matrix metalloproteinase-9,""
MMP9,2-{[Formyl(Hydroxy)Amino]Methyl}-4-Methylpentanoic Acid,DB03683,"",,"",Matrix metalloproteinase-9,""
MMP9,PG-530742,DB05495,"","PG-530742 selectively inhibits certain matrix metalloproteinases that have been implicated in the cartilage degradation that occurs in osteoarthritis. By inhibiting these MMPs, it potentially limits cartilage degradation and disease progression. Studies are currently assessing the efficacy and safety of PG-530742 in the treatment of mild to moderate knee osteoarthritis.",Amines; Carboxylic Acids; Hydroxy Acids; Hydroxylamines,Matrix metalloproteinase-9,""
MMP9,"(3R)-4,4-DIFLUORO-3-[(4-METHOXYPHENYL)SULFONYL]BUTANOIC ACID",DB07285,"",,"",Matrix metalloproteinase-9,""
